

CITATION REPORT

List of articles citing

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

DOI: 10.2337/dc14-2441
Diabetes Care, 2015, 38, 140-9.

Source: <https://exaly.com/paper-pdf/62773083/citation-report.pdf>

Version: 2024-04-17

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2139	.		
2138	.		
2137	Sinnvoller Einsatz der GLP-1-Analoga [Medikament]e Therapie des Typ-2-Diabetes. 2015 , 13, 309-316		
2136	Diabetes-related nutrition knowledge and dietary intake among adults with type 2 diabetes. 2015 , 114, 829-30		
2135	Comment on "Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus". 2015 , 34, 435-8		
2134	Diabetes Has Gotten Pretty Darn Complicated. 2015 , 33, 114-5		
2133	Salutary cardiovascular effects of antidiabetic drugs: myth or fact?. 2015 , 33, 2198-9		2
2132	Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. 2015 , 14, 154		74
2131	Type 2 diabetes: recent advances in diagnosis and management. 2015 , 26, 15-21		2
2130	Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes. 2015 , 17, 616-21		21
2129	Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes. 2015 , 69, 1221-35		15
2128	Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. 2015 , 1358, 28-43		63
2127	The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus. 2015 , 69, 1071-87		22
2126	Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option. 2015 , 69, 1427-37		13
2125	POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS. 2015 , 21, 1054-65		8
2124	Effects of vildagliptin as add-on treatment in patients with type 2 diabetes mellitus: insights from long-term clinical studies in Japan. 2015 , 15, 21		3
2123	Informed shared decision-making programme on the prevention of myocardial infarction in type 2 diabetes: a randomised controlled trial. 2015 , 5, e009116		23

2122	[Factors limiting glycaemic control in insulin-treated type 2 diabetes]. 2015 , 156, 1443-50	
2121	26th Annual Meeting of The North American Menopause Society September 30-October 3, 2015, Las Vegas, NV. 2015 , 22, 1361-1401	2
2120	Clinical Effects of Liraglutide in a Real-World Setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study. 2015 , 6, 173-85	20
2119	National Variations in Comorbidities, Glycosylated Hemoglobin Reduction, and Insulin Dosage in Asian Patients with Type 2 Diabetes: The FINE-Asia Registry. 2015 , 6, 519-530	11
2118	Tripel mit Sitagliptin ist effektiv und sicher. 2015 , 9, 70-70	
2117	Diabetes in Panama: Epidemiology, Risk Factors, and Clinical Management. 2015 , 81, 754-64	11
2116	Comentário a «Associação entre a hipercolesterolemia familiar e a prevalência de diabetes mellitus». 2015 , 34, 435-438	
2115	My name is Eklavya: Indian guidelines are necessary. 2015 , 67, 625-6	0
2114	Programme L&Vous : premiers enseignements de l'Observatoire National de l'Utilisation, en vie réelle, de l'insuline Basale par les patients diabétiques de Type 2. 2015 , 9, 579-588	3
2113	Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. 2015 , 14, 116	36
2112	Dynamics of heart rate variability in patients with type 2 diabetes mellitus during spinal anaesthesia: prospective observational study. 2015 , 15, 141	1
2111	How attractive is the combination of a sodium glucose co-transporter 2 inhibitor with a dipeptidyl peptidase 4 inhibitor in the treatment of type 2 diabetes?. 2015 , 17, 613-5	4
2110	Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis. 2015 , 15, 67	17
2109	Efficacy and tolerability of vildagliptin as first line treatment in patients with diabetes type 2 in an outpatient setting. 2015 , 14, 68	1
2108	Total costs of basal or premixed insulin treatment in 5077 insulin-naïve type 2 diabetes patients: register-based observational study in clinical practice. 2015 , 1, 17	
2107	The Need for a Tool to Assist Health Care Professionals and Patients in Making Medication Treatment Decisions in the Clinical Management of Type 2 Diabetes. 2015 , 28, 227-9	4
2106	The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future. 2015 , 98, 170-84	68
2105	Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism. 2015 , 3, 1094-103	38

2104	Development of a self-management education module for those with type 2 diabetes on injectable therapies. 2015 , 32, 305-310a	1
2103	Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in Type 2 diabetes: a network meta-analysis. 2015 , 32, 1530-40	33
2102	NICE guidelines for Type 2 diabetes: revised but still not fit for purpose. 2015 , 32, 1398-403	7
2101	Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. 2015 , 17, 1065-74	45
2100	Emerging utility of once-weekly exenatide in patients with type 2 diabetes. 2015 , 8, 505-12	3
2099	Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients. 2015 , 8, 241-53	21
2098	Pancreatic β Cell Dysfunction in Type 2 Diabetes: Old Kids on the Block. 2015 , 39, 1-9	28
2097	Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes. 2015 , 8, 483-93	6
2096	Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study. 2015 , 11, 569-78	2
2095	The effects of glucose-lowering therapies on diabetic kidney disease. 2015 , 11, 191-200	9
2094	A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide. 2015 , 8, 363-86	13
2093	Sulphonylurea: Personalized Medicine for Type 2 Diabetes. 2015 , 30, 467-8	
2092	Hypoglycemia with New Generation Basal Analog Insulins: A Descriptive Critical Review. 2015 , 06,	
2091	Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multi-axial approach. 2015 , 6, 1092-6	9
2090	MAXIMIZING PATIENT SAFETY WITH NEWLY APPROVED THERAPIES: FOCUS ON SGLT2 INHIBITORS. 2015 , 21, 1076-8	
2089	A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. 2015 , 4, 212283	198
2088	Triple therapy in type 2 diabetes; a systematic review and network meta-analysis. 2015 , 3, e1461	28
2087	SGLT2 inhibitors - an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. 2015 , 8, 543-54	39

2086	Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK. 2015 , 9, 1611-22	37
2085	The role of empagliflozin in the management of type 2 diabetes by patient profile. 2015 , 11, 739-49	7
2084	Continual evolution of type 2 diabetes: an update on pathophysiology and emerging treatment options. 2015 , 11, 621-32	30
2083	Metformin-associated lactic acidosis. 2015 , 30, 45-6	4
2082	Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes: A Post Hoc Analysis of the BARI 2D. 2015 , 2015, 129891	10
2081	Medicinal Plants Quia Glucagon-Like Peptide-1 Secretagogue via Intestinal Nutrient Sensors. 2015 , 2015, 171742	11
2080	Diabetes Mellitus 2014. 2015 , 2015, 845759	3
2079	Type 2 diabetes drugs: a review. 2015 , 33, 304-10; quiz 311-2	6
2078	FASTING VERSUS POSTPRANDIAL HYPERGLYCEMIA AS A TREATMENT TARGET TO LOWER ELEVATED HEMOGLOBIN A1C. 2015 , 21, 1323-32	4
2077	OPTIMIZED HUMAN REGULAR U-500 INSULIN TREATMENT IMPROVES BCELL FUNCTION IN SEVERELY INSULIN-RESISTANT PATIENTS WITH LONG-STANDING TYPE 2 DIABETES AND HIGH INSULIN REQUIREMENTS. 2015 , 21, 1344-52	6
2076	Weight management in type 2 diabetes: current and emerging approaches to treatment. <i>Diabetes Care</i> , 2015 , 38, 1161-72	14.6 129
2075	Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. 2015 , 36, 2288-96	178
2074	Minimizing Hypoglycemia and Weight Gain with Intensive Glucose Control: Potential Benefits of a New Combination Therapy (IDegLira). 2015 , 32, 391-403	4
2073	Addition of a Gastrointestinal Microbiome Modulator to Metformin Improves Metformin Tolerance and Fasting Glucose Levels. 2015 , 9, 808-14	42
2072	The Evidence is in! It does get better!. <i>Diabetes Care</i> , 2015 , 38, 3-5	14.6 1
2071	Effectiveness and feasibility of a software tool to help patients communicate with doctors about problems they face with their medication regimen (EMPATHy): study protocol for a randomized controlled trial. 2015 , 16, 145	3
2070	Pharmacotherapy for type 2 diabetes in very elderly patients: practicing nihilism or pragmatism?. 2015 , 44, 540-2	3
2069	Polemics of pioglitazone: an appraisal in 2015. 2015 , 10, 447-458	0

2068	Therapeutic Options for the Management of Postprandial Glucose in Patients With Type 2 Diabetes on Basal Insulin. 2015 , 33, 175-80		17
2067	Initiation of human regular U-500 insulin use is associated with improved glycemic control: a real-world US cohort study. 2015 , 3, e000074		18
2066	Dulaglutide, a GLP-1 receptor agonist, for the treatment of type 2 diabetes. 2015 , 10, 581-590		
2065	Rôle du contrôle glyémique sur le risque cardiovasculaire du diabétique de type 2 : le suivi de l'étude VADT, une nouvelle pierre [^] l'édifice. 2015 , 9, 461-462		1
2064	Insulinoterapia. 2015 , 11, 5510-5518		
2063	Investigation of the relationship between patient empowerment and glycaemic control in patients with type 2 diabetes: a cross-sectional analysis. 2015 , 5, e008422		8
2062	IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy. 2015 , 6, 573-591		24
2061	Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?. 2015 , 41, 6S21-6S27		5
2060	Sécurité cardiovasculaire des incrétines et des inhibiteurs des co-transporteurs sodium-glucose de type 2 (SGLT2). Revue. 2015 , 9, 768-775		3
2059	Effect of the GLP-1 Receptor Agonist Lixisenatide on Counterregulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes. <i>Diabetes Care</i> , 2016 , 39, 242-9	14.6	11
2058	Pharmacologic treatment of type 2 diabetes: oral medications. 2015 , 49, 540-56		54
2057	Potential for dipeptidyl peptidase-4 inhibitor and sodium glucose cotransporter 2 inhibitor single-pill combinations. 2015 , 10, 305-317		5
2056	(6) Glycemic targets. <i>Diabetes Care</i> , 2015 , 38 Suppl, S33-40	14.6	191
2055	(7) Approaches to glycemic treatment. <i>Diabetes Care</i> , 2015 , 38 Suppl, S41-8	14.6	181
2054	Setting the hemoglobin A1c target in type 2 diabetes: a priori, a posteriori, or neither?. 2015 , 50, 56-60		5
2053	Empagliflozin for the treatment of type 2 diabetes mellitus: An overview of safety and efficacy based on Phase 3 trials. 2015 , 7, 448-61		11
2052	Empagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes mellitus: a review of the evidence. 2015 , 49, 582-98		19
2051	Once-weekly exenatide as a treatment for Type 2 diabetes. 2015 , 13, 611-26		

2050	Improved Treatment Satisfaction and Self-reported Health Status after Introduction of Basal-Supported Oral Therapy Using Insulin Glargine in Patients with Type 2 Diabetes: Sub-Analysis of ALOHA2 Study. 2015 , 6, 153-71		4
2049	Triple fixed drug combinations in type 2 diabetes. 2015 , 19, 311-3		6
2048	In defence of NICE draft type 2 diabetes guidelines. 2015 , 3, 406		
2047	Hyperglycémie induite par l'analogue de somatostatine pasiròtide au cours de la maladie de Cushing. 2015 , 9, 261-268		
2046	Telephone Intervention to Improve Diabetes Control: A Randomized Trial in the New York City A1c Registry. 2015 , 49, 832-41		29
2045	April 2015 New in Review. 2015 , 115, 663-674		
2044	Minimizing Hypoglycemia in Diabetes. <i>Diabetes Care</i> , 2015 , 38, 1583-91	14.6	132
2043	Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition. <i>Diabetes Care</i> , 2015 , 38, 1730-5	14.6	203
2042	Innovative approaches to understanding and addressing health disparities in diabetes care and research. <i>Diabetes Care</i> , 2015 , 38, 186-8	14.6	4
2041	Type 2 diabetes mellitus treatment patterns in U.S. nursing home residents. 2015 , 127, 429-37		4
2040	Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. 2015 , 11, 1493-503		6
2039	Different binding and recognition modes of GL479, a dual agonist of Peroxisome Proliferator-Activated Receptor α . 2015 , 191, 332-40		30
2038	Type 1 diabetes at a crossroads!. <i>Diabetes Care</i> , 2015 , 38, 968-70	14.6	7
2037	Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus. 2015 , 75, 1141-52		32
2036	Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study. 2015 , 3, 605-14		96
2035	Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy. 2015 , 29, 1266-71		10
2034	SGLT2 inhibitors: the latest "new kids on the block"!. <i>Diabetes Care</i> , 2015 , 38, 352-4	14.6	34
2033	To mix or to separate: that is the question. 2015 , 3, 229-31		0

2032	Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective?. 2015 , 17, 551	20
2031	[Long-acting insulins in the treatment of type 2 diabetes: a hard choice]. 2015 , 157, 65-8	
2030	NICE draft type 2 diabetes guidelines: a cause for concern. 2015 , 3, 403-405	8
2029	Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes?. <i>Diabetes Care</i> , 2015 , 38, 373-5	14.6 35
2028	Pharmacologic treatment of type 2 diabetes: injectable medications. 2015 , 49, 700-14	19
2027	Combination therapy when metformin is not an option for type 2 diabetes. 2015 , 49, 688-99	7
2026	Alogliptin benzoate for management of type 2 diabetes. 2015 , 11, 229-43	9
2025	Is HbA1c a valid surrogate for macrovascular and microvascular complications in type 2 diabetes?. 2015 , 41, 195-201	21
2024	Combination therapy for patients with uncontrolled type 2 diabetes mellitus: adding empagliflozin to pioglitazone or pioglitazone plus metformin. 2015 , 14, 789-93	7
2023	Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). 2015 , 17, 630-8	44
2022	The 2015 standards for diabetes care: maintaining a patient-centered approach. 2015 , 162, 785-6	8
2021	Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. 2015 , 54, 691-708	105
2020	Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin. 2015 , 31, 901-11	9
2019	Antidiabétiques oraux dans le traitement du diabète de type 2 : perspectives historique et médico-économique. 2015 , 9, 186-197	7
2018	Metformin should not be contraindicated in patients with type 2 diabetes and mild to moderate renal impairment. 2015 , 20, 115	2
2017	Optionen zur Intensivierung einer Basalinsulintherapie bei Menschen mit Typ-2-Diabetes. 2015 , 10, 129-140	1
2016	Canagliflozin for the treatment of adults with Type 2 diabetes. 2015 , 5, 183-201	7
2015	Number-Based Approach to Insulin Taxonomy. 2015 , 6, 469-479	2

2014	IL-1B rs1143623 and EEF1A1P11-RPL7P9 rs10783050 polymorphisms affect the glucose-lowering efficacy of metformin in Chinese overweight or obese Type 2 diabetes mellitus patients. 2015 , 16, 1621-9	6
2013	AFREZZA [®] (insulin human) Inhalation Powder: A Review in Diabetes Mellitus. 2015 , 75, 1679-86	21
2012	Gewichtssenkende Medikamente in der Diabetologie. 2015 , 11, 464-470	
2011	Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials. 2015 , 31, 1993-2000	8
2010	Dulaglutide: A Review in Type 2 Diabetes. 2015 , 29, 407-18	11
2009	User's guide to mechanism of action and clinical use of GLP-1 receptor agonists. 2015 , 127, 818-26	13
2008	Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial. 2015 , 35, 675-84	8
2007	Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years. 2015 , 29, 1295-303	92
2006	RSSDI Clinical Practice Recommendations for Management of Type 2 Diabetes Mellitus, 2015. 2015 , 35, 1-71	9
2005	Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy. 2015 , 127, 827-41	10
2004	First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus. 2015 , 16, 2539-47	32
2003	Effects of anti-diabetic drugs on bone metabolism. 2015 , 10, 663-675	12
2002	Better response to the SGLT2 inhibitor dapagliflozin in young adults with type 2 diabetes. 2015 , 16, 2553-9	5
2001	SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. 2015 , 14, 1879-904	49
2000	Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naïve Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents. <i>Diabetes Care</i> , 2015 , 38, 2274-81 ^{14.6}	21
1999	Racial/ethnic disparities in prevalence and care of patients with type 2 diabetes mellitus. 2015 , 31, 913-23	39
1998	Response to Comments on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> 2015 ;38:140-149. <i>Diabetes Care</i> , 2015 , 38, e128-9	14.6 21
1997	Status of Diabetes Care: New Challenges, New Concepts, New Measures--Focusing on the Future!. <i>Diabetes Care</i> , 2015 , 38, 1177-80	14.6 3

1996	Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategies. 2015 , 127, 480-93	5
1995	Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. 2015 , 127, 463-79	10
1994	Shared Decision-Making in Diabetes Care. 2015 , 15, 112	52
1993	Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> , 2015 , 38, 1567-82	14.6 133
1992	Practical Pearls for the Management of Patients on U-500 Regular Human Insulin. 2015 , 3, 34-39	
1991	Glycemic and Cholesterol Control Versus Single-Goal Control in US Veterans with Newly Diagnosed Type 2 Diabetes: A Retrospective Observational Study. 2015 , 6, 339-55	2
1990	Current management of diabetes mellitus and future directions in care. 2015 , 91, 612-21	36
1989	Use of oral combination therapy for type 2 diabetes in primary care: Meeting individualized patient goals. 2015 , 127, 808-17	24
1988	Dipeptidyl peptidase-4 inhibitor use in patients with type 2 diabetes and cardiovascular disease or risk factors. 2015 , 127, 842-54	5
1987	Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes. 2015 , 41, 19S-31S	5
1986	Saxagliptin: A Review in Type 2 Diabetes. 2015 , 75, 1783-96	15
1985	Basal Insulin Initiation in Elderly Patients with Type 2 Diabetes in Taiwan: A Comparison with Younger Patients. 2015 , 9, 142-145	2
1984	GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice. 2015 , 41, 32S-46S	8
1983	Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins. 2015 , 7, 63	1
1982	Sodium glucose co-transporter inhibitors for the management of diabetes mellitus: an opinion paper from the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy. 2015 , 31, 1733-41	3
1981	A new angle for glp-1 receptor agonist: the medical economics argument. Editorial on: Huetson P, Palmer JL, Levorsen A, et al. Cost-effectiveness of the once-daily glp-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway. <i>J Med Econ</i> 2015; 1-13 [Epub ahead of print]. 2015 , 18, 1029-31	0
1980	Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. 2015 , 110, 75-81	39
1979	Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus. 2015 , 24, 1381-7	14

1978	Markers of β Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes. <i>Diabetes Care</i> , 2016 , 39, 250-7	14.6	94
1977	Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). <i>Diabetes Care</i> , 2015 , 38, 2241-9	14.6	145
1976	Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. 2015 , 6, 289-302		32
1975	Primary Care of the Patient with Chronic Kidney Disease. 2015 , 99, 935-52		10
1974	GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach. 2015 , 52, 1129-33		12
1973	Using the respective contributions of postprandial and basal glucose for tailoring treatments in type 2 diabetes. 2015 , 41, 179-82		9
1972	Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection. <i>Diabetes Care</i> , 2015 , 38, 2204-10	14.6	37
1971	Landmark studies on the glucagon subfamily of GPCRs: from small molecule modulators to a crystal structure. 2015 , 36, 1033-42		11
1970	Hypoglycemia and Comorbidities in Type 2 Diabetes. 2015 , 15, 80		9
1969	Algorithms for personalized therapy of type 2 diabetes: results of a web-based international survey. 2015 , 3, e000109		4
1968	Diabetes: Advances in Diagnosis and Treatment. 2015 , 314, 1052-62		232
1967	Empagliflozin/Linagliptin: A Review in Type 2 Diabetes. 2015 , 75, 1547-57		11
1966	Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus. 2015 , 31, 1919-31		13
1965	Response to Comment on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> 2015;38:140-149. <i>Diabetes Care</i> , 2015 , 38, e143	14.6	6
1964	Recognizing and minimizing hypoglycemia: The need for individualized care. 2015 , 127, 801-7		5
1963	Ramadan and diabetes: What we see, learn and understand from continuous glucose monitoring. 2015 , 41, 456-62		9
1962	Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). 2015 , 351, h5364		44
1961	Comment on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> 2015;38:140-149. <i>Diabetes Care</i> , 2015 , 38, e143	14.6	5

1960	Comment on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> 2015;38:140-149. <i>Diabetes Care</i> , 2015, 38, e125-5	14.6	3
1959	Comment on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> 2015;38:140-149. <i>Diabetes Care</i> , 2015, 38, e127	14.6	3
1958	Sodium-glucose co-transporter 2 inhibitors: evidence and place in therapy. 2015 , 10, 645-661		1
1957	Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease. 2015 , 32, 1029-64		23
1956	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials. 2015 , 127, 419-28		3
1955	Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus. 2015 , 16, 2819-33		15
1954	NICE guidance on type 2 diabetes in adults [what's new?]. 2016 , 2016, 17-22		5
1953	A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes. 2016 , 37, 834-42		5
1952	EFFECT OF TOTAL DAILY DOSE ON EFFICACY, DOSING, AND SAFETY OF 2 DOSE TITRATION REGIMENS OF HUMAN REGULAR U500 INSULIN IN SEVERELY INSULIN-RESISTANT PATIENTS WITH TYPE 2 DIABETES. 2016 , 22, 653-65		19
1951	Insulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectives. 2016 , 10, 2097-2106		6
1950	Combination therapies in the management of type 2 diabetes: the use of insulin degludec/liraglutide. 2016 , 12, 471-8		1
1949	DOES CLINICAL INERTIA VARY BY PERSONALIZED A1C GOAL? A STUDY OF PREDICTORS AND PREVALENCE OF CLINICAL INERTIA IN A U.S. MANAGED-CARE SETTING. 2016 , 22, 151-61		32
1948	TREATMENT INTENSIFICATION WITH INSULIN DEGLUDEC/INSULIN ASPART TWICE DAILY: RANDOMIZED STUDY TO COMPARE SIMPLE AND STEP-WISE TITRATION ALGORITHMS. 2016 , 22, 546-54		6
1947	Mode of administration of dulaglutide: implications for treatment adherence. 2016 , 10, 975-82		11
1946	Treatment Strategy to Prevent Hypoglycemia. 2016 , 17, 30		1
1945	The eating habits of Patients with Type 2 diabetes in Algeria. 2016 , 32, 289-93		2
1944	Nationwide trends in glucose-lowering drug use, Denmark, 1999-2014. 2016 , 8, 381-387		40
1943	Vejle Diabetes Biobank - a resource for studies of the etiologies of diabetes and its comorbidities. 2016 , 8, 393-413		17

1942	An indirect comparison of HbA1c treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher method. 2016 , 9, 163-8	1
1941	Profiles of Liver Function Tests among Type 2 Diabetic Patients Who are Receiving Different Anti-Diabetic Drugs Attending Tikur Anbessa Specialized Hospitals. 2016 , 07,	2
1940	Type 2 Diabetes Mellitus. 2016 , 1385-1450	4
1939	Management of diabolical diabetes mellitus and periodontitis nexus: Are we doing enough?. 2016 , 7, 50-66	11
1938	The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) Trial and Its Clinical Impact on Patterns of Prescription for Anti-Diabetes Medication. 2016 , 17, 225	
1937	"Act on Threes" Paradigm for Treatment Intensification of Type 2 Diabetes in Managed Care: Results of a Randomized Controlled Study with an Educational Intervention Targeting Improved Glycemic Control. 2016 , 22, 1028-38	4
1936	Patient considerations in type 2 diabetes - role of combination dapagliflozin-metformin XR. 2016 , 9, 25-35	6
1935	Glycemic Assessment in a Patient with HB Leiden and Type 2 Diabetes. 2016 , 2, e307-e310	2
1934	Factors complicating the diabetes management of visitors to Japan: advices from a Japanese National Center for overseas medical staff. 2016 , 63, 15-8	1
1933	Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin. 2016 , 40, 230-9	13
1932	Reduction of Sulfonylurea with the Initiation of Basal Insulin in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Undergoing Long-Term Sulfonylurea-Based Treatment. 2016 , 40, 454-462	4
1931	Dipeptidyl Peptidase-4 Inhibitor Switching as an Alternative Add-on Therapy to Current Strategies Recommended by Guidelines: Analysis of a Retrospective Cohort of Type 2 Diabetic Patients. 2016 , 7,	5
1930	Improving cardiovascular risk in type 2 diabetes: time to get personal. 2016 , 2, 233-234	3
1929	Effectiveness and Safety of Sitagliptin in Patients with Beta-thalassaemia Major and Diabetes Mellitus: A Case Series. 2017 , 9, e2017004	3
1928	Treatment progression in sulfonylurea and dipeptidyl peptidase-4 inhibitor cohorts of type 2 diabetes patients on metformin. 2016 , 10, 1539-46	0
1927	Dapagliflozin-Induced Acute-on-Chronic Liver Injury. 2016 , 3, e169	4
1926	Economic Evaluation of Canagliflozin versus Glimpiride and Sitagliptin in Dual Therapy with Metformin for the Treatment of Type 2 Diabetes in Italy. 2016 , 3, GRHTA.5000229	1
1925	Cardiovascular safety of type 2 diabetes medications: Review of existing literature and clinical implications. 2016 , 15, 170-185	7

1924	EFFICACY AND SAFETY OF DULAGLUTIDE IN HISPANIC/LATINO PATIENTS WITH TYPE 2 DIABETES IN THE AWARD CLINICAL PROGRAM. 2016 , 22, 1406-1414	10
1923	Rapid Acting Insulin Use and Persistence among Elderly Type 2 Diabetes Patients Adding RAI to Oral Antidiabetes Drug Regimens. 2016 , 2016, 5374931	2
1922	The Impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients. 2016 , 2016, 4350712	25
1921	Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects. 2016 , 10, 2525-34	9
1920	The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. 2016 , 8, 61-81	26
1919	Advances in the treatment of type 2 diabetes: impact of dulaglutide. 2016 , 9, 125-36	8
1918	Repurposing metformin for cancer treatment: current clinical studies. 2016 , 7, 40767-40780	194
1917	Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US. 2017 , 9, 19-29	18
1916	Options for empagliflozin in combination therapy in type 2 diabetes mellitus. 2016 , 9, 155-72	12
1915	PROGENS-HbA study: safety and effectiveness of premixed recombinant human insulin (Gensulin M30). 2016 , 12, 985-991	3
1914	Noninsulin Antidiabetic Drugs for Patients with Type 2 Diabetes Mellitus: Are We Respecting Their Contraindications?. 2016 , 2016, 7502489	13
1913	Metformin Treatment and Homocysteine: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2016 , 8,	28
1912	Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. 2016 , 11, e0166125	126
1911	Update on the treatment of type 2 diabetes mellitus. 2016 , 7, 354-95	269
1910	Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. 2016 , 10, 1299-307	286
1909	Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjects. 2016 , 10, 1411-8	2
1908	Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents. 2016 , 9, 17-29	11
1907	NICE guidance: Translating intentions into practice. 2016 , 22, 58-62	

1906	Glucagon-like peptide-1 and gastric inhibitory polypeptide: new advances. 2016 , 23, 23-7	9
1905	Dose-response relationship between statin therapy and glycaemia in community-based patients with type 2 diabetes: the Fremantle Diabetes Study. 2016 , 18, 1143-1146	4
1904	Efficacy and safety of linagliptin according to patient baseline characteristics: A pooled analysis of three phase 3 trials. 2016 , 26, 886-92	5
1903	Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy. 2016 , 18, 999-1005	28
1902	Management of diabetes in Indigenous communities: lessons from the Australian Aboriginal population. 2016 , 46, 1252-1259	10
1901	Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial. 2016 , 8, 796-808	33
1900	Increasing Patient Acceptance and Adherence Toward Insulin. 2016 , 128 Suppl 1, 11-20	0
1899	Nutritional composition of Stevia rebaudiana, a sweet herb, and its hypoglycaemic and hypolipidaemic effect on patients with non-insulin dependent diabetes mellitus. 2016 , 96, 4231-4	42
1898	Patient engagement impacts glycemic management with vildagliptin and vildagliptin/metformin (single pill) regimens in type 2 diabetes mellitus (the GLORIOUS study). 2016 , 10, 425-433	5
1897	Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes. 2016 , 128, 725-730	8
1896	Assessing Adherence to Insulin Initiation Recommendations at a Suburban Family Medicine Clinic. 2016 , 23, e1542-e1546	
1895	Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register. 2016 , 18, 990-8	39
1894	Making Insulin Accessible: Does Inhaled Insulin Fill an Unmet Need?. 2016 , 33, 1267-78	12
1893	A Novel Partial PPAR α /Dual Agonist SN159 Improves Insulin Sensitivity. 2016 , 37, 226-233	3
1892	Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes. 2016 , 33, 511-4	78
1891	Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study. 2016 , 18, 840-3	11
1890	Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records. 2016 , 18, 916-24	7
1889	Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of Type 2 diabetes. 2016 , 12, 379-88	14

1888	Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective. 2016 , 19, 1127-1134	13
1887	Vildagliptin-induced acute lung injury: a case report. 2016 , 10, 225	8
1886	The combination of dulaglutide and biguanide reduced bodyweight in Japanese patients with type 2 diabetes. 2016 , 18, 1279-1282	6
1885	[Metformin - new data for an "old", but efficient, safe and reliable antidiabetic drug]. 2016 , 157, 882-91	2
1884	Increasing Number of People with Diabetes in Japan: Is This Trend Real?. 2016 , 55, 1827-30	29
1883	Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes. 2016 , 102, 1581-7	25
1882	BeAM value: an indicator of the need to initiate and intensify prandial therapy in patients with type 2 diabetes mellitus receiving basal insulin. 2016 , 4, e000171	12
1881	Beneficial effect of farnesoid X receptor activation on metabolism in a diabetic rat model. 2016 , 13, 2135-42	13
1880	Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial. 2016 , 6, e012185	12
1879	Kardiale Effekte aktueller Antidiabetika. 2016 , 16, 38-42	
1878	IMPACT OF GLUCOSE MANAGEMENT TEAM ON OUTCOMES OF HOSPITALIZATION IN PATIENTS WITH TYPE 2 DIABETES ADMITTED TO THE MEDICAL SERVICE. 2016 , 22, 1401-1405	23
1877	Most add-on therapies to metformin have similar effects on HbA1c. 2016 , 21, 223	
1876	Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study. 2016 , 6, e010210	173
1875	Relationship of cardiometabolic parameters in non-smokers, current smokers, and quitters in diabetes: a systematic review and meta-analysis. 2016 , 15, 158	38
1874	Analytical tools for determination of new oral antidiabetic drugs, glitazones, gliptins, gliflozins and glinides, in bulk materials, pharmaceuticals and biological samples. 2016 , 14, 215-242	6
1873	Effectiveness of a Multicomponent Quality Improvement Strategy to Improve Achievement of Diabetes Care Goals: A Randomized, Controlled Trial. 2016 , 165, 399-408	59
1872	How to Use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies. 2016 , 471-492	
1871	In type 2 diabetes treated with high-dose insulin, liraglutide reduced HbA1c. 2016 , 165, JC40	

1870 Oral Glucose-Lowering Agents. **2016**, 426-454

1869 Pharmacological options for managing type 2 diabetes. **2016**, 14, 330-338

1868 Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus. **2016**, 63, 519-526 4

1867 [Therapy with oral antidiabetic drugs]. **2016**, 158, 48-54

1866 [One year persistence of metformin monotherapy versus metformin/sitagliptin fixed dose combination]. **2016**, 157, 618-22 1

1865 Lactic acidosis and the relationship with metformin usage: Case reports. **2016**, 95, e4998 11

1864 Des essais randomisés contrôlés aux études observationnelles. Apports, limites et leçons. Réflexions à propos de l'étude ODYSSEE. **2016**, 10, 732-740

1863 Under-treatment of type 2 diabetes: Causes and outcomes of clinical inertia. **2016**, 70, 988-995 25

1862 Prevención primaria de diabetes tipo 2 en Argentina: estudio piloto en la provincia de Buenos Aires. **2016**, 53, 135-141 1

1861 Role of Emerging Insulin Technologies in the Initiation and Intensification of Insulin Therapy for Diabetes in Primary Care. **2016**, 34, 34-43 4

1860 Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program. **2016**, 16, 44 11

1859 Capsule Commentary on Min et al., Comparative Effectiveness of Insulin versus Combination Sulfonyleurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes: How to Escalate Therapy for Patients who Fail Sulfonyleureas. **2016**, 31, 650

1858 Liraglutide in clinical practice: Glycemic control, and predictors of good response. **2016**, 146, 415-6 3

1857 Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes. **2016**, 118, 1830-43 46

1856 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Evidence for Good Cardiovascular Outcomes among Patients with Type 2 Diabetes, and Promising Treatment for Patients with Type 1 Diabetes. **2016**, 38, 1274-1278 3919

1855 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Evidence for Good Cardiovascular Outcomes among Patients with Type 2 Diabetes, and Promising Treatment for Patients with Type 1 Diabetes. **2016**, 38, 1274-1278 0

1854 Effect of a macronutrient preload on blood glucose level and pregnancy outcome in gestational diabetes. **2016**, 5, 36-41 5

1853 Pharmacologic Therapy of Type 2 Diabetes. **2016**, 100, 647-63 16

1852	Novel antidiabetic drugs and cardiovascular risk: Primum non nocere. 2016 , 26, 759-66		16
1851	Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial. <i>Diabetes Care</i> , 2016 , 39, 1318-28	14.6	103
1850	Efficacy and safety of a premixed versus a basal-plus insulin regimen as intensification for type 2 diabetes by timing of the main meal. 2016 , 32, 1109-16		3
1849	Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors. 2016 , 72, 1013-23		11
1848	NUEVOS FARMACOS EN DIABETES MELLITUS. 2016 , 27, 235-256		2
1847	Pharmacologic Approaches to Weight Management: Recent Gains and Shortfalls in Combating Obesity. 2016 , 18, 36		9
1846	Interactive Web-Based Learning: Translating Health Policy Into Improved Diabetes Care. 2016 , 50, 122-128		17
1845	EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus. 2016 , 38, 1288-1298		24
1844	Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism. 2016 , 12, 467-84		22
1843	Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes. 2016 , 77, 557-562		10
1842	Exenatide Once Weekly: A Review of Pharmacology and Treatment Considerations in Type 2 Diabetes. 2016 , 38, 582-94		13
1841	Improving drug prescription in elderly diabetic patients. 2016 , 51, 127-9		0
1840	The Effect of Disease Severity on 24-Hour Urine Parameters in Kidney Stone Patients With Type 2 Diabetes. 2016 , 87, 52-9		12
1839	Trend of antihyperglycaemic therapy and glycaemic control in 184,864 adults with type 1 or 2 diabetes between 2002 and 2014: Analysis of real-life data from the DPV registry from Germany and Austria. 2016 , 115, 31-8		30
1838	Novel insight into the dangerous connection between diabetes and heart failure. 2016 , 41, 201-7		9
1837	Glucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trial. 2016 , 41, 208-16		3
1836	[Individualized diabetes therapy in older persons]. 2016 , 57, 502-7		1
1835	[Insulin therapy of diabetes]. 2016 , 128 Suppl 2, S54-61		1

1834	[Antihyperglycemic treatment guidelines for diabetes mellitus type 2]. 2016 , 128 Suppl 2, S45-53	4
1833	Mortality reduction among persons with type 2 diabetes: (-)-Epicatechin as add-on therapy to metformin?. 2016 , 91, 86-89	4
1832	Onset of Glycemic and Weight Outcomes in Patients Initiating Exenatide Once Weekly: The Relationship of Exenatide Exposure with Efficacy over the First 24 Weeks of Treatment. 2016 , 7, 361-8	2
1831	Combination of Saxagliptin and Metformin Is Effective as Initial Therapy in New-Onset Type 2 Diabetes Mellitus With Severe Hyperglycemia. 2016 , 101, 2528-35	7
1830	Combination therapy for the improvement of long-term macrovascular and microvascular outcomes in type 2 diabetes: Rationale and evidence for early initiation. 2016 , 30, 1177-85	13
1829	Personalized intensification of insulin therapy in type 2 diabetes - does a basal-bolus regimen suit all patients?. 2016 , 32, 1425-34	5
1828	Proactive and Progressive Approaches in Managing Obesity. 2016 , 128 Suppl 1, 21-30	5
1827	[Modern antihyperglycaemic agents--what is the patient benefit?]. 2016 , 158, 45-8	
1826	Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods. 2016 , 89, 73-82	12
1825	Ipragliflozin as an Initial Therapy in Drug Naïve Subjects with Type 2 Diabetes. 2016 , 66, 345-50	4
1824	Verwendung der Fixkombination aus Insulin degludec und Liraglutid bei Erwachsenen mit Typ-2-Diabetes als Option bei unzureichender Blutzuckereinstellung unter einer basalunterstützten oralen Therapie. 2016 , 11, 163-171	
1823	Anwendung von GLP-1-Rezeptoragonisten bei Patienten mit Niereninsuffizienz [ein Update. 2016 , 11, 172-177	1
1822	Urinary metabolomic profiling in mice with diet-induced obesity and type 2 diabetes mellitus after treatment with metformin, vildagliptin and their combination. 2016 , 431, 88-100	27
1821	The current role of thiazolidinediones in diabetes management. 2016 , 90, 1861-81	45
1820	Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies. 2016 , 16, 91	30
1819	Small Intestinal Glucose Delivery Affects the Lowering of Blood Glucose by Acute Vildagliptin in Type 2 Diabetes. 2016 , 101, 4769-4778	12
1818	Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1. 2016 , 179, 175-83	51
1817	The effect of local hyperglycemia on skin cells in vitro and on wound healing in euglycemic rats. 2016 , 206, 418-426	16

1816	Diabetes Technology-Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline. 2016 , 101, 3922-3937	124
1815	A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures. 2016 , 16, 356	5
1814	Real-world Canagliflozin Utilization: Glycemic Control Among Patients With Type 2 Diabetes Mellitus-A Multi-Database Synthesis. 2016 , 38, 2071-82	7
1813	SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan. 2016 , 17, 2073-84	14
1812	A comparison of the pharmacodynamic profiles of jet-injected regular human insulin versus conventionally administered insulin aspart in healthy volunteers. 2016 , 121, 86-90	2
1811	Dual oral agent therapy for type 2 diabetes: Why don't our patients stick with it?. 2016 , 30, 1417-1418	1
1810	Guà ESC 2016 sobre prevenci3 de la enfermedad cardiovascular en la pr3ctica cl3nica. 2016 , 69, 939.e1-939.e87	10
1809	Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes. 2016 , 7, 659-678	3
1808	Treatment discontinuation of oral hypoglycemic agents and healthcare utilization among patients with diabetes. 2016 , 30, 1443-1451	3
1807	Factors influencing insulin usage among type 2 diabetes mellitus patients: A study in Turkish primary care. 2016 , 22, 255-261	3
1806	Assessing occurrence of hypoglycemia and its severity from electronic health records of patients with type 2 diabetes mellitus. 2016 , 121, 192-203	38
1805	Efficacy and risk profile of anti-diabetic therapies: Conventional vs traditional drugs-A mechanistic revisit to understand their mode of action. 2016 , 113, 636-674	41
1804	Metformin: From Research to Clinical Practice. 2016 , 45, 819-843	21
1803	Drug therapies in type 2 diabetes: an era of personalised medicine. 2016 , 16, 441-447	3
1802	The effects of exenatide twice daily compared to insulin lispro added to basal insulin in Latin American patients with type 2 diabetes: A retrospective analysis of the 4B trial. 2016 , 122, 38-45	2
1801	Evolving to Personalized Medicine for Type 2 Diabetes. 2016 , 45, 1011-1020	7
1800	Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus. 2016 , 63, 519-526	8
1799	Tratamiento de la diabetes mellitus (III). Insulinoterapia. 2016 , 12, 1026-1034	

1798 Liraglutide in clinical practice: Glycemic control, and predictors of good response. **2016**, 146, 415-416

1797 Current perspectives on cardiovascular outcome trials in diabetes. **2016**, 15, 139 51

1796 Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. **2016**, 70, 775-85 15

1795 Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health. **2016**, 14, 345-350 14

1794 IDegAsp (insulin degludec + insulin aspart) for the management of type 2 diabetes: current status. **2016**, 11, 103-111 1

1793 Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia. **2016**, 128, 747-754 4

1792 Amyloidogenesis of the amylin analogue pramlintide. **2016**, 219, 1-8 29

1791 Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. *Diabetes Care*, **2016**, 39, 1972-1980 14.6 148

1790 Pharmacokinetic evaluation of fixed-ratio combination of insulin degludec and liraglutide in the treatment of type 2 diabetes. **2016**, 12, 1225-32

1789 Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged 65 and . **2016**, 18, 820-8 27

1788 Challenges of implementing personalized (precision) medicine: a focus on diabetes. **2016**, 13, 485-497 5

1787 Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus. **2016**, 128, 828-838 9

1786 Demographic and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Initiating Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Study of UK General Practice. **2016**, 38, 1825-1832.e15 5

1785 Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers. **2016**, 128, 810-821 10

1784 Effect of Serotonin Transporter 5-HTTLPR Polymorphism on Gastrointestinal Intolerance to Metformin: A GoDARTS Study. *Diabetes Care*, **2016**, 39, 1896-1901 14.6 31

1783 [National guidelines for treatment of diabetic retinopathy : Second edition of the national guidelines for treatment of diabetic retinopathy]. **2016**, 113, 623-38 18

1782 The power of two: an update on fixed-dose combinations for type 2 diabetes. **2016**, 9, 1453-1462 16

1781 Targeting hepatic glucose metabolism in the treatment of type 2 diabetes. **2016**, 15, 786-804 164

1780	Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis From the First-in-Human Proof-of-Concept Study. <i>Diabetes Care</i> , 2016 , 39, 2254-2261	14.6	129
1779	Clinical use of the co-formulation of insulin degludec and insulin aspart. 2016 , 70, 657-67		9
1778	Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonists. 2016 , 32, 497-511		14
1777	Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. 2016 , 32, 776-790		78
1776	NICE: type 2 diabetes in adults, 2015. 2016 , 33, 4-5		2
1775	Omarigliptin for the treatment of type 2 diabetes mellitus. 2016 , 17, 1947-52		14
1774	Approaches to treatment 2: Comparison of American Association of Clinical Endocrinologists (AACE) and American Diabetes Association (ADA) type 2 diabetes treatment guidelines. 2016 , 8, 4-6		10
1773	Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes. 2016 , 8, 720-8		19
1772	Personalized medicine in diabetes: the role of 'omics' and biomarkers. 2016 , 33, 712-7		49
1771	Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. 2016 , 18, 401-9		169
1770	Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study). 2016 , 18, 663-70		19
1769	Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes. 2016 , 18, 829-33		6
1768	Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial. 2016 , 18, 803-11		20
1767	Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. 2016 , 18, 812-9		38
1766	Efficacy of canagliflozin combined with antidiabetic drugs in treating type 2 diabetes mellitus: Meta-analysis of randomized control trials. 2016 , 7, 359-65		4
1765	Achieving the composite endpoint of glycated haemoglobin . 2016 , 18, 49-55		15
1764	Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. 2016 , 18, 82-91		65
1763	Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. 2016 , 18, 317-32		173

1762	Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial. 2016 , 18, 274-80	23
1761	Apparent subadditivity of the efficacy of initial combination treatments for type 2 diabetes is largely explained by the impact of baseline HbA1c on efficacy. 2016 , 18, 348-54	9
1760	Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial. 2016 , 18, 528-32	14
1759	A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8). 2016 , 18, 475-82	58
1758	Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment. 2016 , 18, 615-22	22
1757	How much is too much? Outcomes in patients using high-dose insulin glargine. 2016 , 70, 56-65	25
1756	Reductions in Mean 24-Hour Ambulatory Blood Pressure After 6-Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension. 2016 , 18, 43-52	59
1755	Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus. 2016 , 7, 5-16	26
1754	Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis. 2016 , 64, 543-52	43
1753	Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis. 2016 , 82, 1291-1302	31
1752	Safety profiling of pioglitazone and telmisartan combination by sub-chronic toxicity study in rat. 2016 , 81, 155-161	5
1751	Obesity. 2016 ,	2
1750	Beyond Traditional Management: The Use of Medications in the Treatment of Obesity. 2016 , 231-260	
1749	[Comparison of two insulin glargine formulations: biosimilar vs. reference product]. 2016 , 158 Suppl 5, 19-27	1
1748	Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy. 2016 , 6, e217	13
1747	Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes. 2016 , 12, 1367-1380	3
1746	Are patients on basal insulin attaining glycemic targets? Characteristics and goal achievement of patients with type 2 diabetes mellitus treated with basal insulin and physician-perceived barriers to achieving glycemic targets. 2016 , 121, 17-26	44
1745	A novel option for prandial insulin therapy: inhaled insulin. 2016 , 128, 839-847	4

1744	Metformin-associated risk of acute dialysis in patients with type 2 diabetes: A nationwide cohort study. 2016 , 18, 1283-1287		10
1743	Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. <i>Diabetes Care</i> , 2016 , 39, 2026-2035	14.6	150
1742	Predictors of HbA1c levels in patients initiating metformin. 2016 , 32, 2021-2028		5
1741	Glycemic Control for Patients With Type 2 Diabetes Mellitus: Our Evolving Faith in the Face of Evidence. 2016 , 9, 504-12		88
1740	Cardiac implications of drugs used to treat type 2 diabetes. 2016 , 11, 168-172		
1739	Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis. 2016 , 68, 733-742		25
1738	Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study. 2016 , 18, 677-686		32
1737	Intensification of Diabetes Therapy and Time Until A1C Goal Attainment Among Patients With Newly Diagnosed Type 2 Diabetes Who Fail Metformin Monotherapy Within a Large Integrated Health System. <i>Diabetes Care</i> , 2016 , 39, 1527-34	14.6	43
1736	SGLT2 Inhibitors: Benefit/Risk Balance. 2016 , 16, 92		64
1735	Basal Insulin Use With GLP-1 Receptor Agonists. 2016 , 29, 152-60		20
1734	A Test in Context: Hemoglobin A and Cardiovascular Disease. 2016 , 68, 2479-2486		15
1733	Management of patients with diabetes and CKD: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. 2016 , 90, 1175-1183		73
1732	Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. 2016 , 164, 740-51		364
1731	Alpha-glucosidase inhibitors and hepatotoxicity in type 2 diabetes: a systematic review and meta-analysis. 2016 , 6, 32649		36
1730	Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review. 2016 , 15, 77-83		22
1729	Best practice in management of type 2 diabetes. 2016 , 14, S3-S8		
1728	2016 Health Care & Education Presidential Address: If DSME Were a Pill, Would You Prescribe It?. <i>Diabetes Care</i> , 2016 , 39, 2101-2107	14.6	13
1727	Efficacy and safety of thrice-weekly insulin degludec in elderly patients with type 2 diabetes assessed by continuous glucose monitoring. 2016 , 63, 1099-1106		7

1726	Do We Need Updated Guidelines on the Use of Insulin Pump Therapy in Type 2 Diabetes? A Review of National and International Practice Guidelines. 2016 , 10, 1388-1398		2
1725	2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular		341
1724	Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4. 2016 , 18, 1072-1080		18
1723	Impact of frailty in older patients with diabetes mellitus: An overview. 2016 , 63, 291-303		4
1722	Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting. 2016 , 34, 953-66		20
1721	The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes. 2016 , 25, 1133-52		6
1720	Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?. 2016 , 15, 95		39
1719	The prevalence and treatment patterns of diabetes in the Greek population based on real-world data from the nation-wide prescription database. 2016 , 118, 162-7		42
1718	One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin. 2016 , 18, 1128-1133		25
1717	Treatment of Type 2 Diabetes: From "Guidelines" to "Position Statements" and Back: Recommendations of the Israel National Diabetes Council. <i>Diabetes Care</i> , 2016 , 39 Suppl 2, S146-53	14.6	17
1716	Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm. <i>Diabetes Care</i> , 2016 , 39 Suppl 2, S154-64	14.6	28
1715	The cost-effectiveness of exenatide twice daily (BID) vs insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes. 2016 , 19, 1167-1174		6
1714	Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial. 2016 , 18, 1055-1064		34
1713	Pharmacological Approaches in the Treatment and Maintenance of Weight Loss. <i>Diabetes Care</i> , 2016 , 39 Suppl 2, S260-7	14.6	32
1712	Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?. <i>Diabetes Care</i> , 2016 , 39 Suppl 2, S187-95	14.6	37
1711	Persistence with Insulin Therapy in Patients with Type 2 Diabetes in France: An Insurance Claims Study. 2016 , 7, 537-49		22
1710	Efficacy and Safety of Multiple Doses of Exenatide Once-Monthly Suspension in Patients With Type 2 Diabetes: A Phase II Randomized Clinical Trial. <i>Diabetes Care</i> , 2016 , 39, 1768-76	14.6	10
1709	Management of postprandial glucose: Recommended targets and treatment with biphasic insulin. 2016 , 10, 391-397		3

1708	Glucose: archetypal biomarker in diabetes diagnosis, clinical management and research. 2016 , 10, 1153-1166	9
1707	Should GLP-1 Receptor Agonists Be the First Line of Treatment for Type 2 Diabetes?. 2016 , 18, 671-673	1
1706	Cardiovascular Outcomes of New Medications for Type 2 Diabetes. 2016 , 18, 749-758	6
1705	Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes. 2016 , 7, 765-776	9
1704	Case of a woman with acromegaly whose presenting complaint was prolonged post-partum amenorrhea. 2016 , 42, 1379-1384	0
1703	Insulin: Making Sense of Current Options. 2016 , 45, 845-874	9
1702	Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease. 2016 , 7, 621-639	18
1701	Basal-bolus Therapy in Patients with Type 2 Diabetes Mellitus in the UK: Patient Characteristics, Treatment Patterns and the Effect of Switching to Premixed Insulin. 2016 , 7, 793-807	4
1700	Gal3 Links Inflammation and Insulin Resistance. 2016 , 24, 655-656	10
1699	Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. 2016 , 164, 542-52	376
1698	The efficacy and safety of liraglutide added to metformin in patients with diabetes: a meta-analysis of randomized controlled trials. 2016 , 6, 32714	8
1697	SGLT2i: A novel approach to managing type 2 diabetes. 2016 , 22, 450-454	
1696	Changes in Characteristics and Treatment Patterns of Patients with Newly Diagnosed Type 2 Diabetes in a Large United States Integrated Health System between 2008 and 2013. 2016 , 9, 23-30	8
1695	Glycaemic control and antidiabetic treatment trends in primary care centres in patients with type 2 diabetes mellitus during 2007-2013 in Catalonia: a population-based study. 2016 , 6, e012463	49
1694	Dulaglutid: GLP-1-Rezeptoragonist zur einmal wahentlichen Therapie des Typ-2-Diabetes. 2016 , 11, 398-417	1
1693	Management of chronic kidney disease and diabetes: a case study. 2016 , 1, 12-17	
1692	Use of an electronic health record to identify prevalent and incident cardiovascular disease in type 2 diabetes according to treatment strategy. 2016 , 4, e000206	5
1691	Regular Insulin Administered With the V-Go Disposable Insulin Delivery Device in a Clinical Diabetes Setting: A Retrospective Analysis of Efficacy and Cost. 2016 , 34, 201-205	2

1690	Management of Type 2 Diabetes in the Setting of Morbid Obesity: How Can Weight Gain Be Prevented or Reversed?. 2016 , 34, 115-20		2
1689	Effects of lifestyle intervention using patient-centered cognitive behavioral therapy among patients with cardio-metabolic syndrome: a randomized, controlled trial. 2016 , 16, 227		15
1688	Vergleich einer Insulintherapie mit Insulin Glargin und Insulin Degludec/Liraglutid bei Patienten mit Typ-2-Diabetes. 2016 , 12, 201-202		
1687	Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002-2013: Nationwide population-based cohort study. 2016 , 95, e4018		58
1686	Impact of diabetes duration on achieved reductions in glycated haemoglobin, fasting plasma glucose and body weight with liraglutide treatment for up to 28 weeks: a meta-analysis of seven phase III trials. 2016 , 18, 721-4		6
1685	CYP2C8 and SLCO1B1 Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2016 , 39, 1902-1908	14.6	40
1684	Handbook of Incretin-based Therapies in Type 2 Diabetes. 2016 ,		
1683	Cardiovascular effects of anti-diabetes drugs. 2016 , 15, 1239-57		11
1682	Metformin: nicht nur zur Therapie sondern auch zur Prvention?. 2016 , 49, 252-257		
1681	Herz und Diabetes. 2016 , 12, 78-79		
1680	Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone. 2016 , 36, 293-303		11
1679	The 10(th) Annual Cardiometabolic Health Congress General Session Highlights. 2016 , 128 Suppl 1, 1-10		1
1678	Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial. <i>Diabetes Care</i> , 2016 , 39, 1501-9	14.6	100
1677	Safety and efficacy of linagliptin in patients with type 2 diabetes mellitus and coronary artery disease: Analysis of pooled events from 19 clinical trials. 2016 , 30, 1378-84		8
1676	Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes. 2016 , 11, 7-19		16
1675	Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? Yes, They Should Be Relaxed! What's the Fuss?. <i>Diabetes Care</i> , 2016 , 39, 1287-91	14.6	23
1674	Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. 2016 , 12, 566-92		205
1673	[Geriatric aspects for the management of diabetes mellitus]. 2016 , 128 Suppl 2, S124-30		1

1672	Non-Persistence and Non-Adherence of Patients with Type 2 Diabetes Mellitus in Therapy with GLP-1 Receptor Agonists: A Retrospective Analysis. 2016 , 7, 105-24	26
1671	Filling the Knowledge Gap in Diabetes Management During Ramadan: the Evolving Role of Trial Evidence. 2016 , 7, 221-40	4
1670	Predictors for achieving target glycemic control in Japanese patients with type 2 diabetes after initiation of basal supported oral therapy using insulin glargine: sub-analysis of the ALOHA2 study, drug use surveillance in Japan. 2016 , 7, 188-198	5
1669	A higher body mass index attenuates the long-term HbA1c-lowering effects of liraglutide in type 2 diabetes patients treated using sulfonylurea-based therapy. 2016 , 7, 425-431	1
1668	Usó de recursos y costes asociados de episodios de hipoglucemia que requieren hospitalizaci3n en diabetes mellitus tipo 2 tratada con antidiab3ticos orales en Espa1a (Estudio DYSCOVERY). 2016 , 13, 57-65	
1667	Early insulin therapy in patients with type 2 diabetes mellitus. 2016 , 21, 13-15	4
1666	Epidemiology of Diabetes-Status of a Pandemic and Issues Around Metabolic Surgery. <i>Diabetes Care</i> , 2016 , 39, 878-83	14.6 31
1665	GLP-1 receptor agonist as treatment for cancer as well as diabetes: beyond blood glucose control. 2016 , 11, 357-364	5
1664	Glucose, cholesterol, and blood pressure: is lower always better for type 2 diabetes?. 2016 , 54, 32-37	1
1663	Baseline ALT levels as a marker of glycemic response to treatment with GLP-1 receptor agonists. 2016 , 63, 164-170	3
1662	IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes. 2016 , 10, 202-9	9
1661	Linagliptin and pioglitazone combination therapy versus monotherapy with linagliptin or pioglitazone: A randomised, double-blind, parallel-group, multinational clinical trial. 2016 , 13, 286-98	4
1660	Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial. 2016 , 8, 15	7
1659	Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases. 2016 , 27, 689-711	18
1658	Optimizing management of glycaemia. 2016 , 30, 397-411	5
1657	A patient-centric approach to optimise insulin therapy in Asia. 2016 , 30, 973-80	
1656	Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. 2016 , 133, 2459-502	520
1655	SGLT2 inhibitors in the management of type 2 diabetes. 2016 , 53, 364-72	47

1654	Detecting people at high risk of type 2 diabetes- How do we find them and who should be treated?. 2016 , 30, 345-55	19
1653	Optimising the person-centred management of type 2 diabetes. 2016 , 25, 535-8	2
1652	Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. 2016 , 15, 37	129
1651	Precision Medicine in Diabetes: Is It Time?. <i>Diabetes Care</i> , 2016 , 39, 1085-8	14.6 31
1650	Assessing Risks of Glucose Lowering Therapy in Heart Failure: Should We Rely on Post-hoc Analyses?. 2016 , 10, 1	
1649	Impact of sub-gastrectomy on glucose regulation in gastric cancer patients with T2DM: a follow-up study. 2016 , 36, 89-94	
1648	Serum leptin level is associated with glycaemic control in newly diagnosed type 2 diabetes patients: A 1-year cohort study. 2016 , 42, 457-461	5
1647	Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review. 2016 , 7, 411-38	56
1646	2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Do: Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A1c Targets?. <i>Diabetes Care</i> , 2016 , 39, e145-6	445
1645		14.6 5
1644	Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in people with Type 2 diabetes. 2016 , 33, 926-33	6
1643	Effectiveness of insulin therapy in people with Type 2 diabetes in the Hoorn Diabetes Care System. 2016 , 33, 794-802	7
1642	Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion. 2016 , 18, 571-80	55
1641	Metabolic memory and all-cause death in community-based patients with type 2 diabetes: the Fremantle Diabetes Study. 2016 , 18, 598-606	11
1640	Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study. 2016 , 18, 755-65	21
1639	Treatment intensification for patients with type 2 diabetes and poor glycaemic control. 2016 , 18, 892-8	34
1638	Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes. <i>Diabetes Care</i> , 2016 , 39, 353-62	14.6 82
1637	Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. 2016 , 59, 266-74	64

1636	Patient/disease features and glycemic targets in type 2 diabetes: Where do we stand?. 2016 , 53, 673-5	
1635	Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation. 2016 , 16, 209-19	21
1634	A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever. 2016 , 44, 9-20	1
1633	Glycemic excursions are positively associated with changes in duration of asymptomatic hypoglycemia after treatment intensification in patients with type 2 diabetes. 2016 , 113, 108-15	13
1632	Future glucose-lowering drugs for type 2 diabetes. 2016 , 4, 350-9	67
1631	Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience. 2016 , 76, 41-74	22
1630	3. Foundations of Care and Comprehensive Medical Evaluation. <i>Diabetes Care</i> , 2016 , 39 Suppl 1, S23-35	14.6 125
1629	Predictors of glycemic control and diabetes-related costs among type 2 diabetes patients initiating therapy with liraglutide in the United States. 2016 , 19, 403-13	6
1628	Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation. 2016 , 112, 50-56	8
1627	Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials. 2016 , 17, 105-15	7
1626	Metformin inhibits prostate cancer cell proliferation, migration, and tumor growth through upregulation of PEDF expression. 2016 , 17, 507-14	40
1625	Diabetes Care After Transplant: Definitions, Risk Factors, and Clinical Management. 2016 , 100, 535-50	30
1624	Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes. 2016 , 128, 409-17	25
1623	Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimperide in Patients with Type 2 Diabetes on Metformin. 2016 , 7, 269-78	12
1622	Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy. 2016 , 17, 91-101	17
1621	Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study. 2016 , 48, 224-34	29
1620	Avant-propos: Itinfaire des stratgies thrapeutiques du diabte de type 2. 2016 , 10, 97-100	1
1619	Metformin Revisited. 2016 , 18, 113-4	2

1618	Cost-effectiveness of continuous subcutaneous insulin infusion in people with type 2 diabetes in the Netherlands. 2016 , 19, 742-9	13
1617	Échec des antidiabétiques oraux à doses maximales tolérées : Quels traitements injectables?. 2016 , 10, 121-130	4
1616	Ajouter des agonistes des récepteurs du GLP-1 quand l'efficacité de l'insulinothérapie basale est en train de chuter ou d'élouer. 2016 , 10, 131-139	2
1615	Conclusion : Comment équilibrer les buts et besoins thérapeutiques des soignants et des soignés ?. 2016 , 10, 140-146	2
1614	Efficacy and safety assessment of basal supported oral therapy (BOT) with insulin glargine in a real-life clinical setting, stratified by concomitant orally administered antidiabetic agent (OAD) regimens including dipeptidyl peptidase-4 inhibitor (DPP-4i): subanalysis of the ALOHA2 study, drug-use surveillance in Japan. 2016 , 7, 299-307	3
1613	La metformine revisitée et consolidée en 2016 : un point de vue consensuel de l'Afrique à l'Europe. 2016 , 10, 151-154	1
1612	Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes. 2016 , 128, 398-408	2
1611	The diabetic foot in 2015: an overview. 2016 , 32 Suppl 1, 169-78	69
1610	Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. 2016 , 128, 371-80	47
1609	The past, present, and future of basal insulins. 2016 , 32, 478-96	48
1608	Clinical and Economic Outcomes Associated With the Timing of Initiation of Basal Insulin in Patients With Type 2 Diabetes Mellitus Previously Treated With Oral Antidiabetes Drugs. 2016 , 38, 110-21	7
1607	Glycaemic control and cardiovascular risk factor management in patients with diabetes with and without coronary artery disease: insights from the diabetes mellitus status in Canada survey. 2016 , 2, 277-284	12
1606	Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. 2016 , 18, 203-16	248
1605	Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes. 2016 , 31, 638-46	5
1604	Combination therapy of SGLT2 inhibitors with incretin-based therapies for the treatment of type 2 diabetes mellitus: Effects and mechanisms of action. 2016 , 11, 281-296	
1603	Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes. 2016 , 7, 45-60	94
1602	Bariatric Surgery in Obese Patients with Type 1 Diabetes: Effects on Weight Loss and Metabolic Control. 2016 , 26, 2370-8	18
1601	Dulaglutide (LY-2189265) for the treatment of type 2 diabetes. 2016 , 9, 385-99	15

1600	Investigational insulin secretagogues for type 2 diabetes. 2016 , 25, 405-22		30
1599	Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. 2016 , 352, i610		155
1598	Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis. 2016 , 72, 655-63		20
1597	Will delayed release metformin provide better management of diabetes type 2?. 2016 , 17, 627-30		10
1596	Management of Diabetes in Long-term Care and Skilled Nursing Facilities: A Position Statement of the American Diabetes Association. <i>Diabetes Care</i> , 2016 , 39, 308-18	14.6	117
1595	[Diagram of diagnosis and management of type 2 diabetes mellitus. Update]. 2016 , 33, 38-40		
1594	Insulin glargine versus insulin degludec in patients failing on oral therapy in type 2 diabetes: A retrospective real world comparative data from India. 2016 , 10, 161-5		6
1593	Comparative effectiveness of sodium-glucose co-transporter 2 inhibitors for controlling hyperglycaemia in patients with type 2 diabetes: protocol for a systematic review and network meta-analysis. 2016 , 6, e010252		6
1592	Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus. 2016 , 76, 363-74		18
1591	Association Between Severe Hypoglycemia and Cardiovascular Disease Risk in Japanese Patients With Type 2 Diabetes. 2016 , 5, e002875		40
1590	Diabetology and oncology meet in a network model: union is strength. 2016 , 53, 515-24		14
1589	Impact of frailty in older patients with diabetes mellitus: An overview. 2016 , 63, 291-303		17
1588	Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis. 2016 , 6, e009421		46
1587	A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus. 2016 , 7, 27-43		33
1586	Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus White patients with type 2 diabetes mellitus: A pooled analysis. 2016 , 114, 160-72		11
1585	Shared decision making in endocrinology: present and future directions. 2016 , 4, 706-716		69
1584	Insulin glargine 300 units/mL: A new basal insulin product for diabetes mellitus. 2016 , 73, 359-66		11
1583	Attributes Influencing Insulin Pen Preference Among Caregivers and Patients With Diabetes Who Require Greater Than 20 Units of Mealtime Insulin. 2016 , 10, 923-31		14

1582	Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. 2016 , 315, 898-907		138
1581	Premixed insulin regimens for type 2 diabetes. 2016 , 51, 387-9		2
1580	Utilization of a Cloud-Based Diabetes Management Program for Insulin Initiation and Titration Enables Collaborative Decision Making Between Healthcare Providers and Patients. 2016 , 18, 59-67		82
1579	Novel Therapeutic Approaches in Diabetes. 2016 , 31, 43-56		8
1578	Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes. 2016 , 32, 1097-108		12
1577	Hypoglycemia and diabetes: increased need for awareness. 2016 , 32, 1479-86		7
1576	Baseline ALT levels as a marker of glycemic response to treatment with GLP-1 receptor agonists. 2016 , 63, 164-70		3
1575	Fed and Fasted Single-dose Assessment of Bioequivalence of Dapagliflozin and Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects. 2016 , 38, 99-109		9
1574	Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin: rationale and evidences. 2016 , 9, 605-616		3
1573	5. Glycemic Targets. <i>Diabetes Care</i> , 2016 , 39 Suppl 1, S39-46	14.6	199
1572	Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study. 2016 , 17, 59-64		9
1571	Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea. 2016 , 32, 807-16		24
1570	Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US. 2016 , 32, 669-80		31
1569	Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. 2016 , 101, 157-66		290
1568	7. Approaches to Glycemic Treatment. <i>Diabetes Care</i> , 2016 , 39 Suppl 1, S52-9	14.6	204
1567	Cardiovascular risk and fitness in veteran football players. 2016 , 34, 576-83		1
1566	Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies. <i>Diabetes Care</i> , 2016 , 39, 486-94	14.6	45
1565	Combination therapy for type 2 diabetes: dapagliflozin plus metformin. 2016 , 17, 117-26		16

1564	Effect of canagliflozin on liver function tests in patients with type 2 diabetes. 2016 , 42, 25-32	85
1563	Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences. 2016 , 9, 229-40	6
1562	Explaining psychological insulin resistance in adults with non-insulin-treated type 2 diabetes: The roles of diabetes distress and current medication concerns. Results from Diabetes MILES--Australia. 2016 , 10, 75-82	13
1561	An overview of new GLP-1 receptor agonists for type 2 diabetes. 2016 , 25, 145-58	37
1560	Metabolic syndrome update. 2016 , 26, 364-73	378
1559	The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin. 2016 , 128, 137-44	6
1558	Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis. 2016 , 40, 50-7	20
1557	Canagliflozin treatment of Hispanic and non-Hispanic patients with type 2 diabetes in a US managed care setting. 2016 , 32, 13-22	7
1556	Therapeutic Concentrations of Metformin: A Systematic Review. 2016 , 55, 439-59	93
1555	SGLT2 inhibitors. 2016 , 101, 27-39	19
1554	Once Daily Self-Monitoring of Blood Glucose (SMBG) Improves Glycemic Control in Oral Hypoglycemic Agents (OHA)-Treated Diabetes: SMBG-OHA Follow-Up Study. 2015 , 10, 378-82	8
1553	Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. 2016 , 25, 1199-207	4
1552	[Differential characteristics of type 2 diabetes in the elderly. Role of dipeptidyl peptidase 4 inhibitors]. 2016 , 51, 44-51	3
1551	Evaluation and management of diabetic and non-diabetic hypoglycemia in end-stage renal disease. 2016 , 31, 8-15	23
1550	Effects of diabetes drugs on the skeleton. 2016 , 82, 93-100	110
1549	Effect of meal composition on postprandial glucagon-like peptide-1, insulin, glucagon, C-peptide, and glucose responses in overweight/obese subjects. 2017 , 56, 1053-1062	12
1548	Glycemic excursions are positively associated with HbA1c reduction from baseline after treatment with acarbose in patients with type 2 diabetes on metformin monotherapy. 2017 , 9, 248-255	3
1547	Impact and Feasibility of Personalized Decision Support for Older Patients with Diabetes: A Pilot Randomized Trial. 2017 , 37, 611-617	6

1546	A comparison of the clinical usefulness of neck circumference and waist circumference in individuals with severe obesity. 2017 , 42, 6-14	34
1545	Examining factors associated with excess mortality in older people (age \geq 70 years) with diabetes - a 10-year cohort study of older people with and without diabetes. 2017 , 34, 387-395	7
1544	Evolution and degree of control of cardiovascular risk factors after 5 years of follow-up and their relationship with the incidence of peripheral arterial disease: ARTPER cohort. 2017 , 148, 107-113	3
1543	Comparison of the diabetes guidelines from the ADA/EASD and the AACE/ACE. 2017 , 57, 261-265	23
1542	Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden. 2017 , 15, 237-248	20
1541	[Introduction of capillary glycosylated haemoglobin determination in a Primary Care Health Area: Multicentre study of the evolution of patients with type 2 diabetes mellitus]. 2017 , 32, 66-72	
1540	Special Considerations in Choosing Diabetes Therapy. 2017 , 2, 39-52	
1539	Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy. 2017 , 124, 57-65	27
1538	Addition of once daily prandial lixisenatide to basal insulin therapy in patients with type-2 diabetes results in a reduction of HbA1c as an effect of postprandial glucose lowering. 2017 , 11 Suppl 1, S91-S97	3
1537	[Spanish adaptation of the 2016 European Guidelines on cardiovascular disease prevention in clinical practice]. 2017 , 34, 24-40	2
1536	Changes in the management of type 2 diabetic patients in family medicine practices in the Bursa region. 2017 , 11, 178-183	1
1535	Attitudes of patients and physicians to insulin therapy in Japan: an analysis of the Global Attitude of Patients and Physicians in Insulin Therapy study. 2017 , 18, 5-11	10
1534	The effects of liraglutide in mice with diet-induced obesity studied by metabolomics. 2017 , 233, 93-104	16
1533	Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study. 2017 , 8, 321-334	24
1532	Diabetes: A diabetes mellitus guideline gone wrong - the 2017 ACP update. 2017 , 13, 191-192	1
1531	Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes. 2017 , 16, 387-396	11
1530	Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes. 2017 , 16, 18	34
1529	Basal insulin treatment intensification in patients with type 2 diabetes mellitus: A comprehensive systematic review of current options. 2017 , 43, 110-124	9

1528	Efficacy and safety of fixed-dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: A phase 3 trial. 2017 , 19, 754-758	15
1527	Sitagliptin: A Review in Type 2 Diabetes. 2017 , 77, 209-224	46
1526	Exenatide: pharmacokinetics, clinical use, and future directions. 2017 , 18, 555-571	39
1525	Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. 2017 , 5, 251-260	206
1524	Metformin: New Preparations and Nonglycemic Benefits. 2017 , 17, 5	48
1523	Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. 2017 , 5, 391-402	42
1522	Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes. 2017 , 129, 231-241	5
1521	Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. 2017 , 19, 831-841	60
1520	Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial. 2017 , 19, 858-865	47
1519	Evaluation of a Premixed Insulin Analog Suspension in Japanese People with Type 2 Diabetes and the Clinical Importance of Improved Injection Techniques: A Cross-Sectional Pilot Study. 2017 , 8, 445-449	1
1518	Diabète de type 2 : concilier Médecine de Précision et Primauté des Soins de Premier recours. Pas simple !: Quid du rôle des diabétologues et de l'hôpital ?. 2017 , 11, 5-7	1
1517	Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials. 2017 , 126, 230-239	16
1516	No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives. 2017 , 19, 970-978	16
1515	Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study. 2017 , 19, 979-988	26
1514	Delays in treatment intensification with oral antidiabetic drugs and risk of microvascular and macrovascular events in patients with poor glycaemic control: An individual patient simulation study. 2017 , 19, 1006-1013	10
1513	Spanish adaptation of the 2016 European Guidelines on cardiovascular disease prevention in clinical practice. 2017 , 29, 69-85	4
1512	The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy. 2017 , 34, 638-657	3
1511	Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus. 2017 , 8, 275-291	23

1510	Consensus recommendations on exploring effective solutions for the rising cost of diabetes. 2017 , 11, 141-147	6
1509	Evaluating drug cost per responder and number needed to treat associated with lixisenatide on top of glargine when compared to rapid-acting insulin intensification regimens on top of glargine, in patients with type 2 diabetes in the UK, Italy, and Spain. 2017 , 20, 633-639	8
1508	The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes. 2017 , 33, 1045-1055	7
1507	A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges. 2017 , 19, 255-264	17
1506	Hydrothermal Duodenal Mucosal Resurfacing: Role in the Treatment of Metabolic Disease. 2017 , 27, 299-311	25
1505	Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study. 2017 , 19, 1097-1105	2
1504	Predictors of insulin uptake among adults with type 2 diabetes in the Stepping Up Study. 2017 , 133, 204-210	6
1503	Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial. 2017 , 19, 1127-1134	7
1502	Review of insulin-associated hypoglycemia and its impact on the management of diabetes in Southeast Asian countries. 2017 , 8, 635-645	13
1501	Management of Type 2 Diabetes in 2017: Getting to Goal. 2017 , 317, 1015-1016	87
1500	Antidiabetic effect of SN158 through PPAR α dual activation in ob/ob mice. 2017 , 268, 24-30	5
1499	Rapid Discovery of Potent and Selective Glycosidase-Inhibiting De Novo Peptides. 2017 , 24, 381-390	35
1498	Insulin glargine 300 units/mL: a guide for healthcare professionals involved in the management of diabetes. 2017 , 33, 785-793	2
1497	Association of DPP-4 activity with BMD, body composition, and incident hip fracture: the Cardiovascular Health Study. 2017 , 28, 1631-1640	10
1496	Change in HbA1c associated with treatment intensification among patients with type 2 diabetes and poor glycemic control. 2017 , 33, 853-858	13
1495	Bile acid sequestrants for glycemic control in patients with type 2 diabetes: A systematic review with meta-analysis of randomized controlled trials. 2017 , 31, 918-927	46
1494	Retrospective Study on the Impact of Adherence in Achieving Glycemic Goals in Type 2 Diabetes Mellitus Patients Receiving Canagliflozin. 2017 , 34, 937-953	12
1493	Dulaglutide for the treatment of type 2 diabetes. 2017 , 17, 485-496	20

1492	Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide. 2017 , 19, 953-961		72
1491	Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial. <i>Diabetes Care</i> , 2017 , 40, 485-493	14.6	19
1490	Association of dipeptidyl peptidase 4 inhibitors with risk of metastases in patients with type 2 diabetes and breast, prostate or digestive system cancer. 2017 , 31, 687-692		17
1489	Therapeutics for Equine Endocrine Disorders. 2017 , 33, 127-139		17
1488	Persistence with rapid-acting insulin and its association with A1C level and severe hypoglycemia among elderly patients with type 2 diabetes. 2017 , 33, 1309-1316		5
1487	'Knowing what Matters in diabetes: Healthier below 7': results of the campaign's first 10 years (part 2), participants without known diabetes history. 2017 , 6, 48-54		1
1486	[Diabetes and heart failure : Update 2017]. 2017 , 42, 329-340		0
1485	Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States. 2017 , 33, 1317-1328		15
1484	Translating U-500R Randomized Clinical Trial Evidence to the Practice Setting: A Diabetes Educator/Expert Prescriber Team Approach. 2017 , 43, 311-323		1
1483	Use of GLP-1 receptor agonists for type 2 diabetes treatment intensification after basal insulin failure. 2017 , 43 Suppl 1, 2S34-2S38		
1482	Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS. 2017 , 19, 1587-1593		18
1481	Evaluating new HbA1c methods for adoption by the IFCC and NGSP reference networks using international quality targets. 2017 , 55, 1426-1434		17
1480	Hypoglycemic and Hypolipidemic Effects of Leucine, Zinc, and Chromium, Alone and in Combination, in Rats with Type 2 Diabetes. 2017 , 180, 246-254		16
1479	Implantable batteryless device for on-demand and pulsatile insulin administration. 2017 , 8, 15032		23
1478	Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease. 2017 , 66, 2310-2315		17
1477	Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects. 2017 , 56, 1391-1401		26
1476	Diabetes Mellitus Treatment Deintensification: When Well-Controlled Diabetes Mellitus Becomes Overcontrolled. 2017 , 10,		2
1475	Real-world Clinical Outcomes Among Patients With Type 2 Diabetes Receiving Canagliflozin at a Specialty Diabetes Clinic: Subgroup Analysis by Baseline HbA and Age. 2017 , 39, 1123-1131		6

1474	Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial. <i>Diabetes Care</i> , 2017 , 40, 951-957	14.6	75
1473	LX2761, a Sodium/Glucose Cotransporter 1 Inhibitor Restricted to the Intestine, Improves Glycemic Control in Mice. 2017 , 362, 85-97		20
1472	GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries. 2017 , 8, 115-128		22
1471	Risks of Metformin in Type 2 Diabetes and Chronic Kidney Disease: Lessons Learned from Taiwanese Data. 2017 , 135, 147-153		18
1470	Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures. 2017 , 19, 315-322		3
1469	Gaps and barriers in the control of blood glucose in people with type 2 diabetes. 2017 , 14, 172-183		59
1468	A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus. 2017 , 19, 1645-1654 ²¹		
1467	Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis. 2017 , 18, 843-851		14
1466	Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes. 2017 , 19, 1546-1554		6
1465	Diabetes type 2 management: what are the differences between DPP-4 inhibitors and how do you choose?. 2017 , 18, 839-841		11
1464	Impact on Diabetes Self-Management and Glycemic Control of a New Color-Based SMBG Meter. 2017 , 11, 1218-1225		11
1463	Increased healthcare utilization costs following initiation of insulin treatment in type 2 diabetes: A long-term follow-up in clinical practice. 2017 , 11, 184-192		5
1462	Prescription of oral antidiabetic drugs in Tyrol - Data from the Tyrol diabetes registry 2012-2015. 2017 , 129, 46-51		5
1461	Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial. <i>Diabetes Care</i> , 2017 , 40, 201-209	14.6	77
1460	Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. 2017 , 217, 282-302		139
1459	Which Patients Will Benefit from a Switch in Therapy from Premixed Insulin to Insulin Glargine plus Oral Antidiabetic Drugs? Further Analysis of the Lantus Registry Study. 2017 , 8, 887-898		2
1458	[Sex and gender differences in diabetes management]. 2017 , 159, 61-69		0
1457	Features of glycemic variations in drug naïve type 2 diabetic patients with different HbA values. 2017 , 7, 1583		10

1456	[Cardiovascular Effects of Antidiabetic Therapies]. 2017 , 142, 737-745	1
1455	Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data. 2017 , 34, 1235-1243	11
1454	Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus. 2017 , 71, e12948	14
1453	Academy of Nutrition and Dietetics Nutrition Practice Guideline for Type 1 and Type 2 Diabetes in Adults: Systematic Review of Evidence for Medical Nutrition Therapy Effectiveness and Recommendations for Integration into the Nutrition Care Process. 2017 , 117, 1659-1679	112
1452	[Trends in antidiabetic treatment prescribed for patients with type 2 diabetes in Hungary between 2001 and 2014 - results from the database analysis of the National Health Insurance Fund]. 2017 , 158, 770-778	5
1451	Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide. 2017 , 39, 1347-1359	15
1450	Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management. 2017 , 102, 3621-3634	84
1449	Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. 2017 , 19, 1610-1619	98
1448	Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. 2017 , 34, 1193-1204	12
1447	The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL. 2017 , 16, 66	9
1446	The Role of SGLT-2 Inhibitors as Part of Optimal Medical Therapy in Improving Cardiovascular Outcomes in Patients with Diabetes and Coronary Artery Disease. 2017 , 31, 311-318	7
1445	Assessing Psychological Insulin Resistance in Type 2 Diabetes: a Critical Comparison of Measures. 2017 , 17, 46	7
1444	Bolstering your armamentarium with SGLT2 inhibitors. 2017 ,	
1443	A behavioral sensing system that promotes positive lifestyle changes and improves metabolic control among adults with type 2 diabetes. 2017 ,	3
1442	Long-Standing Problem of β Blocker-Elicited Hypoglycemia in Diabetes Mellitus. 2017 , 70, 42-43	4
1441	Is diabetes self-management education still the Cinderella of diabetes care?. 2017 , 100, 1957-1960	14
1440	Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies. 2017 , 130, S4-S17	59
1439	Effect of anti-diabetic drugs on bone metabolism: Evidence from preclinical and clinical studies. 2017 , 69, 1328-1340	37

1438	A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. 2017 , 33, 1853-1860	8
1437	Synthesis and pharmacological evaluation of glycine amide derivatives as novel vascular adhesion protein-1 inhibitors without CYP3A4 and CYP2C19 inhibition. 2017 , 25, 4110-4122	7
1436	Practical Recommendations for Transitioning Patients with Type 2 Diabetes from Hospital to Home. 2017 , 17, 52	15
1435	Dulce Digital: An mHealth SMS-Based Intervention Improves Glycemic Control in Hispanics With Type 2 Diabetes. <i>Diabetes Care</i> , 2017 , 40, 1349-1355	14.6 69
1434	Metformin: clinical topics and new mechanisms of action. 2017 , 8, 4-6	2
1433	Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors. 2017 , 17, 32	4
1432	Mining the Genome for Therapeutic Targets. 2017 , 66, 1770-1778	11
1431	Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies. 2017 , 120, S4-S16	41
1430	Extending Metformin Use in Diabetic Kidney Disease: A Pharmacokinetic Study in Stage 4 Diabetic Nephropathy. 2017 , 2, 705-712	14
1429	CONCENTRATED INSULINS: CLINICAL APPLICATIONS & USE IN PRACTICAL SETTINGS. 2017 , 23, 1-30	
1428	Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. 2017 , 5, 341-354	189
1427	Diabetes medication pharmacology. 2017 , 17, 198-207	2
1426	Considerations on glycaemic control in older and/or frail individuals with diabetes and advanced kidney disease. 2017 , 32, 591-597	6
1425	Evidence-based recommendations for insulin intensification strategies after basal insulin in type 2 diabetes. 2017 , 11 Suppl 1, S507-S521	3
1424	Evolution and degree of control of cardiovascular risk factors after 5 years of follow-up and their relationship with the incidence of peripheral arterial disease: ARTPER cohort. 2017 , 148, 107-113	
1423	SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus. 2017 , 129, 409-420	25
1422	Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naïve patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. 2017 , 5, 355-366	180
1421	Effectiveness of chronic care models for the management of type 2 diabetes mellitus in Europe: a systematic review and meta-analysis. 2017 , 7, e013076	30

1420	Renal function preservation with pioglitazone or with basal insulin as an add-on therapy for patients with type 2 diabetes mellitus. 2017 , 54, 561-568	7
1419	Mobile health (m-Health) for diabetes management. 2017 , 23, 102-108	4
1418	Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates. 2017 , 33, 1155-1163	4
1417	Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus. 2017 , 18, 545-549	4
1416	Factors associated with improved glycemic control following continuous subcutaneous insulin infusion therapy in patients with type 2 diabetes uncontrolled with bolus-basal insulin regimens: An analysis from the OpT2mise randomized trial. 2017 , 19, 1490-1494	7
1415	Trial watch: Insulin initiation for type 2 diabetes mellitus in primary care. 2017 , 13, 317-318	
1414	The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study. 2017 , 14, 295-303	12
1413	Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data. 2017 , 16, 40	14
1412	CARDIOVASCULAR OUTCOME TRIALS OF THE INCRETIN-BASED THERAPIES: WHAT DO WE KNOW SO FAR?. 2017 , 23, 89-99	10
1411	Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom. 2017 , 8, 335-353	19
1410	Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3). 2017 , 19, 1389-1396 ³¹	
1409	Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK. 2017 , 8, 513-530	15
1408	The use of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and hypertension: a focus on African-American populations. 2017 , 129, 421-429	0
1407	Improving glycaemic control in type 2 diabetes: Stimulate insulin secretion or provide beta-cell rest?. 2017 , 19, 1205-1213	39
1406	[Spanish adaptation of the 2016 European Guidelines on cardiovascular disease prevention in clinical practice]. 2017 , 31, 255-268	2
1405	Pharmacologic Therapy for Type 2 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes. 2017 , 166, 572-578	78
1404	Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?. 2017 , 17, 21	22
1403	Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis. 2017 , 129, 436-445	18

1402	Cardiovascular inflammation is reduced with methotrexate in diabetes. 2017 , 432, 159-167		8
1401	2016 European Guidelines on cardiovascular disease prevention in clinical practice : The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). 2017 , 24, 321-419		54
1400	A Large Difference in Dose Timing of Basal Insulin Introduces Risk of Hypoglycemia and Overweight: A Cross-Sectional Study. 2017 , 8, 385-399		6
1399	Diabetes Self-Management Education and Medical Nutrition Therapy Improve Patient Outcomes: A Pilot Study Documenting the Efficacy of Registered Dietitian Nutritionist Interventions through Retrospective Chart Review. 2017 , 117, 1254-1264		25
1398	Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Diabetes Care</i> , 2017 , 40, 614-624	14.6	72
1397	Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials. 2017 , 7, 44865		19
1396	Exenatide Add-on to Continuous Subcutaneous Insulin Infusion Therapy Reduces Bolus Insulin Doses in Patients with Type 2 Diabetes: A Randomized, Controlled, Open-Label Trial. 2017 , 8, 177-187		13
1395	Efficacy and safety of linagliptin/metformin single-pill combination as initial therapy in drug-naïve Asian patients with type 2 diabetes. 2017 , 124, 48-56		10
1394	Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia. 2017 , 123, 199-208		35
1393	Nutrition in Lifestyle Medicine. 2017 ,		0
1392	Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes. <i>Diabetes Care</i> , 2017 , 40, 832-838	14.6	177
1391	The economic impact of insulin-related hypoglycemia in Denmark: an analysis using the Local Impact of Hypoglycemia Tool. 2017 , 20, 363-370		5
1390	Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. 2017 , 166, 191-200		155
1389	Nutrition Therapy for the Prevention and Treatment of Prediabetes and Diabetes. 2017 , 151-171		
1388	Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide. 2017 , 56, 719-731		10
1387	Behaviours, thoughts and perceptions around mealtime insulin usage and wastage among people with type 1 and type 2 diabetes mellitus: A cross-sectional survey study. 2017 , 126, 30-42		8
1386	8. Pharmacologic Approaches to Glycemic Treatment. <i>Diabetes Care</i> , 2017 , 40, S64-S74	14.6	307
1385	4. Lifestyle Management. <i>Diabetes Care</i> , 2017 , 40, S33-S43	14.6	208

1384	Resolving the KgA1c paradox in the management of type 2 diabetes mellitus. 2017 , 11 Suppl 1, S159-S168	
1383	The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial. 2017 , 8, 101-114	74
1382	Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. 2017 , 66, 241-255	292
1381	Factors associated with reaching or not reaching target HbA after initiation of basal or premixed insulin in patients with type 2 diabetes. 2017 , 43, 69-78	6
1380	6. Glycemic Targets. <i>Diabetes Care</i> , 2017 , 40, S48-S56	14.6 277
1379	Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies. 2017 , 19, 429-435	12
1378	Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes. 2017 , 35, 141-153	1
1377	Cost-Effectiveness of IDegLira Versus Insulin Intensification Regimens for the Treatment of Adults with Type 2 Diabetes in the Czech Republic. 2017 , 8, 1331-1347	8
1376	Noninsulin Diabetes Medications. 2017 , 52, 523-537	7
1375	[Implementation of the National Guidelines for the treatment of Diabetes mellitus type 2 in secondary diabetes centers]. 2017 , 142, e131-e139	2
1374	Long-Term Effectiveness of Liraglutide in Association with Patients' Baseline Characteristics in Real-Life Setting in Croatia: An Observational, Retrospective, Multicenter Study. 2017 , 8, 1297-1308	10
1373	Pratique de l'auto-surveillance glycémique en France : données d'une enquête nationale. 2017 , 11, 458-467	0
1372	Incretins and Their Endocrine and Metabolic Functions. 2017 , 32, 38-48	3
1371	Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes. 2017 , 10, 1303-1316	4
1370	Sitagliptin 100 mg vs glimepiride 1-3 mg as an add-on to insulin and metformin in type 2 diabetes (SWIM). 2017 , 6, 748-757	2
1369	Stroke Revisited: Diagnosis and Treatment of Ischemic Stroke. 2017 ,	3
1368	Synthesis and structure activity relationships of carbamimidoyl carbamate derivatives as novel vascular adhesion protein-1 inhibitors. 2017 , 25, 6024-6038	2
1367	Caring for older people with diabetes in primary care. 2017 , 14, 16-19	

1366	Impact of improving postprandial glycemic control with intensifying insulin therapy in type 2 diabetes. 2017 , 129, 791-800	4
1365	Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c \geq 10.0%: Two pooled analyses including 20 randomised controlled trials. 2017 , 71, e13029	3
1364	Diabetes: Predicting severe hypoglycaemia - a step forward. 2017 , 13, 692-693	
1363	The effect of care intervention for obese patients with type II diabetes. 2017 , 96, e7524	7
1362	COMPARING CLINICAL OUTCOMES AND COSTS FOR DIFFERENT TREATMENT INTENSIFICATION APPROACHES IN PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED ON BASAL INSULIN: ADDING GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS VERSUS ADDING RAPID-ACTING INSULIN OR INCREASING BASAL INSULIN DOSE. 2017 , 23, 1316-1324	5
1361	Lactate Levels with Chronic Metformin Use: A Narrative Review. 2017 , 37, 991-1007	9
1360	Safety evaluation of trelagliptin in the treatment of Japanese type 2 diabetes mellitus patients. 2017 , 16, 1313-1322	8
1359	Canagliflozin: A Review in Type 2 Diabetes. 2017 , 77, 1577-1592	21
1358	Rationale and design of the DARWIN-T2D (Dapagliflozin Real World evIdence in Type 2 Diabetes): A multicenter retrospective nationwide Italian study and crowdsourcing opportunity. 2017 , 27, 1089-1097	19
1357	Hypoglycemia awareness among insulin-treated patients with diabetes in Malaysia: A cohort subanalysis of the HAT study. 2017 , 133, 40-49	12
1356	Relation Between Different Measures of Glycemic Exposure and Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes Mellitus: An Observational Cohort Study. 2017 , 8, 1097-1109	17
1355	Bolstering your armamentarium with SGLT2 inhibitors. 2017 , 42, 28-34	1
1354	Improved Glycemic Control Achieved by Switching to Insulin Degludec in Insulin-Treated Patients with Type 2 Diabetes in a Real-World Setting: a Non-interventional, Retrospective Cohort Study. 2017 , 8, 1047-1055	5
1353	Treatment of Diabetes and Obesity by Rationally Designed Peptide Agonists Functioning at Multiple Metabolic Receptors. 2017 , 32, 165-182	9
1352	Antihyperglycemic Medications: A Claims-Based Estimate of First-line Therapy Use Prior to Initialization of Second-line Medications. <i>Diabetes Care</i> , 2017 , 40, 1500-1505	14.6 4
1351	A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes. 2017 , 16, 1399-1405	6
1350	Marine collagen peptides reduce endothelial cell injury in diabetic rats by inhibiting apoptosis and the expression of coupling factor 6 and microparticles. 2017 , 16, 3947-3957	8
1349	Incidence, Demographics, and Clinical Characteristics of Diabetes of the Exocrine Pancreas (Type 3c): A Retrospective Cohort Study. <i>Diabetes Care</i> , 2017 , 40, 1486-1493	14.6 113

1348	Diabetes Management After Stroke. 2017 , 271-283		1
1347	SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. 2017 , 60, 1862-1872		80
1346	Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes. 2017 , 8, 739-752		19
1345	Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm. <i>Diabetes Care</i> , 2017 , 40, 1121-1127	14.6	32
1344	Is It Time to Change the Type 2 Diabetes Treatment Paradigm? No! Metformin Should Remain the Foundation Therapy for Type 2 Diabetes. <i>Diabetes Care</i> , 2017 , 40, 1128-1132	14.6	21
1343	Diabetes mellitus: Complex interplay between metformin, AKI and lactic acidosis. 2017 , 13, 521-522		12
1342	Initiating insulin: How to help people with type 2 diabetes start and continue insulin successfully. 2017 , 71, e12973		21
1341	Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes. 2017 , 26, 1083-1089		10
1340	Individualising treatment and care of patients with diabetes. 2017 , 28, 23-25		2
1339	Individualisation du traitement de l'hyperglycémie du diabète de type 2 : choix selon la classe thérapeutique, ou selon la molécule: Quel poids accorder aux résultats des grandes études de sécurité cardiovasculaire exigés par la FDA ?. 2017 , 11, 2S2-2S14		
1338	Incidence and Trends in Hypoglycemia Hospitalization in Adults With Type 1 and Type 2 Diabetes in England, 1998-2013: A Retrospective Cohort Study. <i>Diabetes Care</i> , 2017 , 40, 1651-1660	14.6	35
1337	The Use of Decomposition Methods in Real-World Treatment Benefits Evaluation for Patients with Type 2 Diabetes Initiating Different Injectable Therapies: Findings from the INITIATOR Study. 2017 , 20, 1252-1259		4
1336	[Spanish adaptation of the 2016 European Guidelines on cardiovascular disease prevention in clinical practice]. 2017 , 43, 295-311		1
1335	iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents. 2017 , 33, 2187-2194		3
1334	[Combination of oral antidiabetic drugs: What fits together?]. 2017 , 159, 47-52		
1333	Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9. 2017 , 9, 890-893		8
1332	Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence. 2017 , 3, 342-351		18
1331	Experience of Home Telehealth Technology in Older Patients With Diabetes. 2017 , 35, 530-537		9

1330	Hypoglycemia After Initiation of Basal Insulin in Patients with Type 2 Diabetes in the United States: Implications for Treatment Discontinuation and Healthcare Costs and Utilization. 2017 , 34, 2083-2092		24
1329	Treatment patterns and clinical characteristics of patients with type 2 diabetes mellitus according to body mass index: findings from an electronic medical records database. 2017 , 5, e000382		11
1328	A novel free fatty acid receptor 1 (GPR40/FFAR1) agonist, MR1704, enhances glucose-dependent insulin secretion and improves glucose homeostasis in rats. 2017 , 5, e00340		9
1327	New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin. 2017 , 17, 91		11
1326	Dipeptidyl peptidase-4 inhibitors and risk of arthralgia: A systematic review and meta-analysis. 2017 , 43, 493-500		18
1325	Minimizing Glycemic Fluctuations in Patients with Type 2 Diabetes: Approaches and Importance. 2017 , 19, 498-506		37
1324	Examining Factors Associated With Nonadherence And Identifying Providers Caring For Nonadherent Subgroups. 2017 , 8, 247-253		5
1323	Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control. <i>Diabetes Care</i> , 2017 , 40, 1425-1432	14.6	160
1322	Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2017 , 40, 1469-1478	14.6	88
1321	Risk Factors for Nocturnal Hypoglycemia in Insulin-treated Patients With Type 2 Diabetes: A Secondary Analysis of Observational Data Derived From an Integrated Clinical Trial Database. 2017 , 39, 1790-1798.e7		7
1320	Self-reported hypoglycemia in insulin-treated patients with diabetes: Results from an international survey on 7289 patients from nine countries. 2017 , 134, 17-28		27
1319	A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data. 2017 , 31, 1719-1727		43
1318	Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes. 2017 , 6, 175-186		12
1317	Towards a personalized assessment of pancreatic function in diabetes. 2017 , 2, 275-285		
1316	Insulin Degludec 200 Units/mL Is Associated With Lower Injection Frequency and Improved Patient-Reported Outcomes Compared With Insulin Glargine 100 Units/mL in Patients With Type 2 Diabetes Requiring High-Dose Insulin. 2017 , 35, 90-95		11
1315	Characteristics Associated with the Choice of First Injectible Therapy Among US Patients With Type 2 Diabetes. 2017 , 39, 2399-2408		13
1314	Individualized Glycemic Goals and an Expanded Classification of Severe Hypoglycemia in Diabetes. <i>Diabetes Care</i> , 2017 , 40, 1641-1643	14.6	21
1313	Patient Preferences for Attributes of Type 2 Diabetes Mellitus Medications in Germany and Spain: An Online Discrete-Choice Experiment Survey. 2017 , 8, 1365-1378		19

1312	Optimizing Glycemic Control Through Titration of Insulin Glargine 100 U/mL: A Review of Current and Future Approaches with a Focus on Asian Populations. 2017 , 8, 1197-1214	6
1311	Use of 50/50 Premixed Insulin Analogs in Type 2 Diabetes: Systematic Review and Clinical Recommendations. 2017 , 8, 1265-1296	4
1310	Factors Associated with Type 2 Diabetes Mellitus Treatment Choice Across Four European Countries. 2017 , 39, 2296-2310.e14	11
1309	Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9). 2017 , 39, 2284-2295	7
1308	Tratamiento de los factores de riesgo cardiovascular. 2017 , 12, 2494-2502	
1307	Care of older people with diabetes. 2017 , 32, 50-63	3
1306	Practical Approaches to Diagnosing, Treating and Preventing Hypoglycemia in Diabetes. 2017 , 8, 1427-1435	8
1305	Three-year data from 5 HARMONY phase 3 clinical trials of abiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy. 2017 , 131, 49-60	16
1304	Pleiotropic effects of metformin to rescue statin-induced muscle injury and insulin resistance: A proposed mechanism and potential clinical implications. 2017 , 107, 39-44	7
1303	Visit-to-Visit Variations in Fasting Plasma Glucose and HbA Associated With an Increased Risk of Alzheimer Disease: Taiwan Diabetes Study. <i>Diabetes Care</i> , 2017 , 40, 1210-1217	14.6 46
1302	A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes. 2017 , 34, 1791-1814	15
1301	Antidiabetika bei älteren, multimorbiden Patienten. 2017 , 13, 91-99	
1300	An RCT Investigating Patient-Driven Versus Physician-Driven Titration of BIAsp 30 in Patients with Type 2 Diabetes Uncontrolled Using NPH Insulin. 2017 , 8, 767-780	3
1299	Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014. 2017 , 8, 863-873	121
1298	The Economic Burden of Insulin-Related Hypoglycemia in Spain. 2017 , 8, 899-913	16
1297	Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes. 2017 , 129, 686-697	32
1296	[Why is a combination of basal insulin with a GLP-1 receptor agonist useful in many patients with type 2 diabetes?]. 2017 , 159, 7-15	2
1295	Effectiveness of shared goal setting and decision making to achieve treatment targets in type 2 diabetes patients: A cluster-randomized trial (OPTIMAL). 2017 , 20, 1172-1180	9

1294	iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes. 2017 , 51, 990-999	7
1293	Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients. 2017 , 16, 24	31
1292	Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. 2017 , 16, 42	49
1291	Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies. 2017 , 15, 123	7
1290	Change in life expectancy with type 2 diabetes: a study using claims data from lower Saxony, Germany. 2017 , 15, 5	21
1289	Cardioprotective potential of N-acetyl cysteine against hyperglycaemia-induced oxidative damage: a protocol for a systematic review. 2017 , 6, 96	20
1288	Assessing the Therapeutic Utility of Professional Continuous Glucose Monitoring in Type 2 Diabetes Across Various Therapies: A Retrospective Evaluation. 2017 , 34, 1918-1927	17
1287	Differential Treatment Response to Insulin Intensification Therapy: A Post Hoc Analysis of a Randomized Trial Comparing Premixed and Basal-Bolus Insulin Regimens. 2017 , 8, 915-928	3
1286	Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes. 2017 , 77, 1353-1362	11
1285	Impact of Metformin Use on Lactate Kinetics in Patients with Severe Sepsis and Septic Shock. 2017 , 47, 582-587	22
1284	Integrated Diabetes Care. 2017 ,	6
1283	Hypoglycemia in patients with type 2 diabetes newly initiated on basal insulin in the US in a community setting: impact on treatment discontinuation and hospitalization. 2017 , 33, 209-214	11
1282	Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM). 2017 , 35, 375-396	19
1281	Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus. 2017 , 8, 33-53	12
1280	Essentials of SGLT2 Inhibitors in Diabetes. 2017 ,	1
1279	Non-insulin anti-diabetic drugs: An update on pharmacological interactions. 2017 , 115, 14-24	15
1278	Place of sodium-glucose cotransporter-2 inhibitors in East Asian subjects with type 2 diabetes mellitus: Insights into the management of Asian phenotype. 2017 , 31, 494-503	14
1277	Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview. 2017 , 34, 41-59	14

1276	Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective. 2017 , 39, 1012-1025	12
1275	The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies. 2017 , 18, 937-965	11
1274	Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients. 2017 , 19, 108-117	19
1273	Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials. 2017 , 19, 266-274	33
1272	Management of newly treated diabetes in Medicare beneficiaries with and without heart failure. 2017 , 40, 38-45	11
1271	Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials. 2017 , 19, 275-283	9
1270	Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes. 2017 , 13, 211-223	12
1269	Effect of Metformin Use on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. 2017 , 15, 221-229	15
1268	Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. 2017 , 33, e2818	42
1267	Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors. 2017 , 49, 51-62	13
1266	Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations. 2017 , 8, 19-28	12
1265	Controversy of oral hypoglycemic agents in type 2 diabetes mellitus: Novel move towards combination therapies. 2017 , 11 Suppl 1, S5-S13	17
1264	Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. 2017 , 19, 142-147	39
1263	Following the LEADER - why this and other recent trials signal a major paradigm shift in the management of type 2 diabetes. 2017 , 31, 517-519	6
1262	Mechanisms of diabetes mellitus-induced bone fragility. 2017 , 13, 208-219	411
1261	Glycemic control and safety in Chinese patients with type 2 diabetes mellitus who switched from premixed insulin to insulin glargine plus oral antidiabetics: a large, prospective, observational study. 2017 , 33, e2863	4
1260	Clinical inertia to insulin initiation and intensification in the UK: A focused literature review. 2017 , 11, 3-12	116
1259	Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. 2017 , 19, 228-238	46

1258	Targeting postprandial blood sugar over fasting blood sugar: A clinic based comparative study. 2017 , 11, 133-136		3
1257	Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300U/mL. 2017 , 56, 449-458		11
1256	Metformin, beyond an insulin sensitizer, targeting heart and pancreatic β cells. 2017 , 1863, 1984-1990		51
1255	Center-based patient care enhances survival of elderly patients suffering from peripheral arterial disease. 2017 , 49, 291-298		16
1254	Could metformin be used in patients with diabetes and advanced chronic kidney disease?. 2017 , 19, 156-161		4
1253	Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabetes: the real world experience. 2017 , 55, 173-178		21
1252	A Shared Decision-Making System for Diabetes Medication Choice Utilizing Electronic Health Record Data. 2017 , 21, 1280-1287		19
1251	A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. 2017 , 19, 216-227		83
1250	A real-world study of treatment patterns and outcomes in US managed-care patients with type 2 Diabetes initiating injectable therapies. 2017 , 19, 375-386		17
1249	Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice. 2017 , 794, 37-44		55
1248	Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials. 2017 , 17, 143-155		30
1247	Vildagliptin and caloric restriction for cardioprotection in pre-diabetic rats. 2017 , 232, 189-204		11
1246	A Proposal for an Out-of-Range Glycemic Population Health Safety Measure for Older Adults With Diabetes. <i>Diabetes Care</i> , 2017 , 40, 518-525	14.6	14
1245	Hypoglycemia in Frail Elderly Patients With Type 2 Diabetes Mellitus Treated With Sulfonylurea. 2017 , 11, 438-439		5
1244	A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin. 2017 , 33, e2858		21
1243	Lessons in Care: Insights Into Recent Changes in the American Diabetes Association's Clinical Practice Recommendations. 2017 , 35, 96-99		
1242	Inhibition of C1-Ten PTPase activity reduces insulin resistance through IRS-1 and AMPK pathways. 2017 , 7, 17777		6
1241	Diabetes and older people: ensuring individualised practice. 2017 , 19, 390-392		0

1240	Personalizing Type 2 Diabetes Management: Use of a Patient-Centered Approach to Individualizing A1C Goals and Pharmacological Regimens. 2017 , 35, 321-328	0
1239	If DSME Were a Pill, Would You Prescribe It?. 2017 , 30, 51-57	1
1238	Glucose-lowering drugs. 2017 , 298-322	
1237	Consommation des antidiabétiques oraux. Une étude comparative dans les cinq principaux pays européens. 2017 , 11, IIS6-IIS15	
1236	Metabolische Chirurgie zur Prävention des Typ-2-Diabetes. 2017 , 13, 403-407	
1235	Deprescribing in Older Nursing Home Patients: Focus on Innovative Composite Measures for Dosage Deintensification. 2017 , 1, igx031	7
1234	Stroke: the key risk factors. 2017 , 12, 552-559	2
1233	Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. 2017 , 357, j2499	32
1232	Provider Decisions and Patient Outcomes After Premature Metformin Discontinuation. 2017 , 30, 17-22	3
1231	A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes. 2017 , 9, 567-572	5
1230	Effects of glucose-lowering agents on ischemic stroke. 2017 , 8, 270-277	3
1229	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON TESTING FOR AUTONOMIC AND SOMATIC NERVE DYSFUNCTION. 2017 , 23, 1472-1478	9
1228	Umsetzung der Nationalen VersorgungsLeitlinie (NVL) zur Therapie des Diabetes mellitus Typ 2 in diabetologischen Schwerpunktpraxen. 2017 , 15, 257-270	0
1227	Working with patients to promote self-management. 2017 , 23, 308-312	
1226	Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus. 2017 , 10, 273-284	16
1225	Effects of Intensive Control of Glycemia on Clinical Kidney Outcomes in Type 2 Diabetes Patients Compared with Standard Control: A Meta-Analysis. 2017 , 8, 845	7
1224	Comparison of the efficacy and safety of 10-mg empagliflozin every day versus every other day in Japanese patients with Type 2 Diabetes Mellitus: a pilot trial. 2017 , 64, 50-57	1
1223	Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. 2017 , 10, 123-139	64

1222	Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy. 2017 , 12, 1-10	5
1221	Insulin Therapy for Adult Patients with Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association, 2017. 2017 , 41, 367-373	8
1220	Indexing Natural Products for Their Potential Anti-Diabetic Activity: Filtering and Mapping Discriminative Physicochemical Properties. 2017 , 22,	15
1219	Cinnamic Acid and Its Derivatives: Mechanisms for Prevention and Management of Diabetes and Its Complications. 2017 , 9,	122
1218	Hypoglycemia and Dementia. 2017 , 32, 195-199	6
1217	Isolated Compounds from Natural Products with Potential Antidiabetic Activity - A Systematic Review. 2018 , 14, 36-106	29
1216	Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management. 2017 , 8, 6	463
1215	Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial. 2017 , 41, 135-145	14
1214	Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials. 2017 , 13, 405-423	88
1213	A Novel Index Using Soluble CD36 Is Associated with the Prevalence of Type 2 Diabetes Mellitus: Comparison Study with Triglyceride-Glucose Index. 2017 , 32, 375-382	3
1212	Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus. 2017 , 41, 69-74	12
1211	Clinical Decision Support System for Diabetes Based on Ontology Reasoning and TOPSIS Analysis. 2017 , 2017, 4307508	8
1210	Effectiveness of Vildagliptin in Clinical Practice: Pooled Analysis of Three Korean Observational Studies (the VICTORY Study). 2017 , 2017, 5282343	2
1209	Diabetes Mellitus Treatment. 2017 , 288-293	3
1208	Comparative Liquid Chromatographic Study for Concurrent Determination of Canagliflozin and Metformin in Combined Tablets. 2017 , 2017, 9197230	5
1207	An International Position Statement on the Management of Frailty in Diabetes Mellitus: Summary of Recommendations 2017. 2018 , 7, 10-20	50
1206	Personalized Care and the Role of Insulin as a Vehicle to Optimizing Treatments in Diabetes Care. 2017 , 23, 1160-1168	2
1205	Economic Impact of Treatment Duration and Persistence with Basal Insulin in Previously Insulin-Naive Users. 2017 , 23, 327-336	2

1204	Determinants of Long-Term Durable Glycemic Control in New-Onset Type 2 Diabetes Mellitus. 2017 , 41, 284-295	9
1203	Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin. 2017 , 10, 317-332	7
1202	Risk factors for unstable blood glucose level: integrative review of the risk factors related to the nursing diagnosis. 2017 , 25, e2893	6
1201	Aspalathin Protects the Heart against Hyperglycemia-Induced Oxidative Damage by Up-Regulating Nrf2 Expression. 2017 , 22,	43
1200	Canagliflozin. 2017 , 349-365	
1199	Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome. 2017 , 10, 47-55	10
1198	Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists. 2017 , 10, 79-87	17
1197	Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. 2017 , 61, 188-192	16
1196	Drug-class-specific changes in the volume and cost of antidiabetic medications in Poland between 2012 and 2015. 2017 , 12, e0178764	7
1195	Exploring differences in the use of the statin choice decision aid and diabetes medication choice decision aid in primary care. 2017 , 17, 118	9
1194	The impact of cardiovascular co-morbidities and duration of diabetes on the association between microvascular function and glycaemic control. 2017 , 16, 114	20
1193	Diabetes mellitus Typ 2. 2017 ,	
1192	Insulin lispro 25/75 and insulin lispro 50/50 as starter insulin in Japanese patients with type 2 diabetes: subanalysis of the CLASSIFY randomized trial. 2017 , 64, 705-717	0
1191	Insulin therapy for adult patients with type 2 diabetes mellitus: a position statement of the Korean Diabetes Association, 2017. 2017 , 32, 967-973	4
1190	Semaglutide-the "" in the field of glucagon-like peptide-1 receptor agonists?. 2017 , 5, 475	7
1189	Diabetes mellitus and stroke: A clinical update. 2017 , 8, 235-248	64
1188	Efficacy and Safety of Insulin Glargine 300 U/mL in North Americans and Non-North Americans with Type 2 Diabetes: A Patient-Level Meta- Analysis of the EDITION 1, 2 and 3 Studies. 2017 , 09,	
1187	Highlights From the American Diabetes Association's 2017 Standards of Medical Care in Diabetes for Osteopathic Physicians. 2017 , 117, 457-472	2

1186	Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials. 2017 , 10, 111-122	19
1185	Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system. 2017 , 9, 749-762	7
1184	Association between Metformin Use and Risk of Lactic Acidosis or Elevated Lactate Concentration in Type 2 Diabetes. 2017 , 58, 312-318	11
1183	Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale. 2017 , 11, 923-937	2
1182	Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. 2017 , 11, 2905-2919	36
1181	Coronary Artery Bypass Grafting in Patients with Diabetes Mellitus: A Cardiologist's View. 2017 ,	1
1180	Comparative Effectiveness of Rapid-Acting Insulins in Adults with Diabetes. 2017 , 23, 291-298	3
1179	Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association. 2017 , 41, 337-348	38
1178	Monotherapy in Patients with Type 2 Diabetes Mellitus. 2017 , 41, 349-356	12
1177	GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. 2017 , 13, 605-628	154
1176	DPPH Radical Scavenging and Postprandial Hyperglycemia Inhibition Activities and Flavonoid Composition Analysis of Hawk Tea by UPLC-DAD and UPLC-Q/TOF MS. 2017 , 22,	11
1175	Comparative Study on Adding Pioglitazone or Sitagliptin to Patients with Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin. 2017 , 5, 955-962	3
1174	Managing problems with medications for type 2 diabetes. 2017 , 28, 148-153	
1173	Type 2 diabetes mellitus treatment habits in a specialized care setting: the START-DIAB study. 2017 , 10, 165-179	2
1172	The Role of Diet in the Prevention and Treatment of Diabetes. 2017 , 691-707	
1171	Quality of diabetes mellitus therapy in patients with chronic kidney disease in the real world. 2017 , 11, 48	
1170	Novel Pure Component Contribution Algorithm (PCCA) and UHPLC Methods for Separation and Quantification of Amlodipine, Valsartan, and Hydrochlorothiazide in Ternary Mixture. 2017 , 100, 692-699	1
1169	Treatment of type 2 diabetes mellitus in elderly patients. 2018 , 218, 74-88	3

1168	Higher mortality rate in patients with heart failure who are taking commonly prescribed antidiabetic medications and achieve recommended levels of glycaemic control. 2018 , 20, 1766-1769	2
1167	Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?. 2018 , 36, 138-147	5
1166	RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017. 2018 , 38, 1-115	57
1165	EADSG Guidelines: Insulin Therapy in Diabetes. 2018 , 9, 449-492	52
1164	Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. 2018 , 6, 370-381	137
1163	Physical activity and exercise on diabetic foot related outcomes: A systematic review. 2018 , 139, 81-90	32
1162	Real-world evaluation of Hba1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin: an analysis of electronic medical records from a network of hospitals in Florida. 2018 , 34, 1099-1115	3
1161	The safety of gliptins : updated data in 2018. 2018 , 17, 387-405	70
1160	Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period. 2018 , 34, 981-994	9
1159	Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study. 2018 , 20, 1602-1614	38
1158	Work-loss years among people diagnosed with diabetes: a reappraisal from a life course perspective. 2018 , 55, 485-491	10
1157	Clinical Benefit of Basal Insulin Analogue Treatment in Persons with Type 2 Diabetes Inadequately Controlled on Prior Insulin Therapy: A Prospective, Noninterventional, Multicenter Study. 2018 , 9, 651-662	3
1156	Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know. 2018 , 36, 174-182	3
1155	Pharmacological management of diabetes in severe mental illness: a comprehensive clinical review of efficacy, safety and tolerability. 2018 , 11, 411-424	6
1154	Impact of metformin on gastric adenocarcinoma survival: A Belgian population based study. 2018 , 53, 149-155	10
1153	Changes in metformin use and other antihyperglycemic therapies after insulin initiation in patients with type 2 diabetes. 2018 , 139, 221-229	5
1152	Study design and baseline characteristics of inpatients with diabetes mellitus in a tertiary hospital in China: A database study based on electronic medical records. 2018 , 11, 152-157	15
1151	Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification. 2018 , 35, 694-706	2

1150	Why prescribe exercise as therapy in type 2 diabetes? We have a pill for that!. 2018 , 34, e2999	14
1149	The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin. 2018 , 132, 489-507	55
1148	Pharmacokinetics of metformin in patients with gastrointestinal intolerance. 2018 , 20, 1593-1601	20
1147	Development of an Injectable Slow-Release Metformin Formulation and Evaluation of Its Potential Antitumor Effects. 2018 , 8, 3929	16
1146	Identification des rpondeurs au traitement par exhatide ou liraglutide : rultats de deux tudes en vie relle. 2018 , 12, 62-68	
1145	Do sulphonylureas still have a place in clinical practice?. 2018 , 6, 821-832	61
1144	Consenso sobre tratamiento con insulina en la diabetes tipo 2. 2018 , 65, 1-8	2
1143	Quantitative determination of metformin, saxagliptin and 5-hydroxy saxagliptin simultaneously by hydrophilic interaction liquid chromatography - electrospray ionization mass spectrometry and its application to a bioequivalence study with a single-pill combination in human. 2018 , 1081-1082, 109-117	6
1142	Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers. 2018 , 130, 381-393	17
1141	Consequences of non-medical switch among patients with type 2 diabetes. 2018 , 34, 1475-1481	3
1140	Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes: Protocol for a systematic review and meta-analysis. 2018 , 97, e0420	3
1139	Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?. 2018 , 32, 213-222	32
1138	The role of K channels in cerebral ischemic stroke and diabetes. 2018 , 39, 683-694	41
1137	Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis. 2018 , 2, 209-219	18
1136	Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes. 2018 , 36, 322-324	12
1135	Treatment of type 2 diabetes: future approaches. 2018 , 126, 123-137	11
1134	Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment. 2018 , 58, 1314-1323	41
1133	Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?. 2018 , 20, 1937-1943	3

1132	Is the management of diabetes different in dialysis patients?. 2018 , 31, 367-376	5
1131	Consensus on insulin treatment in type 2 diabetes. 2018 , 65, 1-8	
1130	SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis. 2018 , 20, 1972-1976	15
1129	Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial. 2018 , 20, 1520-1525	18
1128	Japanese Clinical Practice Guideline for Diabetes 2016. 2018 , 9, 657	136
1127	Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics. 2018 , 57, 1307-1322	6
1126	Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. 2018 , 20, 2000-2003	20
1125	Type 2 diabetes mellitus in older people: a brief statement of key principles of modern day management including the assessment of frailty. A national collaborative stakeholder initiative. 2018 , 35, 838-845	59
1124	Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes: A randomized, placebo-controlled study. 2018 , 20, 1911-1920	2
1123	Insulin Treatment. 2018 , 1-24	
1122	Metformin for non-small cell lung cancer patients: Opportunities and pitfalls. 2018 , 125, 41-47	19
1121	Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important?. 2018 , 142, 19-25	10
1120	Coronary artery disease severity modifies associations between glycemic control and both mortality and myocardial infarction. 2018 , 32, 480-487	4
1119	The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes. 2018 , 20, 1585-1592	7
1118	Relation between HbA and incident cardiovascular disease over a period of 6 years in the Hong Kong population. 2018 , 44, 415-423	1
1117	Impact of the severity of hypoglycemia on health - Related quality of life, productivity, resource use, and costs among US patients with type 2 diabetes. 2018 , 32, 451-457	13
1116	Treatment of type 2 diabetes mellitus in elderly patients. 2018 , 218, 74-88	22
1115	[Treatment of type 2 diabetes mellitus in elderly patients]. 2018 , 53, 89-99	8

1114	Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes. 2018 , 18, 343-351	7
1113	Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. <i>Diabetes Care</i> , 2018 , 41, 705-712	14.6 36
1112	Two-year trial of intermittent insulin therapy vs metformin for the preservation of β cell function after initial short-term intensive insulin induction in early type 2 diabetes. 2018 , 20, 1399-1407	16
1111	Impact of Canagliflozin Treatment on Health-Related Quality of Life among People with Type 2 Diabetes Mellitus: A Pooled Analysis of Patient-Reported Outcomes from Randomized Controlled Trials. 2018 , 11, 341-352	6
1110	Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study. 2018 , 9, 253-268	56
1109	Real-world clinical responses in patients with type 2 diabetes mellitus adding exenatide BID (EBID) or mealtime insulin to basal insulin: a retrospective study using electronic medical record data. 2018 , 34, 1045-1051	1
1108	Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment. 2018 , 9, 521-543	34
1107	Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus. 2018 , 47, 81-96	30
1106	Personalizing Glucose-Lowering Therapy in Patients with Type 2 Diabetes and Cardiovascular Disease. 2018 , 47, 137-152	6
1105	Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients : Recommendations for updated ESUR Contrast Medium Safety Committee guidelines. 2018 , 28, 2856-2869	131
1104	Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States. 2018 , 9, 565-581	10
1103	Smart Care Based on Telemonitoring and Telemedicine for Type 2 Diabetes Care: Multi-Center Randomized Controlled Trial. 2018 , 24, 604-613	17
1102	New Diabetes Medications Raise New Perioperative Concerns for the Anesthesiologist. 2018 , 126, 390-392	2
1101	No Impact of Pre-existing Cardiovascular Disease on Prescribing Patterns of Sulphonylureas in Denmark - A Registry-based Nationwide Study. 2018 , 122, 606-611	1
1100	Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials. 2018 , 20 Suppl 1, 68-76	24
1099	What have we learnt from "real world" data, observational studies and meta-analyses. 2018 , 20 Suppl 1, 47-58	32
1098	Temporal changes in glycaemic thresholds for treatment intensification in type 2 diabetes in an urban Australian setting: the Fremantle Diabetes Study. 2018 , 48, 1215-1221	
1097	Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment. 2018 , 34, 995-1003	30

1096	Metformin-induced anticancer activities: recent insights. 2018 , 399, 321-335	38
1095	Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs. 2018 , 254, 291-296	23
1094	Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: A European analysis of over 60 million glucose tests. 2018 , 137, 37-46	116
1093	Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of a phase 3 randomized clinical trial. 2018 , 9, 840-849	5
1092	Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study. 2018 , 35, 243-253	12
1091	Normalizing fibromyalgia as a chronic illness. 2018 , 130, 9-18	20
1090	Switching basal insulins in type 2 diabetes: practical recommendations for health care providers. 2018 , 130, 229-238	4
1089	Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial. 2018 , 20, 1202-1212	49
1088	Association of hypoglycaemia severity with clinical, patient-reported and economic outcomes in US patients with type 2 diabetes using basal insulin. 2018 , 20, 1156-1165	9
1087	Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study. 2018 , 35, 43-55	19
1086	Characteristics of Elderly Patients Initiating Sitagliptin or Non-DPP-4-Inhibitor Oral Antihyperglycemic Agents: Analysis of a Cross-Sectional US Claims Database. 2018 , 9, 309-315	5
1085	Investigation of in vitro genotoxic effects of an anti-diabetic drug sitagliptin. 2018 , 112, 235-241	11
1084	Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: A meta-analysis. 2018 , 137, 137-148	63
1083	Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. <i>Diabetes Care</i> , 2018 , 41, 596-603	14.6 44
1082	When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy. 2018 , 34, e2981	12
1081	Changes in patient characteristics, glucose lowering treatment, glycemic control and complications in type 2 diabetes in general practices (Disease Analyzer, Germany: 2008-2016). 2018 , 130, 244-250	6
1080	Rationale and Design for the J-DISCOVER Study: DISCOVERing the Treatment Reality of Type 2 Diabetes in a Real-World Setting in Japan-A Protocol. 2018 , 9, 165-175	16
1079	Effects of nutrition therapy on HbA1c and cardiovascular disease risk factors in overweight and obese patients with type 2 diabetes. 2018 , 17, 42	19

1078	Factors Influencing the Prescribing Preferences of Physicians for Drug-Naive Patients with Type 2 Diabetes Mellitus in the Real-World Setting in Japan: Insight from a Web Survey. 2018 , 9, 1185-1199	9
1077	Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials. 2018 , 20, 2291-2297	20
1076	Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia. 2018 , 9, 1201-1216	7
1075	Hypoglycemia. 2018 , 506-530	
1074	The Economic Burden of Insulin-Related Hypoglycemia in Adults with Diabetes: An Analysis from the Perspective of the Italian Healthcare System. 2018 , 9, 1037-1047	8
1073	Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3). 2018 , 6, e000464	13
1072	A qualitative study exploring patients' experiences regarding insulin pump use. 2018 , 26, 487-495	6
1071	Treatment with Oral Drugs. 2018 , 1-44	
1070	Dyspnoe bei Diabetes und Herzinsuffizienz. 2018 , 14, 36-43	1
1069	A review of the new GLP-1 receptor agonist/basal insulin fixed-ratio combination products. 2018 , 9, 69-79	14
1068	Bioequivalence of Dapagliflozin/Metformin Extended-release Fixed-combination Drug Product and Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Russian Subjects. 2018 , 40, 550-561.e3	7
1067	A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects. 2018 , 35, 531-544	7
1066	Similar Efficacy and Safety of Basaglar and Lantus in Patients with Type 2 Diabetes in Age Groups (. 2018 , 9, 827-837	3
1065	Comparison of non-insulin antidiabetic agents as an add-on drug to insulin therapy in type 2 diabetes: a network meta-analysis. 2018 , 8, 4095	5
1064	Glycaemic control and treatment of type 2 diabetes in adults aged 75 years or older. 2018 , 72, e13075	5
1063	Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study. 2018 , 9, 789-801	21
1062	Dipeptidyl peptidase-4 inhibitors as preferable oral hypoglycemic agents in terms of treatment satisfaction: Results from a multicenter, 12-week, open label, randomized controlled study in Japan (PREFERENCE 4 study). 2018 , 9, 137-145	11
1061	Different insulin concentrations in resuspended vs. unsuspended NPH insulin: Practical aspects of subcutaneous injection in patients with diabetes. 2018 , 44, 368-372	2

1060	Insights Into the Current Management of Older Adults With Type 2 Diabetes in the Ontario Primary Care Setting. 2018 , 42, 23-30	12
1059	Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy: Review of current strategies. 2018 , 10, 94-111	12
1058	Severe hypoglycaemia among patients with type 2 diabetes requiring emergency hospital admission: The Hypoglycaemia In Portugal Observational Study-Emergency Room (HIPOS-ER). 2018 , 20, 50-59	11
1057	Therapeutic inertia in patients treated with two or more antidiabetics in primary care: Factors predicting intensification of treatment. 2018 , 20, 103-112	38
1056	Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit. 2018 , 12, 45-50	26
1055	Our First 825 T2DM Patients on 14-Day Factory-Calibrated Glucose Monitoring System: Clinical Utility and Challenges. 2018 , 12, 230-231	3
1054	Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial. 2018 , 20, 200-205	9
1053	Therapeutic application of GPR119 ligands in metabolic disorders. 2018 , 20, 257-269	29
1052	The Real-Life Effectiveness and Care Patterns of Type 2 Diabetes Management in Greece. 2018 , 126, 53-60	8
1051	Glycaemic outcomes of an Individualized treatment approach for older vulnerable patients: A randomized, controlled study in type 2 diabetes Mellitus (IMPERIUM). 2018 , 20, 148-156	7
1050	Diabetic Kidney Disease. 2018 , 13, 335-338	16
1049	Treatment satisfaction with ITCA 650, a novel drug-device delivering continuous exenatide, versus twice-daily injections of exenatide in type 2 diabetics using metformin. 2018 , 20, 638-645	4
1048	Effectiveness of certified diabetes educators following pre-approved protocols to redesign diabetes care delivery in primary care: Results of the REMEDIES 4D trial. 2018 , 64, 201-209	8
1047	Registered nurses' knowledge of medical care for older adults with diabetes in long-term care facilities in Taiwan. 2018 , 25, 271-275	1
1046	HbA variability and hypoglycemia hospitalization in adults with type 1 and type 2 diabetes: A nested case-control study. 2018 , 32, 203-209	17
1045	Identifying insulin treatment responders with a composite measure: beyond Hba1c . 2018 , 34, 329-336	2
1044	Effects of dosage and dosing frequency on the efficacy and safety of high-dose metformin in Japanese patients with type 2 diabetes mellitus. 2017 , 9, 587	21
1043	Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons. 2018 , 20, 508-519	25

1042	Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes. 2018 , 78, 141-154	28
1041	Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes. 2018 , 34, 313-318	5
1040	Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study. 2018 , 196, 18-27	13
1039	Clinical considerations for use of insulin degludec/insulin aspart in Japanese patients. 2018 , 18, 77-85	
1038	Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial. 2018 , 9, 831-839	3
1037	Real-world comparison of treatment patterns and effectiveness of albiglutide and liraglutide. 2018 , 7, 89-100	1
1036	Biphasic insulin aspart-30 reduces glycemic variability to a greater degree than insulin detemir: A randomized controlled trial of once-daily insulin regimens using continuous glucose monitoring. 2017 , 9, 573	2
1035	Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes. 2018 , 20, 541-548	56
1034	Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach. 2018 , 20, 497-507	22
1033	Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy. 2018 , 34, 1-10	9
1032	Associations of Residential Socioeconomic, Food, and Built Environments With Glycemic Control in Persons With Diabetes in New York City From 2007-2013. 2018 , 187, 736-745	23
1031	Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: Subgroup analysis of a randomized clinical trial. 2017 , 9, 579	8
1030	Initiation of Basal Insulin Analog Treatment for Type 2 Diabetes and Reasons Behind Patients' Treatment Persistence Behavior: Real-World Data from Germany. 2018 , 126, 287-297	3
1029	Postprandial glucose and healthcare resource use: a cross-sectional survey of adults with diabetes treated with basal-bolus insulin. 2018 , 21, 66-73	9
1028	Pharmacotherapy of type 2 diabetes: An update. 2018 , 78, 13-42	103
1027	Incidence rate and patient characteristics of severe hypoglycemia in treated type 2 diabetes mellitus patients in Japan: Retrospective Diagnosis Procedure Combination database analysis. 2018 , 9, 925-936	16
1026	Spanish consensus on treat to target for osteoporosis. 2018 , 29, 489-499	12
1025	Does insulin therapy matter? Determinants of diabetes care outcomes. 2018 , 12, 224-230	3

1024	Concordance with prescribing information dosage recommendations for dipeptidyl-peptidase-4 inhibitors among type 2 diabetes mellitus patients with moderate to severe chronic kidney disease. 2018 , 34, 1021-1027		5
1023	Control of cardiovascular disease risk factors among patients with type II diabetes in a primary-care setting in Beijing. 2018 , 12, 128-134		2
1022	An Indirect Comparison of Changes in the Impact of Weight on Quality of Life Among Subjects with Type 2 Diabetes Treated with Antihyperglycemic Agents in Dual Therapy with Metformin. 2018 , 9, 125-140		
1021	Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. <i>Diabetes Care</i> , 2018 , 41, 258-266	14.6	208
1020	Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial. <i>Diabetes Care</i> , 2018 , 41, 333-340	14.6	30
1019	The nutritional supplement FFD-002 attenuates streptozotocin-induced diabetes and decelerates diabetes-related tissue injury. 2018 , 42, e12486		0
1018	An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin. 2018 , 21, 340-347		14
1017	4. Lifestyle Management:.. <i>Diabetes Care</i> , 2018 , 41, S38-S50	14.6	391
1016	6. Glycemic Targets:.. <i>Diabetes Care</i> , 2018 , 41, S55-S64	14.6	590
1015	8. Pharmacologic Approaches to Glycemic Treatment:.. <i>Diabetes Care</i> , 2018 , 41, S73-S85	14.6	551
1014	Leukocyte telomere length correlates with glucose control in adults with recently diagnosed type 2 diabetes. 2018 , 135, 30-36		13
1013	Primary care physician perspectives on basal insulin initiation and maintenance in patients with type 2 diabetes mellitus. 2018 , 12, 155-162		7
1012	INSULIN GLARGINE 300 U/ML IS ASSOCIATED WITH LESS WEIGHT GAIN WHILE MAINTAINING GLYCEMIC CONTROL AND LOW RISK OF HYPOGLYCEMIA COMPARED WITH INSULIN GLARGINE 100 U/ML IN AN AGING POPULATION WITH TYPE 2 DIABETES. 2018 , 24, 143-149		10
1011	Comparison of medication adherence and persistence in type 2 diabetes: A systematic review and meta-analysis. 2018 , 20, 1040-1043		56
1010	Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind, placebo-controlled trial. 2018 , 20, 1044-1049		7
1009	Baseline factors associated with better response to insulin lispro low mixture or insulin glargine: A post hoc analysis of the DURABLE study. 2018 , 135, 134-142		
1008	Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database. 2018 , 20, 831-839		11
1007	Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus. 2018 , 9, 27-36		5

1006	Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. 2018 , 20, 344-351	124
1005	Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New. 2018 , 42, 325-334	10
1004	Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future. 2018 , 48, 52-108	46
1003	Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c. 2018 , 20, 409-418	36
1002	Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. 2018 , 20, 378-388	48
1001	Regarding Insulin Initiation in Type 2 Diabetes Mellitus and the Risk for Hypoglycemia. 2018 , 42, 221	1
1000	Postoperative euglycaemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitors (gliflozins): a report of two cases and review of the literature. 2018 , 46, 215-219	15
999	Biochemical Markers Present in a Population Susceptible to Suffering From Metabolic Syndrome. 2018 , 10, 85	
998	Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: A system review and meta-analysis. 2018 , 97, e12633	9
997	Keeping up-to-date with diabetes care and education. 2018 , 48, 22-29	1
996	Impact of pharmacotherapeutic education on medication adherence and adverse outcomes in patients with type 2 diabetes mellitus: a prospective, randomized study. 2018 , 59, 290-297	6
995	Fresh Bitter Melon Fruit (<i>Momordica charantia</i>) Attenuated Oxidative Stress, Fibrosis and Renal Injury in Carbon Tetrachloride Treated Rats. 2018 , 16, 205-214	2
994	Prevençã en diabetes mellitus y riesgo cardiovascular: enfoque mđico y nutricional. 2018 , 66, 459-468	2
993	La bithřapie antidiabřique orale en pratique mđicale courante en Afrique subsaharienne : rřultats dřune řtude observationnelle multicentrique sur six mois. 2018 , 12, 306-312	2
992	A systematic review comparing the evidence for kidney function outcomes between oral antidiabetic drugs for type 2 diabetes. 2018 , 3, 74	3
991	Monotherapy in Type 2 Diabetes Mellitus Patients 2017: A Position Statement of the Korean Diabetes Association. 2018 , 19, 15	1
990	Goal Attainment Rate for Parameters of Metabolic Adjustment in Elderly Patients with Type 2 Diabetes Taking a Hypoglycemic Agent. 2018 , 19, 58	0
989	Canagliflozin in the Diabetic-Obese and Poorly Controlled. 2018 , 08,	

988	Reduktion des kardiovaskulären Risikos. 2018 , 18, 43-47	
987	Dynamic Treatment Regimes. 2018 , 1-5	
986	Overview of the burden of illness and the role of once-weekly glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes. 2018 , 30, S4-S11	0
985	Diabetes and cognitive decline: Extra care required. 2018 , 29, 76-82	
984	Myotonic Dystrophy. 2018 ,	1
983	A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes. 2018 , 2018, 2791584	1
982	Management of bone and metabolic effects of androgen deprivation therapy. 2021 , 39, 704-712	7
981	Safety and efficacy of Momordica charantia Linnaeus in pre-diabetes and type 2 diabetes mellitus patients: a systematic review and meta-analysis protocol. 2018 , 7, 192	3
980	Calorie Restriction Mimetics: Upstream-Type Compounds for Modulating Glucose Metabolism. 2018 , 10,	38
979	Type-2 diabetes mellitus and cardiovascular disease. 2018 , 14, 491-509	87
978	Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes: a systematic review and network meta-analysis study protocol. 2018 , 8, e023206	4
977	Expert Opinion: Patient Selection for Premixed Insulin Formulations in Diabetes Care. 2018 , 9, 2185-2199	14
976	Glucose Intolerance in Myotonic Dystrophy. 2018 , 149-159	
975	[Use of dipeptidyl peptidase-4 inhibitors in patients with diabetes]. 2018 , 44 Suppl 1, 10-17	
974	THE EFFICACY AND SAFETY OF CO-ADMINISTRATION OF SITAGLIPTIN WITH METFORMIN IN PATIENTS WITH TYPE 2 DIABETES AT HOSPITAL DISCHARGE. 2018 , 24, 556-564	9
973	Comparison of HBA1c Goals Proposed by an Algorithm To Those Set By Different Members of Healthcare Teams Within the Dartmouth Hitchcock Health System. 2018 , 24, 705-709	2
972	Informed shared decision-making programme for patients with type 2 diabetes in primary care: cluster randomised controlled trial. 2018 , 8, e024004	7
971	A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus. 2018 , 146, 240-250	14

970 [Recommendations of the main clinical practice guidelines]. **2018**, 44 Suppl 1, 3-9

969 Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. **2018**, 363, k4880 23

968 Factors associated with choice of intensification treatment for type 2 diabetes after metformin monotherapy: a cohort study in UK primary care. **2018**, 10, 1639-1648 5

967 Clinical and Investigative Endocrinology and Diabetes. **2018**, 24 Suppl 2, 1-22 0

966 Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). **2018**, 17, 150 73

965 Treatment choice, medication adherence and glycemic efficacy in people with type 2 diabetes: a UK clinical practice database study. **2018**, 6, e000512 22

964 Health Literacy and Adults With Low Basic Skills. **2018**, 68, 297-315 7

963 Clinical inertia in basal insulin-treated patients with type 2 diabetes - Results from a retrospective database study in Japan (JDDM 43). **2018**, 13, e0198160 11

962 Development of an HPLC-MS/MS method to determine janagliflozin in human plasma and urine: application in clinical study. **2018**, 10, 1439-1454 2

961 Cardiovascular Outcomes Trials Update: Insights from the DEVOTE Trial. **2018**, 18, 102 6

960 SGLT-2 Inhibitors and DPP-4 Inhibitors as Second-Line Drugs in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Clinical Trials. **2018**, 50, 768-777 7

959 [LY2963016 insulin glargine: The first biosimilar insulin approved in the European Union]. **2018**, 47, 854-866 1

958 Association of metformin administration with gut microbiome dysbiosis in healthy volunteers. **2018**, 13, e0204317 60

957 The Trend of High-Dose Insulin Usage Among Patients with Diabetes in the UK: A Retrospective Study. **2018**, 9, 2245-2257 11

956 Effect of high-flow high-volume-intermittent hemodiafiltration on metformin-associated lactic acidosis with circulatory failure: a case report. **2018**, 12, 280 6

955 Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). **2018**, 61, 2461-2498 656

954 Risk of Serious Trauma with Glucose-Lowering Drugs in Older Persons: A Nested Case-Control Study. **2018**, 66, 2086-2091 2

953 mHealth for diabetes self-management in the Kingdom of Saudi Arabia: barriers and solutions. **2018**, 11, 535-546 6

952	Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study. 2018 , 1, e00036	18
951	Enquête sur la prise en charge des patients diabétiques de type 2 par les médecins généralistes en Bourgogne. Implications pour l'enseignement post-universitaire. 2018 , 12, 520-526	
950	Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease - Implications for Clinical Practice. 2018 , 14, 40-49	9
949	Le traitement du diabète de type 2 en France est dynamique plutôt qu'îlot : analyse des prescriptions de 847 122 patients. 2018 , 12, 346-352	3
948	Automatic processing of Electronic Medical Records using Deep Learning. 2018 ,	3
947	Mechanisms of Drug-Induced Cardiovascular Toxicity: Cardiotoxicity Associated With Diabetes Medications. 2018 , 419-431	
946	[Who will kick off the digital transformation of health?]. 2018 , 34, 587-589	0
945	Diabetes and Atherosclerosis: Old Players in a New Field, Osteoporosis. 2018 , 16, 524-527	9
944	Effects of exenatide versus insulin glargine on body composition in overweight and obese T2DM patients: a randomized controlled trial. 2018 , 15, 67	6
943	Treatment with Oral Drugs. 2018 , 527-569	
942	Stacked classifiers for individualized prediction of glycemic control following initiation of metformin therapy in type 2 diabetes. 2018 , 103, 109-115	11
941	The effects of 12-month administration of tofogliflozin on electrolytes and dehydration in mainly elderly Japanese patients with type 2 diabetes mellitus. 2018 , 46, 5117-5126	3
940	Modern Sulfonylureas Strike Back - Exploring the Freedom of Flexibility. 2018 , 14, 20-22	1
939	Preclinical discovery and development of colesevelam for the treatment of type 2 diabetes. 2018 , 13, 1161-1167	5
938	Metformin use is associated with a low risk of tuberculosis among newly diagnosed diabetes mellitus patients with normal renal function: A nationwide cohort study with validated diagnostic criteria. 2018 , 13, e0205807	21
937	Effect of different methods for estimating persistence and adherence to new glucose-lowering drugs: results of an observational, inception cohort study in Portugal. 2018 , 12, 1471-1482	4
936	[Bone and metabolism]. 2018 , 79 Suppl 1, S40-S47	1
935	Risk of hypoglycaemia in people aged \geq 65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus. 2018 , 72, e13240	5

934	Improved Treatment Engagement Among Patients with Diabetes Treated with Insulin Glargine 300 U/mL Who Participated in the COACH Support Program. 2018 , 9, 2143-2153	5
933	Second-Generation Insulin Analogues - a Review of Recent Real-World Data and Forthcoming Head-to-Head Comparisons. 2018 , 14, 2-9	17
932	The "A to Z" of Managing Type 2 Diabetes in Culturally Diverse Populations. 2018 , 9, 479	14
931	Predictive factors of efficacy of combination therapy with basal insulin and liraglutide in type 2 diabetes when switched from longstanding basal-bolus insulin: Association between the responses of β and β cells to GLP-1 stimulation and the glycaemic control at 6 months after switching	4
930	Twice-daily insulin degludec/insulin aspart effectively improved morning and evening glucose levels and quality of life in patients previously treated with premixed insulin: an observational study. 2018 , 10, 64	7
929	Characterization of changes in HbA1c in patients with and without secondary failure after metformin treatments by a population pharmacodynamic analysis using mixture models. 2018 , 33, 264-269	1
928	Sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes in North India: A 12-month prospective study in real-world setting. 2018 , 72, e13237	6
927	Predictors of glycemic control in type-2 diabetes mellitus: Evidence from a multicenter study in Ghana. 2018 , 1, 1-8	12
926	2018 Standards of Care Update: Pharmacologic Approaches to Glycemic Management in People With Type 2 Diabetes. 2018 , 31, 254-260	3
925	Periodontal complications of hyperglycemia/diabetes mellitus: Epidemiologic complexity and clinical challenge. 2018 , 78, 59-97	76
924	iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes. 2018 , 31, 145-154	15
923	Gastric Emptying and the Personalized Management of Type 1 Diabetes. 2018 , 103, 3503-3506	4
922	Association of Patient Profile with Glycemic Control and Hypoglycemia with Insulin Glargine 300 U/mL in Type 2 Diabetes: A Post Hoc Patient-Level Meta-Analysis. 2018 , 9, 2043-2053	6
921	Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis. 2018 , 13, e0202563	8
920	Neuroprotective exendin-4 enhances hypothermia therapy in a model of hypoxic-ischaemic encephalopathy. 2018 , 141, 2925-2942	17
919	Metformin in cancer. 2018 , 143, 409-419	122
918	European Medicines Agency: Approval of new glucose-lowering medicines for type 2 diabetes. 2018 , 20, 2057-2058	
917	Initial combination therapy with vildagliptin plus metformin in drug-naïve patients with T2DM: a 24-week real-life study from Asia. 2018 , 34, 1605-1611	5

916	Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial. 2018 , 20, 2200-2209	23
915	Effect of short-term treatment with sitagliptin or glibenclamide on daily glucose fluctuation in drug-naïve Japanese patients with type 2 diabetes mellitus. 2018 , 20, 2274-2281	4
914	Diabetes del paciente anciano. 2018 , 22, 1-8	
913	Discovery of potent α-glucosidase inhibitor flavonols: Insights into mechanism of action through inhibition kinetics and docking simulations. 2018 , 79, 257-264	48
912	Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?. 2018 , 19, 773-777	4
911	The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting. 2018 , 20, 2371-2378	12
910	Effectiveness of a computerised system of patient education in clinical practice: a longitudinal nested cohort study. 2018 , 8, e020621	3
909	Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations. 2018 , 35, 939-965	7
908	Fatal Case of Metformin-Associated Lactic Acidosis Associated With Temporary Ileostomy: A Case Report. 2018 , 45, 364-365	1
907	Metformin use in the first year after kidney transplant, correlates, and associated outcomes in diabetic transplant recipients: A retrospective analysis of integrated registry and pharmacy claims data. 2018 , 32, e13302	13
906	Diabetes and Hyperglycemia in Lower-Extremity Total Joint Arthroplasty: Clinical Epidemiology, Outcomes, and Management. 2018 , 6, e10	6
905	Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study. 2018 , 9, 1477-1490	8
904	Antidiabetic Drugs (A10). 2018 , 1-37	0
903	Persistence et durabilité de l'efficacité du liraglutide : au-delà des études randomisées. 2018 , 12, 279-283	
902	Systematic review and meta-analysis of the effect of SGLT-2 inhibitors on microvascular outcomes in patients with type 2 diabetes: a review protocol. 2018 , 8, e020692	3
901	Women with Type 1 Diabetes Mellitus: Effect of Disease and Psychosocial-Related Correlates on Health-Related Quality of Life. 2018 , 2018, 4079087	7
900	2020 vision - An overview of prospects for diabetes management and prevention in the next decade. 2018 , 143, 101-112	22
899	Calendar time as an instrumental variable in assessing the risk of heart failure with antihyperglycemic drugs. 2018 , 27, 857-866	6

898	Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons. 2018 , 9, 1491-1500	7
897	Empagliflozin: A Review in Type 2 Diabetes. 2018 , 78, 1037-1048	40
896	HbA1c presents low sensitivity as a post-pregnancy screening test for both diabetes and prediabetes in Greek women with history of gestational diabetes mellitus. 2018 , 17, 255-259	4
895	Discovery of a potent glucokinase activator with a favorable liver and pancreas distribution pattern for the treatment of type 2 diabetes mellitus. 2018 , 156, 269-294	17
894	A path model linking health literacy, medication self-efficacy, medication adherence, and glycemic control. 2018 , 101, 1906-1913	29
893	Efficacy and Renal Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Also Receiving Metformin: A Real-Life Experience. 2018 , 2018, 8501418	2
892	Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulin-naive individuals with type 2 diabetes mellitus. 2018 , 20, 2894-2898	2
891	Evolution of Glucose-Lowering Drugs for Type 2 Diabetes. 2018 , 431-454	2
890	The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents. 2018 , 143, 1-14	28
889	Efficacy of iGlarLixi, a fixed-ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements. 2018 , 20, 2680-2684	4
888	Diabetic Foot. 2018 , 1-22	
887	Management Strategies for Posttransplant Diabetes Mellitus after Heart Transplantation: A Review. 2018 , 2018, 1025893	13
886	Agonism of receptors in the gut-pancreas axis in type 2 diabetes: are two better than one?. 2018 , 391, 2577-2578	4
885	Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes. 2018 , 52, 1224-1232	3
884	Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis. 2018 , 168, 170-178	19
883	Diagnosis and management of bone fragility in diabetes: an emerging challenge. 2018 , 29, 2585-2596	141
882	Association of metformin use with vitamin B deficiency in the institutionalized elderly. 2018 , 79, 57-62	10
881	Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial. <i>Diabetes Care</i> , 2018 , 41, 2136-2146	14.6 51

880	Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2018 , 9, 576		18
879	Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea. 2018 , 48, 395-405		6
878	Insulin Monotherapy Versus Insulin Combined with Other Glucose-Lowering Agents in Type 2 Diabetes: A Narrative Review. 2018 , 16, e65600		13
877	In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER. 2018 , 168, JC46		
876	Valsartan prevents glycerol-induced acute kidney injury in male albino rats by downregulating TLR4 and NF- κ B expression. 2018 , 119, 565-571		12
875	Lack of coordination between partners: investigation of Physician-Preferred and Patient-Preferred (4P) basal insulin titration algorithms in the real world. 2018 , 12, 1253-1259		3
874	GOAL study: clinical and non-clinical predictive factors for achieving glycemic control in people with type 2 diabetes in real clinical practice. 2018 , 6, e000519		17
873	Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series. 2018 , 13, 156-160		13
872	Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. 2018 , 169, 165-174		27
871	Association of health literacy and medication self-efficacy with medication adherence and diabetes control. 2018 , 12, 793-802		28
870	A Population-Based Study of the Bidirectional Association Between Obstructive Sleep Apnea and Type 2 Diabetes in Three Prospective U.S. Cohorts. <i>Diabetes Care</i> , 2018 , 41, 2111-2119	14.6	48
869	Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. <i>Diabetes Care</i> , 2018 , 41, 1844-1853	14.6	43
868	Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients. 2018 , 9, 1030		21
867	Should Metformin Remain First-Line Medical Therapy for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease? An Alternative Approach. 2018 , 18, 64		19
866	Predictors and Clinical Outcomes of Treatment Intensification in Patients With Type 2 Diabetes Uncontrolled on Basal Insulin in a Real-World Setting. 2018 , 24, 805-814		5
865	HbA1c method performance: The great success story of global standardization. 2018 , 55, 408-419		18
864	Decreasing incidence of pharmacologically and non-pharmacologically treated type 2 diabetes in Norway: a nationwide study. 2018 , 61, 2310-2318		26
863	Real-world clinical experience of Xultophy in the management of patients with type 2 diabetes in a secondary care clinic. 2018 , 12, 1079-1082		4

862	Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. 2018 , 16, 116	28
861	Metformin use during pregnancy: Is it really safe?. 2018 , 10, 984-985	1
860	Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild-to-moderate renal impairment. 2018 , 20, 2860-2868	15
859	Mechanisms of beneficial effects of metformin on fatty acid-treated human islets. 2018 , 61, 91-99	12
858	Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials. 2018 , 21, 222-235	19
857	A genetic perspective of Metformin induced Vitamin B12 deficiency in Type 2 Diabetes mellitus patients. 2018 , 9, 11-14	2
856	Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes. 2018 , 18, 78	13
855	A utility valuation study assessing the impact of postprandial glucose control on quality of life of individuals with type 1 or type 2 diabetes. 2017 , 2, 20	1
854	Regression modeling strategy for prediction of AUC of evogliptin, a novel dipeptidyl peptidase IV inhibitor in humans, using single dose PK data. 2018 , 3, 23-38	
853	Japanese Clinical Practice Guideline for Diabetes 2016. 2018 , 9, 1-45	114
852	Why, when and how to use insulin in type 2 diabetes mellitus. 2018 , 2018, 23-26	0
851	Does hypoglycaemia affect the improvement in QoL after the transition to insulin in people with type 2 diabetes?. 2018 , 41, 249-258	6
850	Individualised treatment targets in patients with type-2 diabetes and hypertension. 2018 , 17, 18	13
849	Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study. 2018 , 17, 20	28
848	DMTO: a realistic ontology for standard diabetes mellitus treatment. 2018 , 9, 8	35
847	Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006-2014. 2018 , 2, 393-402	11
846	Efficacy and safety of sodium-glucose cotransporter 2 inhibitors as add-on to metformin and sulfonylurea treatment for the management of type 2 diabetes: a meta-analysis. 2018 , 65, 335-344	13
845	Study Protocol for the Initial Choice of DPP-4 Inhibitor in Japanese Patients with Type 2 diabetes Mellitus: Effect of Linagliptin on QOL (INTEL-QOL) Trial. 2018 , 9, 1403-1412	3

844	Effects of linagliptin versus voglibose on treatment-related quality of life in patients with type 2 diabetes: sub-analysis of the L-STEP study. 2018 , 65, 657-668		2
843	Characteristics of insulin-Naïve people with type 2 diabetes who successfully respond to insulin glargine U100 after 24 weeks of treatment: a meta-analysis of individual participant data from 3 randomized clinical trials. 2018 , 4, 10		4
842	Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017. 2018 , 20, 2159-2168		38
841	Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-Analysis. 2018 , 9, 1945-1958		13
840	Current Level of Glycemic Control and Clinical Inertia in Subjects Using Insulin for the Treatment of Type 1 and Type 2 Diabetes in the Czech Republic and the Slovak Republic: Results of a Multinational, Multicenter, Observational Survey (DIAINFORM). 2018 , 9, 1897-1906		16
839	Metabolic Syndrome. 2018 , 1-37		
838	Male Patients with Longstanding Type 2 Diabetes Have a Higher Incidence of Hypoglycemia Compared with Female Patients. 2018 , 9, 1969-1977		5
837	Cardiac Autonomic Neuropathy in Diabetes: A Predictor of Cardiometabolic Events. 2018 , 12, 591		49
836	Development of a model to predict 5-year risk of severe hypoglycemia in patients with type 2 diabetes. 2018 , 6, e000527		11
835	A Comparison of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline and the 2017 American Diabetes Association Diabetes and Hypertension Position Statement for U.S. Adults With Diabetes. <i>Diabetes Care</i> , 2018 , 41, 2322-2329	14.6	26
834	The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis. 2018 , 62, 535-545		9
833	Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. 2018 , 379, 633-644		518
832	Approaches to rapid acting insulin intensification in patients with type 2 diabetes mellitus not achieving glycemic targets. 2018 , 50, 453-460		
831	Anti-inflammatory Action of Metformin with Respect to CX3CL1/CX3CR1 Signaling in Human Placental Circulation in Normal-Glucose Versus High-Glucose Environments. 2018 , 41, 2246-2264		4
830	Adjuvant Pharmacotherapies to Insulin for the Treatment of Type 1 Diabetes. 2018 , 18, 79		7
829	Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement. 2018 , 12, 707-719		37
828	Could vagus nerve stimulation have a role in the treatment of diabetes?. 2018 , 1, 13-15		4
827	GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES: A COMPREHENSIVE REVIEW OF HOW TO WEIGH THE OPTIONS, SELECT THE RIGHT PATIENTS, AND MAXIMIZE BENEFITS. 2018 ,		

826	Diabetes Management and Healthcare Resource Use When Intensifying from Basal Insulin to Basal-Bolus: A Survey of Type 2 Diabetes Patients. 2018 , 9, 1931-1944	6
825	Effects of Insulin Treatment with Glargine or Premixed Insulin Lispro Programs in Type 2 Diabetes Mellitus Patients: A Meta-analysis of Randomized Clinical Trials. 2018 , 20, 622-627	7
824	Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function: A Community-Based Cohort Study. 2018 , 178, 903-910	81
823	Diabetes and the Cardiovascular System. 2018 , 1-29	
822	Contribution of basal and postprandial hyperglycaemia in type 2 diabetes patients treated by an intensified insulin regimen: Impact of pump therapy in the OPT2mise trial. 2018 , 20, 2435-2441	3
821	The value of fast-acting insulin aspart compared with insulin aspart for patients with diabetes mellitus treated with bolus insulin from a UK health care system perspective. 2018 , 9, 187-197	4
820	Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies. 2018 , 44, 386-392	19
819	Reduced Glucose Variability With Glucose-Dependent Versus Glucose-Independent Therapies Despite Similar Glucose Control and Hypoglycemia Rates in a Randomized, Controlled Study of Older Patients With Type 2 Diabetes Mellitus. 2018 , 12, 1184-1191	2
818	Type 1 diabetes. 2018 , 391, 2449-2462	384
817	Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes. 2018 , 13, e0191953	8
816	The relationship between intensification of blood glucose-lowering therapies, health status and quality of life in type 2 diabetes: The Fremantle Diabetes Study Phase II. 2018 , 142, 294-302	5
815	Les quelques années qui ont bouleversé le paysage du diabète de type 2 : les grandes études, les nouveaux traitements 2018 , 12, 133-137	1
814	Glycaemic impact of treatment intensification in patients with type 2 diabetes uncontrolled with oral antidiabetes drugs or basal insulin. 2018 , 1, e00019	1
813	Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes. 2019 , 43, 136-145	26
812	Effectiveness and safety of empagliflozin-based quadruple therapy compared with insulin glargine-based therapy in patients with inadequately controlled type 2 diabetes: An observational study in clinical practice. 2019 , 21, 173-177	13
811	Effects of Metformin on Cellular Proliferation and Steroid Hormone Receptors in Patient-Derived, Low-Grade Endometrial Cancer Cell Lines. 2019 , 26, 609-618	7
810	Combination urate-lowering therapy in the treatment of gout: What is the evidence?. 2019 , 48, 658-668	8
809	Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial. 2019 , 10, 399-407	50

808	Oral Pharmacotherapy as Alternative Treatment for Type 2 Diabetes Mellitus in a 61 Year Old Ethnic Filipino Man with Insulin Allergies. 2019 , 50, 93-95		1
807	Development of a self-efficacy questionnaire, 'Insulin Therapy Self-efficacy Scale (ITSS)', for insulin users in Japanese: The Self-Efficacy-Q study. 2019 , 10, 358-366		3
806	Efficacy and safety of MYL-1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study. 2019 , 21, 129-135		13
805	Cause-specific risk of major adverse cardiovascular outcomes and hypoglycemic in patients with type 2 diabetes: a multicenter prospective cohort study. 2019 , 63, 44-51		5
804	Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials. 2019 , 21, 3-14		29
803	The Role of Occupational Therapy in Secondary Prevention of Diabetes. 2019 , 2019, 3424727		1
802	Metformin as Anti-Aging Therapy: Is It for Everyone?. 2019 , 30, 745-755		75
801	Associations of obesity with antidiabetic medication use after living kidney donation: An analysis of linked national registry and pharmacy fill records. 2019 , 33, e13696		5
800	Relevant patient characteristics for estimating healthcare needs according to healthcare providers and people with type 2 diabetes: a Delphi survey. 2019 , 19, 575		2
799	Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). <i>Diabetes Care</i> , 2019 , 42, 2098-2107	14.6	15
798	Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects. 2019 , 11, 938-948		16
797	Diabetes and the Cardiovascular System. 2019 , 1-29		
796	The future of new drugs for diabetes management. 2019 , 155, 107785		18
795	Relationship between diet/exercise and pharmacotherapy to enhance the GLP-1 levels in type 2 diabetes. 2019 , 2, e00068		7
794	The Oral Antidiabetics. 2019 , 501-513		
793	Foot self-care in diabetes mellitus: Evaluation of patient awareness. 2019 , 13, 515-520		7
792	The statins effects on HbA1c control among diabetic patients: An umbrella review of systematic reviews and meta-analyses of observational studies and clinical trials. 2019 , 13, 2557-2564		6
791	Initial Therapeutic Choices for Type 2 Diabetes in the Portuguese Sentinel Practice Network. 2019 , 32, 375-380		

790	Effectiveness and Safety of Physician-Led Versus Patient-Led Titration of Insulin Glargine in Indian Patients with Type 2 Diabetes Mellitus: A Subanalysis of the Asian Treat to Target Lantus Study (ATLAS). 2019 , 21, 656-664	5
789	Simplifying Complex Insulin Regimens While Preserving Good Glycemic Control in Type 2 Diabetes. 2019 , 10, 1869-1878	15
788	Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force. 2019 , 10, 1645-1717	17
787	Quality of life and metabolic control in type 2 diabetes mellitus diagnosed individuals. 2019 , 13, 2827-2832	2
786	Improving empowerment, motivation, and medical adherence in patients with poorly controlled type 2 diabetes: A randomized controlled trial of a patient-centered intervention. 2019 , 102, 2238-2245	5
785	Effect of Rice Processing towards Lower Rapidly Available Glucose (RAG) Favors , a South Indian Fermented Food Suitable for Diabetic Patients. 2019 , 11,	1
784	Reduction in HbA1c using professional flash glucose monitoring in insulin-treated type 2 diabetes patients managed in primary and secondary care settings: A pilot, multicentre, randomised controlled trial. 2019 , 16, 385-395	27
783	Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on metformin: a meta-analysis. 2019 , 63, 478-486	9
782	Frailty in the older person: Implications for pharmacists. 2019 , 76, 1980-1987	1
781	Rosiglitazone metformin adduct inhibits hepatocellular carcinoma proliferation via activation of AMPK/p21 pathway. 2019 , 19, 13	11
780	Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus. 2019 , 42, 1311-1327	9
779	Influence of gallic and tannic acid on therapeutic properties of acarbose in vitro and in vivo in <i>Drosophila melanogaster</i> . 2019 , 42, 317-327	13
778	Prevalence of Hypoglycemia Among Patients With Type 2 Diabetes Mellitus in a Rural Health Center in South India. 2019 , 10, 2150132719880638	7
777	High-Intensity Interval Training Versus Moderate-Intensity Continuous Training in Middle-Aged and Older Patients with Type 2 Diabetes: A Randomized Controlled Crossover Trial of the Acute Effects of Treadmill Walking on Glycemic Control. 2019 , 16,	13
776	Patient-centred care in type 2 diabetes mellitus - Key aspects of PDM-ProValue are reflected in the 2018 ADA/EASD consensus report. 2019 , 158, 107897	3
775	Patient and physician preferences for type 2 diabetes medications: a systematic review. 2019 , 18, 643-656	9
774	Treatment patterns of drug-naive patients with type 2 diabetes mellitus: a retrospective cohort study using a Japanese hospital database. 2019 , 11, 90	12
773	A Glimepiride-Metformin Multidrug Crystal: Synthesis, Crystal Structure Analysis, and Physicochemical Properties. 2019 , 24,	10

772	Safe Multiquadcopter System Continuum Deformation Over Moving Frames. 2019 , 6, 737-749	3
771	The Role of Vildagliptin in Treating Hypertension Through Modulating Serum VEGF in Diabetic Hypertensive Patients. 2019 , 24, 254-261	4
770	Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes. 2019 , 10, 1733-1752	26
769	Effect of Empagliflozin on Free Fatty Acids and Ketone Bodies in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial. 2019 , 36, 2769-2782	8
768	Verbesserung der Adhärenz zur Lebensstiländerung von Menschen mit Diabetes. 2019 , 15, 542-548	
767	An up-to-date evaluation of alogliptin benzoate for the treatment of type 2 diabetes. 2019 , 20, 1679-1687	
766	A retrospective cross-sectional study of type 2 diabetes overtreatment in patients admitted to the geriatric ward. 2019 , 19, 242	6
765	Reduction of Severe Hypoglycaemia in People with Type 2 Diabetes after a Structured Inpatient Intervention. 2021 , 129, 587-592	4
764	Stakeholder perceptions on patient-centered care at primary health care level in rural eastern Uganda: A qualitative inquiry. 2019 , 14, e0221649	7
763	Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: Prescription According to Reimbursement Constraints and Guideline Recommendations in Catalonia. 2019 , 8,	4
762	Insulin glargine/lixisenatide in type 2 diabetes: a profile of its use. 2019 , 35, 470-480	2
761	Disturbances in Insulin-Glucose Metabolism in Patients With Advanced Renal Disease With and Without Diabetes. 2019 , 104, 4949-4966	10
760	Feasibility Studies on Nafion Membrane Actuated Micropump Integrated With Hollow Microneedles for Insulin Delivery Device. 2019 , 28, 987-996	9
759	Effektivität der glukosesenkenden Therapie bei Patienten mit Typ-2-Diabetes in primärärztlichen Praxen. 2019 , 15, 89-95	
758	Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings. 2019 , 45, 528-535	12
757	A systematic review exploring characteristics of lifestyle modification interventions in newly diagnosed type 2 diabetes for delivery in community pharmacy. 2019 , 27, 3-16	1
756	Glucocentric risk factors for macrovascular complications in diabetes: Glucose 'legacy' and 'variability'-what we see, know and try to comprehend. 2019 , 45, 401-408	17
755	The challenge of managing Type 1 diabetes in frail older people. 2019 , 36, 453-456	

754	Albuminuria Regression and All-Cause Mortality among Insulin-Treated Patients with Type 2 Diabetes: Analysis of a Large UK Primary Care Cohort. 2019 , 49, 146-155		8
753	Does Adjuvant Treatment with Chinese Herbal Medicine to Antidiabetic Agents Have Additional Benefits in Patients with Type 2 Diabetes? A System Review and Meta-Analysis of Randomized Controlled Trials. 2019 , 2019, 1825750		3
752	Trends in global prescribing of antidiabetic medicines in primary care: A systematic review of literature between 2000-2018. 2019 , 13, 409-421		8
751	Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials. 2019 , 21, 2315-2326		7
750	Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. 2019 , 43, 287-301		7
749	Effects of vitamin D supplementation on depressive symptoms in type 2 diabetes mellitus patients: Randomized placebo-controlled double-blind clinical trial. 2019 , 13, 2375-2380		16
748	Controversies for Glucose Control Targets in Type 2 Diabetes: Exposing the Common Ground. <i>Diabetes Care</i> , 2019 , 42, 1615-1623	14.6	5
747	Cardiorespiratory Fitness and Health Care Costs in Diabetes: The Veterans Exercise Testing Study. 2019 , 132, 1084-1090		7
746	Post-Basal Insulin Intensification and Healthcare Resource Use in Type 2 Diabetes: A Web-Based Physician Survey in the United States and United Kingdom. 2019 , 10, 1323-1336		3
745	Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease. 2019 , 2, e00072		1
744	Biodistribution of [C]-Metformin and mRNA Expression of Placentae Metformin Transporters in the Pregnant Chinchilla. 2019 , 2019, 9787340		2
743	Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial. <i>Diabetes Care</i> , 2019 , 42, 1464-1472	14.6	4
742	Guidelines for Medical Nutrition Therapy in Gestational Diabetes Mellitus: Systematic Review and Critical Appraisal. 2019 , 119, 1320-1339		19
741	Racial differences in performance of HbA _{1c} for the classification of diabetes and prediabetes among US adults of non-Hispanic black and white race. 2019 , 36, 1234-1242		5
740	Mean centering-triple divisor and ratio derivative-zero crossing for simultaneous determination of some diabetes drugs in their quaternary mixture with severely overlapping spectra. 2019 , 222, 117261		7
739	Individual and Combined Relationship between Reduced eGFR and/or Increased Urinary Albumin Excretion Rate with Mortality Risk among Insulin-Treated Patients with Type 2 Diabetes in Routine Practice. 2019 , 5, 91-99		3
738	Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDI-liraglutide study 5). 2019 , 5, 130-140		6
737	Association between Metformin Use and Coronary Artery Calcification in Type 2 Diabetic Patients. 2019 , 2019, 9484717		6

736	Intensification to injectable therapy in type 2 diabetes: mixed methods study (protocol). 2019 , 19, 284	1
735	Modulation of Diabetes by Natural Products and Medicinal Plants via Incretins. 2019 , 85, 825-839	7
734	Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes:real-world evidence from a Mediterranean area. 2019 , 35, 1735-1744	7
733	High level of clinical inertia in insulin initiation in type 2 diabetes across Central and South-Eastern Europe: insights from SITIP study. 2019 , 56, 1045-1049	11
732	Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report. <i>Diabetes Care</i> , 2019 , 42, 731-754	14.6 356
731	Proximal HbA1C Level and First Hypoglycemia Hospitalization in Adults With Incident Type 2 Diabetes. 2019 , 104, 1989-1998	1
730	Clinical Management of Intermittent Fasting in Patients with Diabetes Mellitus. 2019 , 11,	39
729	Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials. 2019 , 12, 447-455	9
728	Effect of a single dose of insulin glargine/lixisenatide fixed ratio combination (iGlarLixi) on postprandial glucodynamic response in Japanese patients with type 2 diabetes mellitus: A phase I randomized trial. 2019 , 21, 2001-2005	5
727	Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin. 2019 , 21, 2048-2057	12
726	A Greek registry of current type 2 diabetes management, aiming to determine core clinical approaches, patterns and strategies. 2019 , 19, 39	5
725	A View Beyond HbA1c: Role of Continuous Glucose Monitoring. 2019 , 10, 853-863	60
724	Impact of ischaemic heart disease severity and age on risk of cardiovascular outcome in diabetes patients in Sweden: a nationwide observational study. 2019 , 9, e027199	2
723	Use of Insulin Glargine 100 U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review. 2019 , 10, 805-833	4
722	Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA. 2019 , 11, 271-282	3
721	GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data. 2019 , 10, 1067-1088	20
720	Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. 2019 , 21, 273-285	14
719	Physical activity and risk of diabetic retinopathy: a systematic review and meta-analysis. 2019 , 56, 823-837	17

718	Insulin Initiation and Titration in Patients With Type 2 Diabetes. 2019 , 32, 104-111	12
717	Metformin and Breast Cancer: Molecular Targets. 2019 , 24, 111-123	29
716	An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes. 2019 , 20, 781-790	4
715	Accuracy of a composite event definition for hypoglycemia. 2019 , 28, 625-631	0
714	Drug treatment of type 2 diabetes: Its cost is significantly associated with HbA1c levels. 2019 , 73, e13336	2
713	Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study. 2019 , 9, e025806	45
712	Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. 2019 , 104, 1520-1574	146
711	Real-World Effectiveness and Safety of Lixisenatide as Add-On to Oral Antidiabetic Drugs as Part of Routine Clinical Practice in Bulgaria: LIXODAR Study. 2019 , 10, 981-993	2
710	GREATER COMBINED REDUCTIONS IN HbA 1c AND WEIGHT B.0% WITH SEMAGLUTIDE VERSUS COMPARATORS IN TYPE 2 DIABETES. 2019 , 25, 589-597	6
709	Subphenotypes des Diabetes. 2019 , 15, 288-295	3
708	Implications of Removing Rosiglitazone's Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes. 2019 , 25, 72-79	8
707	PANCREATIC SAFETY IN STUDIES OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST ALBIGLUTIDE. 2019 , 25, 698-716	
706	Prognostic impact of visit-to-visit glycemic variability on the risks of major adverse cardiovascular outcomes and hypoglycemia in patients with different glycemic control and type 2 diabetes. 2019 , 64, 536-543	13
705	Updates on Managing Type 2 Diabetes Mellitus with Natural Products: Towards Antidiabetic Drug Development. 2018 , 25, 5395-5431	38
704	Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care. 2019 , 139, 2822-2830	116
703	Diabetes management and treatment approaches outside of North America and West Europe in 2006 and 2015. 2019 , 56, 889-897	4
702	[Diagnosis and management of patients with diabetes and co-existing osteoporosis (Update 2019) : Common guideline of the Austrian Society for Bone and Mineral Research and the Austrian Diabetes Society]. 2019 , 131, 174-185	3
701	Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. 2019 , 9, 5389	33

700	Consensus pour la prise en charge de l'hyperglycémie dans le diabète de type 2 en Afrique subsaharienne. Rédigé par un groupe d'experts africains du diabète. 2019 , 13, 210-216	2
699	The Self-Management Assessment Scale: Development and psychometric testing of a screening instrument for person-centred guidance and self-management support. 2019 , 6, 504-513	3
698	Deintensification in older patients with type 2 diabetes: A systematic review of approaches, rates and outcomes. 2019 , 21, 1668-1679	26
697	Efficacy and Safety of Basal Analog Regimens in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2019 , 10, 1051-1066	4
696	Factors influencing safe glucose-lowering in older adults with type 2 diabetes: A Person-centred Approach To Individualised (PROACTIVE) Glycemic Goals for older people: A position statement of Primary Care Diabetes Europe. 2019 , 13, 330-352	14
695	Decision aids for people with Type 2 diabetes mellitus: an effectiveness rapid review and meta-analysis. 2019 , 36, 557-568	4
694	Association of smoking and cardiometabolic parameters with albuminuria in people with type 2 diabetes mellitus: a systematic review and meta-analysis. 2019 , 56, 839-850	13
693	Metformin and tenovin-6 synergistically induces apoptosis through LKB1-independent SIRT1 down-regulation in non-small cell lung cancer cells. 2019 , 23, 2872-2889	17
692	The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world setting. 2019 , 21, 1429-1436	21
691	Weight loss in patients with type 2 diabetes receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post-hoc analysis of the AWARD-4 study across baseline body mass index subgroups. 2019 , 21, 1340-1348	6
690	Effect of Weight Change on Economic Outcomes Among Persons with Type 2 Diabetes Mellitus in the United States: Beyond Glycemic Control. 2019 , 25, 658-668	5
689	Metformin triggers the intrinsic apoptotic response in human AGS gastric adenocarcinoma cells by activating AMPK and suppressing mTOR/AKT signaling. 2019 , 54, 1271-1281	26
688	Sodium-glucose cotransporter 2 inhibitor plus pioglitazone vs pioglitazone alone in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. 2019 , 2, e00050	7
687	Relative contribution of basal and postprandial hyperglycaemia stratified by HbA1c categories before and after treatment intensification with dulaglutide. 2019 , 21, 1365-1372	4
686	Hypertriglyceridemia and Its Association with HbA1c Test: A Prospective Controlled Study. 2019 , 2019, 4784313	2
685	Managing care for people with diabetes undergoing dialysis. 2019 , 45, 59-67	3
684	Importance of Postprandial Glucose in Relation to A1C and Cardiovascular Disease. 2019 , 37, 250-259	3
683	Influence of Sodium Glucose Cotransporter 2 Inhibition on Physiological Adaptation to Endurance Exercise Training. 2019 , 104, 1953-1966	14

682	A Pilot Study to Assess Clinical Utility and User Experience of Professional Continuous Glucose Monitoring Among People With Type 2 Diabetes. 2019 , 37, 57-64		2
681	ANTIDIABETIC MEDICINAL PLANTS: A REVIEW. 2019 , 10, 31-37		2
680	Mortality and potential years of life lost attributable to non-optimal glycaemic control in men and women with diabetes in the United Arab Emirates: a population-based retrospective cohort study. 2019 , 9, e032654		
679	6. Glycemic Targets:. <i>Diabetes Care</i> , 2019 , 42, S61-S70	14.6	447
678	ApoB/ApoA1 ratio and non-HDL-cholesterol/HDL-cholesterol ratio are associated to metabolic syndrome in patients with type 2 diabetes mellitus subjects and to ischemic cardiomyopathy in diabetic women. 2019 , 66, 502-511		3
677	[De-escalation of antihyperglycemic treatment in patients with type 2 diabetes - when less is more]. 2019 , 160, 1207-1215		1
676	Glucose Control In Diabetic Patients Considering Daily Real Life Factors. 2019 ,		0
675	Factors affecting follow-up non-attendance in patients with Type 2 diabetes mellitus and hypertension: a systematic review. 2019 , 60, 216-223		20
674	Why are there Variations in the Responses of Glucagon-like Peptide-1 Agonists among the Type 2 Diabetic Patients?. 2019 , 14, 247-248		
673	Insulin Glargine U100 Utilization in Patients with Type 2 Diabetes in an Italian Real-World Setting: A Retrospective Study. 2019 , 2019, 3174654		
672	Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus. 2019 , 12, 2725-2733		1
671	Benefits and harms of intensive glycemic control in patients with type 2 diabetes. 2019 , 367, l5887		42
670	Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks. 2019 , 7, e000728		5
669	Association between clinical outcomes and metformin use in adults with sickle cell disease and diabetes mellitus. 2019 , 3, 3297-3306		4
668	Recognising the importance of self-management for people with diabetes. 2019 , 25, 224-229		
667	Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus. 2019 , 9, e024954		45
666	Management of patients with type 2 diabetes in cardiovascular rehabilitation. 2019 , 26, 133-144		6
665	ApoB/ApoA1 ratio and non-HDL-cholesterol/HDL-cholesterol ratio are associated to metabolic syndrome in patients with type 2 diabetes mellitus subjects and to ischemic cardiomyopathy in diabetic women. 2019 , 66, 502-511		1

664	Practical Guidance on Effective Basal Insulin Titration for Primary Care Providers. 2019 , 37, 368-376	3
663	Eurotium Cristatum Fermented Okara as a Potential Food Ingredient to Combat Diabetes. 2019 , 9, 17536	13
662	Decreases in Circulating Concentrations of Long-Chain Acylcarnitines and Free Fatty Acids During the Glucose Tolerance Test Represent Tissue-Specific Insulin Sensitivity. 2019 , 10, 870	7
661	Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study. 2019 , 16, e1002999	5
660	Expression of the Biologically Active Insulin Analog SCI-57 in. 2019 , 10, 1335	6
659	Impacts of nurse-led clinic and nurse-led prescription on hemoglobin A1c control in type 2 diabetes: A meta-analysis. 2019 , 98, e15971	4
658	Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?. 2019 , 35, e3070	104
657	Effects of metformin and alogliptin on body composition in people with type 2 diabetes. 2019 , 10, 723-730	9
656	Towards a better understanding of postprandial hyperglycemic episodes in people with diabetes: impact on daily functioning. 2019 , 35, 525-533	2
655	Titration and optimization trial for the initiation of insulin glargine 100 U/mL in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs. 2019 , 21, 439-443	8
654	Evolution of type 2 diabetes mellitus treatment approaches. 2019 , 11, 4-6	1
653	Pharmacists' role in glycemic management in the inpatient setting: An opinion of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy. 2019 , 2, 167-176	0
652	Efficacy and safety of sitagliptin added to treatment of patients with type 2 diabetes inadequately controlled with premixed insulin. 2019 , 21, 408-411	2
651	A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide. 2019 , 10, 21-33	9
650	Sustained low-efficiency dialysis for metformin-associated lactic acidosis in patients with acute kidney injury. 2019 , 32, 297-306	10
649	Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. 2019 , 56, 605-617	29
648	Health-related quality of life in adults with type 2 diabetes mellitus starting with new glucose lowering drugs: An inception cohort study. 2019 , 13, 221-232	5
647	Heart Failure in Type 2 Diabetes Mellitus. 2019 , 124, 121-141	210

646	New pharmacological strategies for protecting kidney function in type 2 diabetes. 2019 , 7, 397-412	44
645	Efficacy and Safety of IDegAsp Versus BAsp 30, Both Twice Daily, in Elderly Patients with Type 2 Diabetes: Post Hoc Analysis of Two Phase 3 Randomized Controlled BOOST Trials. 2019 , 10, 107-118	4
644	Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study. 2019 , 21, 781-790	14
643	Metabolomics Based on MS in Mice with Diet-Induced Obesity and Type 2 Diabetes Mellitus: the Effect of Vildagliptin, Metformin, and Their Combination. 2019 , 188, 165-184	10
642	Efficacy of DPP-4 inhibitors, GLP-1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: a model-based meta-analysis. 2019 , 85, 393-402	10
641	Diabetes: the place of new therapies. 2019 , 10, 2042018818807599	6
640	Temporal trends in optimal diabetic care and complications of elderly type 2 diabetes patients in Thailand: A nationwide study. 2019 , 12, 22-28	5
639	Pharmacoeconomic evaluation of sodium-glucose transporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes. 2019 , 20, 151-161	15
638	Chronic kidney disease among US adults with type 2 diabetes and cardiovascular diseases: A national estimate of prevalence by KDIGO 2012 classification. 2019 , 13, 612-615	10
637	Type 2 diabetes treatment and progression of chronic kidney disease in Italian family practice. 2019 , 42, 787-796	2
636	Conceptualizing multiple drug use in patients with comorbidity and multimorbidity: proposal for standard definitions beyond the term polypharmacy. 2019 , 106, 98-107	6
635	Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study. 2019 , 21, 1128-1135	6
634	Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centre, randomized, controlled trial. 2019 , 21, 939-948	1
633	Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis. 2019 , 36, 444-452	20
632	Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes. 2019 , 79, 173-186	13
631	Comparative Effectiveness of Metformin Dosage Uptitration Versus Adding Another Antihyperglycemic Medication on Glycemic Control in Type 2 Diabetes Patients Failing Initial Metformin Monotherapy: A Retrospective Cohort Study. 2019 , 22, 457-463	2
630	Patterns and trends in insulin initiation and intensification among patients with Type 2 diabetes mellitus in the Middle East and North Africa region. 2019 , 149, 18-26	12
629	Exercise training for patients with type 2 diabetes and cardiovascular disease: What to pursue and how to do it. A Position Paper of the European Association of Preventive Cardiology (EAPC). 2019 , 26, 709-727	36

628	Changing the Concept of Type 2 Diabetes: Beta Cell Workload Hypothesis Revisited. 2019 , 19, 121-127	6
627	Toward Better Understanding of Insulin Therapy by Translation of a PK-PD Model to Visualize Insulin and Glucose Action Profiles. 2019 , 59, 258-270	1
626	Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial. 2019 , 21, 631-639	5
625	Nutrition and Disease: Type 2 Diabetes Mellitus. 2019 , 43-48	1
624	Kidney Transplant Management. 2019 ,	
623	Pharmacokinetics of a Lobeglitazone/Metformin Fixed-Dose Combination Tablet (CKD-395 0.5/1000 mg) Versus Concomitant Administration of Single Agents and the Effect of Food on the Metabolism of CKD-395 in Healthy Male Subjects. 2019 , 8, 576-584	2
622	Basal insulin therapy: Unmet medical needs in Asia and the new insulin glargine in diabetes treatment. 2019 , 10, 560-570	6
621	Predictive factors associated with three years of response to HbA1c goals with exenatide QW or insulin glargine: Post-hoc analysis of the DURATION-3 study. 2019 , 21, 1049-1053	
620	Medications for the Treatment of Type II Diabetes. 2019 , 101-106	
619	Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. 2019 , 170, 423-426	22
618	Long-Term Clinical Benefits of Canagliflozin 100 mg Versus Sulfonylurea in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin in India. 2019 , 18, 65-73	2
617	The Effect of Linagliptin versus Metformin Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus. 2019 , 10, 119-134	3
616	Oral semaglutide for the treatment of type 2 diabetes. 2019 , 20, 133-141	25
615	A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes. 2019 , 10, 5-19	30
614	Type 1 and 2 diabetes mellitus: A review on current treatment approach and gene therapy as potential intervention. 2019 , 13, 364-372	98
613	Artificial Pancreas Systems for People With Type 2 Diabetes: Conception and Design of the European CLOSE Project. 2019 , 13, 261-267	7
612	Metformin for lung cancer prevention and improved survival: a novel approach. 2019 , 28, 311-315	5
611	Impact of sex and glucose-lowering treatments on hypoglycaemic symptoms in people with type 2 diabetes and chronic kidney disease. The French Chronic Kidney Disease - Renal Epidemiology and Information Network (CKD-REIN) Study. 2019 , 45, 175-183	5

610	Heart Failure With Preserved Ejection Fraction: Prevention and Management. 2019 , 13, 182-189	10
609	Impact of Timing Between Insulin Administration and Meal Consumption on Glycemic Fluctuation and Outcomes in Hospitalized Patients With Type 2 Diabetes. 2020 , 33, 449-456	2
608	Real-World Adequacy of Glycaemic Control in Treatment-Naïve Greek Patients with Type 2 Diabetes Mellitus Initiating Treatment with Metformin Monotherapy at the Maximum Tolerated Dose: The Reload Study. 2020 , 128, 224-230	1
607	Liraglutide vs. lixisenatide in obese type 2 diabetes mellitus patients: What effect should we expect in routine clinical practice?. 2020 , 14, 68-74	1
606	The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE. 2020 , 105,	8
605	Pharmacological treatment initiation for type 2 diabetes in Australia: are the guidelines being followed?. 2020 , 37, 1367-1373	2
604	Mexican population sub-analysis of the lixilan clinical program with the fixed ratio combination of insulin glargine and lixisenatide (iGlarLixi). 2020 , 34, 107389	1
603	Incretins in obesity and diabetes. 2020 , 1461, 104-126	32
602	The association between diabetes medication and weight change in a non-surgical weight management intervention: an intervention cohort study. 2020 , 37, 248-255	3
601	In Silico Examination of Initiation of Long-Acting Insulin Analogs Toujeo Compared to Lantus Under 3 Dosing Titration Rules in Virtual Type 2 Diabetes Subjects. 2020 , 14, 898-907	2
600	Diabetes, dysglycemia, and vascular surgery. 2020 , 71, 701-711	1
599	Titration of insulin glargine 100 U/mL when added to oral antidiabetic drugs in patients with type 2 diabetes: results of the TOP-1 real-world study. 2020 , 57, 89-99	6
598	The relationship between urinary albumin excretion, cardiovascular outcomes and total mortality among a large cohort of insulin-treated patients with type 2 diabetes in routine primary care practices. 2020 , 35, 471-477	1
597	Glycaemic control among patients with type 2 diabetes followed in a rural African primary care setting - A reality check in the Democratic Republic of Congo. 2020 , 14, 139-146	1
596	Efficacy of Intermittently Scanned Continuous Glucose Monitoring in the Prevention of Recurrent Severe Hypoglycemia. 2020 , 22, 367-373	8
595	A population-based analysis of antidiabetic medications in four Canadian provinces: Secular trends and prescribing patterns. 2020 , 29 Suppl 1, 86-92	3
594	Adult attachment insecurity and associations with diabetes distress, daily stressful events and self-management in type 1 diabetes. 2020 , 43, 695-706	1
593	Combination of Oligofructose and Metformin Alters the Gut Microbiota and Improves Metabolic Profiles, Contributing to the Potentiated Therapeutic Effects on Diet-Induced Obese Animals. 2019 , 10, 939	7

592	Insulin Glargine 300 U/mL and Insulin Glulisine Treatment in Patients with Type 2 Diabetes: A Non-Interventional Study of Effectiveness in Routine Clinical Practice. 2020 , 11, 467-478			1
591	Adaptive Treatment Strategies With Survival Outcomes: An Application to the Treatment of Type 2 Diabetes Using a Large Observational Database. 2020 , 189, 461-469			5
590	The EMPagliflozin compaRative effectiveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care. 2020 , 3, e00103			3
589	New Antidiabetic Targets of α -Glucosidase Inhibitory Peptides, SVPA, SEPA, STYV and STY: Inhibitory Effects on Dipeptidyl Peptidase-IV and Lipid Accumulation in 3T3-L1 Differentiated Adipocytes with Scavenging Activities Against Methylglyoxal and Reactive Oxygen Species. 2020 , 26, 1949-1963			1
588	Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes. 2020 , 11, 573-584			10
587	Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. <i>Diabetes Care</i> , 2020 , 43, 643-652	14.6	19	
586	Male and female sexual dysfunction in diabetic subjects: Focus on new antihyperglycemic drugs. 2020 , 21, 57-65			8
585	User Centered Design to Improve Information Exchange in Diabetes Care Through eHealth : Results from a Small Scale Exploratory Study. 2019 , 44, 2			3
584	Cardiovascular risk following metformin treatment in patients with type 2 diabetes mellitus: Results from meta-analysis. 2020 , 160, 108001			30
583	Analysis of urinary metabolic alteration in type 2 diabetic rats treated with metformin using the metabolomics of quantitative spectral deconvolution 1H NMR spectroscopy. 2020 , 153, 104513			7
582	Gardenia fructus antidepressant formula for depression in diabetes patients: A systematic review and meta-analysis. 2020 , 48, 102248			1
581	The right place for metformin today. 2020 , 159, 107946			16
580	Biosynthetic Human Insulin and Insulin Analogs. 2020 , 27, e42-e51			10
579	Chronic Kidney Disease as Risk Factor for Enlarged Perivascular Spaces in Patients With Stroke and Relation to Racial Group. 2020 , 51, 3348-3351			1
578	Development and Validation of a Hypoglycemia Risk Model for Intensive Insulin Therapy in Patients with Type 2 Diabetes. 2020 , 2020, 7292108			0
577	Postprandial Glucose Spikes, an Important Contributor to Cardiovascular Disease in Diabetes?. 2020 , 7, 570553			8
576	Validity of the Good Practice Guidelines: The example of type 2 diabetes. 2020 , 169, 108459			0
575	Quality-of-Life Comparison of Dapagliflozin Versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (J-BOND Study). 2020 , 11, 2959-2977			3

574	Clinical inertia in type 2 diabetes management in a middle-income country: A retrospective cohort study. 2020 , 15, e0240531	4
573	Total Synthesis of Semaglutide Based on a Soluble Hydrophobic-Support-Assisted Liquid-Phase Synthetic Method. 2020 , 22, 821-825	2
572	Adherence to the National Guidelines for Follow-Up Protocol in Subjects with Type 2 Diabetes Mellitus in Greece: The GLANCE Study. 2020 , 11, 2887-2908	0
571	Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Societ^ Italiana Farmacologia (SIF) multidisciplinary consensus position paper. 2020 , 154, 103066	2
570	Patient decisional needs when considering treatment intensification for type 2 diabetes: A qualitative study in China. 2020 , 170, 108471	2
569	Titrateable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus. 2020 , 170, 108478	2
568	Level of glycemic control and its associated factors among type II diabetic patients in debre tabor general hospital, northwest Ethiopia. 2020 , 8, 100056	5
567	DIA-DB: A Database and Web Server for the Prediction of Diabetes Drugs. 2020 , 60, 4124-4130	4
566	Effect of clinical inertia and trial participation in younger and older adults with diabetes having comorbidities and progressive complications. 2020 , 166, 108310	1
565	Does Renal Function or Heart Failure Diagnosis Affect Primary Care Prescribing for Sodium-Glucose Co-Transporter 2 Inhibitors in Type 2 Diabetes?. 2020 , 11, 2169-2175	1
564	The effectiveness of insulin glargine 300 U/mL among type 2 diabetes patients: Analysis of a real-world data in Israel. 2020 , 3, e00124	
563	Versatile Nutraceutical Potentials of Watermelon-A Modest Fruit Loaded with Pharmaceutically Valuable Phytochemicals. 2020 , 25,	7
562	Trends in national pharmaceutical expenditure on diabetes in Ireland 2011-2015: a repeated cross-sectional study. 2020 , 10, e037382	2
561	RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020. 2020 , 40, 1-122	8
560	Suboptimal glycemic control among subjects with diabetes mellitus in India: a subset analysis of cross-sectional wave-7 (2016) data from the International Diabetes Management Practices Study (IDMPS). 2020 , 11, 2042018820937217	5
559	Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. <i>Diabetes Care</i> , 2020 , 43, 2509-2518	14.6 12
558	The Boomers Come of Age. 2020 , 5, 247-258	
557	Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, metformin, and thiazolidinediones. 2020 , 155, 37-64	10

556 Diabetes und Krebs. **2020**, 16, 675-684

555 6. Glycemic Targets:. *Diabetes Care*, **2020**, 43, S66-S76 14.6 417

554 Evaluation of the Antidiabetic and Insulin Releasing Effects of , Including Isolation and Characterization of Active Phytochemicals. **2020**, 9, 4

553 Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012-2018. **2020**, 8, 12

552 Time course and dose effect of metformin on weight in patients with different disease states. **2020**, 13, 1169-1177 3

551 Social Support, Strain, and Glycemic Control: A Path Analysis. **2020**, 27, 592-612 3

550 Efficacy and safety of insulin glargine 300 U/mL (Gla-300) during hospitalization and therapy intensification at discharge in patients with insufficiently controlled type 2 diabetes: results of the phase IV COBALTA trial. **2020**, 8, 4

549 Formation of β 3 and MIN6 Pseudoislets Changes the Expression Pattern of Gpr40, Gpr55, and Gpr119 Receptors and Improves Lysophosphatidylcholines-Potentiated Glucose-Stimulated Insulin Secretion. **2020**, 9, 2

548 An online mobile/desktop application for supporting sustainable chronic disease self-management and lifestyle change. **2020**, 26, 2860-2876 1

547 Decreased Antihyperglycemic Drug Use Driven by High Out-of-Pocket Costs Despite Medicare Coverage Gap Closure. *Diabetes Care*, **2020**, 43, 2121-2127 14.6 5

546 Type of diabetes mellitus and health-related quality of life in Nigeria: Ethnic and sex differences. **2020**, 30, 529-534

545 Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds. **2020**, 15, 10215-10240 14

544 Real World Use of Antidiabetic Drugs in the Years 2011-2017: A Population-Based Study from Southern Italy. **2020**, 17, 2

543 MicroRNAs (-146a, -21 and -34a) are diagnostic and prognostic biomarkers for diabetic retinopathy.. **2020**, 0

542 Health behaviour change considerations for weight loss and type 2 diabetes: nutrition, physical activity and sedentary behaviour. **2020**, 37, 228 3

541 Antimicrobial Susceptibility Testing and Phenotypic Detection of MRSA Isolated from Diabetic Foot Infection. **2020**, 13, 1349-1357 3

540 The overtreatment of type 2 diabetes in frail older people. **2020**, 2, 496-502

539 Sulfonylureas use and fractures risk in elderly patients with type 2 diabetes mellitus: a meta-analysis study. **2021**, 33, 2133-2139 2

538	Overview of Therapeutic Inertia in Diabetes: Prevalence, Causes, and Consequences. 2020 , 33, 8-15	11
537	Variations in the Delivery of Primary Diabetes Care in Malaysia: Lessons to Be Learnt and Potential for Improvement. 2020 , 7, 2333392820918744	1
536	Descending Expression of miR320 in Insulin-Resistant Adipocytes Treated with Ascending Concentrations of Metformin. 2020 , 58, 661-676	3
535	Pathophysiology and Management of Type 2 Diabetes Mellitus Bone Fragility. 2020 , 2020, 7608964	25
534	Finding the clinical utility of 1,5-anhydroglucitol among primary care practitioners. 2020 , 20, 100224	1
533	Initial Therapy, Regimen Change, and Persistence in a Spanish Cohort of Newly Treated Type 2 Diabetes Patients: A Retrospective, Observational Study Using Real-World Data. 2020 , 17,	2
532	Evaluation of the safety of sodium-glucose co-transporter-2 inhibitors for treating patients with type 1 diabetes. 2020 , 22, 1767-1776	3
531	The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes. 2020 , 109, 154295	7
530	The overtreatment of type 2 diabetes in frail older people. 2020 , 31, 240-244	
529	Hemoglobin structure at higher levels of hemoglobin A1C in type 2 diabetes and associated complications. 2020 , 133, 1138-1143	3
528	Cancer Biology and Prevention in Diabetes. 2020 , 9,	16
527	Metformin Promotes Beclin1-Dependent Autophagy to Inhibit the Progression of Gastric Cancer. 2020 , 13, 4445-4455	8
526	Baseline Characteristics of Patients with Type 2 Diabetes Initiating Second-Line Treatment in Japan: Findings from the J-DISCOVER Study. 2020 , 11, 1563-1578	3
525	Scientific independence and objectivity: many questions linger about treatment of type 2 diabetes, such as scientific study design, optimal glucose control and the safety of injecting exogenous insulin. 2020 , 132, 667-675	
524	Centella asiatica: its potential for the treatment of diabetes. 2020 , 213-222	1
523	The impact of online self-management interventions on midlife adults with type 2 diabetes: a systematic review. 2020 , 29, 266-272	4
522	Physicians' choices in the first- and second-line management of type 2 diabetes in the Kingdom of Saudi Arabia. 2020 , 28, 329-337	4
521	Improving Dissolution and Cytotoxicity by Forming Multidrug Crystals. 2020 , 25,	3

520	Correlates of Blood Pressure and Cholesterol Level Testing Among a Socially-Disadvantaged Population in Poland. 2020 , 17,		1
519	Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial. 2020 , 57, 991-1000		2
518	Risk Factors for Peri-implant Diseases . 2020 ,		1
517	A Cohort Study of Exposure to Antihyperglycemic Therapy and Survival in Patients with Lung Cancer. 2020 , 17,		1
516	How Significant Is Severe Hypoglycemia in Older Adults With Diabetes?. <i>Diabetes Care</i> , 2020 , 43, 512-514	14.6	4
515	The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease. <i>Diabetes Care</i> , 2020 , 43, 948-955	14.6	38
514	Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain. 2020 , 8,		26
513	Approximate Bayesian Bootstrap procedures to estimate multilevel treatment effects in observational studies with application to type 2 diabetes treatment regimens. 2020 , 29, 3362-3380		0
512	Functional loss of pancreatic islets in type 2 diabetes: How can we halt it?. 2020 , 110, 154304		14
511	Advanced Nanoscale Build-Up Sensors for Daily Life Monitoring of Diabetics. 2020 , 7, 2000153		16
510	Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights. 2020 , 21,		16
509	Metformin Alleviates Left Ventricular Diastolic Dysfunction in a Rat Myocardial Ischemia Reperfusion Injury Model. 2020 , 21,		5
508	Effect of a mindfulness programme for long-term care residents with type 2 diabetes: A cluster randomised controlled trial measuring outcomes of glycaemic control, relocation stress and depression. 2020 , 15, e12312		4
507	Nanoscale dynamic chemical, biological sensor material designs for control monitoring and early detection of advanced diseases. 2020 , 5, 100044		12
506	Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods. 2020 , 147, 105281		2
505	The Growing Epidemic of Diabetes Mellitus. 2020 , 18, 104-109		48
504	The Invested in Diabetes Study Protocol: a cluster randomized pragmatic trial comparing standardized and patient-driven diabetes shared medical appointments. 2020 , 21, 65		4
503	The impact of pharmacist care on diabetes outcomes in primary care settings: An umbrella review of published systematic reviews. 2020 , 14, 393-400		9

502	Metformin upregulates mitophagy in patients with T2DM: A randomized placebo-controlled study. 2020 , 24, 2832-2846	19
501	Utility of Precision Medicine in the Management of Diabetes: Expert Opinion from an International Panel. 2020 , 11, 411-422	2
500	A Practitioner's Toolkit for Insulin Motivation in Adults with Type 1 and Type 2 Diabetes Mellitus: Evidence-Based Recommendations from an International Expert Panel. 2020 , 11, 585-606	5
499	Current molecular aspects in the development and treatment of diabetes. 2020 , 76, 13-35	6
498	A sustained zero-order release carrier for long-acting, peakless basal insulin therapy. 2020 , 8, 1952-1959	10
497	Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study. 2020 , 369, m1186	27
496	Metformin Treatment Is Associated with a Decreased Risk of Nonproliferative Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study. 2020 , 2020, 9161039	8
495	Glucose Lowering Treatment Modalities of Type 2 Diabetes Mellitus. 2021 , 1307, 7-27	4
494	Prevalence and correlation of glycemic control achievement in patients with type 2 diabetes in Iraq: A retrospective analysis of a tertiary care database over a 9-year period. 2020 , 14, 265-272	8
493	The effect of L-carnitine supplementation on blood pressure in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. 2020 , 18, 100230	1
492	Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study. <i>Diabetes Care</i> , 2020 , 43, 1326-1335	14.6 20
491	Lifestyle advice, processes of care and glycaemic control amongst patients with type 2 diabetes in a South African primary care facility. 2020 , 12, e1-e6	1
490	Lysophosphatidylcholine Containing Anisic Acid Is Able to Stimulate Insulin Secretion Targeting G Protein Coupled Receptors. 2020 , 12,	6
489	Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?. 2020 , 107, 154242	8
488	Successful Treatment with Bedtime Basal Insulin Added to Metformin without Weight Gain or Hypoglycaemia over Three Years. 2020 , 9,	1
487	An evaluation of empagliflozin and it's applicability to hypertension as a therapeutic option. 2020 , 21, 1157-1166	3
486	Metabolic endoscopy by duodenal mucosal resurfacing: expert review with critical appraisal of the current technique and results. 2020 , 14, 375-381	3
485	Efficacy and safety of metformin and sitagliptin-based dual and triple therapy in elderly Chinese patients with type 2 diabetes: Subgroup analysis of STRATEGY study. 2020 , 11, 1532-1541	0

484	Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States. 2020 , 13, 1023-1033	2
483	Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes. 2020 , 105,	7
482	Evidence gap on antihyperglycemic pharmacotherapy in frail older adults : A systematic review. 2021 , 54, 278-284	4
481	Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis. 2021 , 58, 5-18	8
480	Effect of the FreeStyle LibreFlash glucose monitoring system on glycemic control in individuals with type 2 diabetes treated with basal-bolus insulin therapy: An open label, prospective, multicenter trial in Japan. 2021 , 12, 82-90	1
479	Current comments on contrast media administration in patients with renal insufficiency. 2021 , 69, 37-44	2
478	Mobile Diabetes Telemedicine Clinics for Aboriginal First Nation People With Reported Diabetes in British Columbia. 2021 , 45, 89-95	3
477	Close relationships and diabetes management across the lifespan: The good, the bad, and autonomy. 2021 , 26, 226-237	2
476	Self-Compassion, Metabolic Control and Health Status in Individuals with Type 2 Diabetes: A UK Observational Study. 2021 , 129, 413-419	7
475	Vascular risk factor control and adherence to secondary preventive medication after ischaemic stroke. 2021 , 289, 355-368	5
474	Metformin Prescription Associated with Reduced Abdominal Aortic Aneurysm Growth Rate and Reduced Chemokine Expression in a Swedish Cohort. 2021 , 70, 425-433	11
473	The perspectives of physicians regarding antidiabetic therapy de-intensification and factors affecting their treatment choices-A cross-sectional study. 2021 , 75, e13662	1
472	Acute effects of delayed-release hydrolyzed pine nut oil on glucose tolerance, incretins, ghrelin and appetite in healthy humans. 2021 , 40, 2169-2179	2
471	Metformin dosage patterns in type 2 diabetes patients in a real-world setting in the United States. 2021 , 172, 108531	0
470	The Novel Phosphate and Bile Acid Sequestrant Polymer SAR442357 Delays Disease Progression in a Rat Model of Diabetic Nephropathy. 2021 , 376, 190-203	0
469	6. Glycemic Targets:. <i>Diabetes Care</i> , 2021 , 44, S73-S84	14.6 231
468	Safety and efficacy of empagliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post hoc analysis of data from the SACRA study. 2021 , 23, 860-869	5
467	A study to assess the unmet medical needs associated with the use of basal insulin in patients with type 2 diabetes. 2021 , 4, e00164	1

466	Psychometric Analysis Regarding the Barriers to Providing Effective Insulin Treatment in Type 2 Diabetic Patients. 2021 , 12, 159-170	1
465	Risk factors for diabetic foot complications in type 2 diabetes-A systematic review. 2021 , 4, e00175	8
464	Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. 2021 , 12, 537-545	0
463	Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition. 2021 , 11, 1166-1185	18
462	Liraglutide and Dulaglutide Have Comparable HbA1c Reduction in Emirati Patients with T2DM. 2021 , 11, 103-117	
461	Acute coronary syndrome in diabetes mellitus: features of pathogenesis, course and therapy. 2021 , 24, 89	
460	Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus. 2021 , 20, 30	20
459	Inspiratory Muscle Training on Glucose Control in Diabetes: A Randomized Clinical Trial. 2020 , 31, 21-31	0
458	Hospitalization for hypoglycaemia in people with diabetes in Denmark, 1997-2017: Time trends in incidence and HbA and glucose-lowering drug use before and after hypoglycaemia. 2021 , 4, e00227	
457	Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis. 2021 , 10, 210-222	1
456	Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice. 2021 , 12, 20420188211042145	2
455	The ICF Classification System to Assess Risk Factors for CVD in Secondary Prevention after Ischemic Stroke and Intracerebral Hemorrhage. 2021 , 57,	1
454	Drug-Drug Interactions at Organic Cation Transporter 1. 2021 , 12, 628705	5
453	Design, Synthesis, and In Silico Multitarget Pharmacological Simulations of Acid Bioisosteres with a Validated In Vivo Antihyperglycemic Effect. 2021 , 26,	2
452	Engineering of smart nanoconstructs for delivery of glucagon-like peptide-1 analogs. 2021 , 597, 120317	3
451	Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns. 2021 , 12, 616514	1
450	Therapeutic inertia in patients with type 2 diabetes treated with non-insulin agents. 2021 , 35, 107828	2
449	Report from the CVOT Summit 2020: new cardiovascular and renal outcomes. 2021 , 20, 75	3

448	Krebs cycle: activators, inhibitors and their roles in the modulation of carcinogenesis. 2021 , 95, 1161-1178	14
447	Diabetes duration and glycaemic control as predictors of cardiovascular disease and mortality. 2021 , 23, 1361-1370	6
446	Association Between Preadmission Metformin Use and Outcomes in Intensive Care Unit Patients With Sepsis and Type 2 Diabetes: A Cohort Study. 2021 , 8, 640785	5
445	Using Natural Language Processing to Measure and Improve Quality of Diabetes Care: A Systematic Review. 2021 , 15, 553-560	3
444	Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis. 2021 , 64, 1563-1571	7
443	Diabetes duration and glycaemic control as predictors of cardiovascular disease and mortality. 2021, 23, 1361-1370	0
442	Patient Work and Treatment Burden in Type 2 Diabetes: A Mixed-Methods Study. 2021 , 5, 359-367	1
441	Natural Antidiabetic Agents: Molecular Docking Study using the Extra Precision Method. 2021 , 18, 143-171	
440	One Hundred Years of Insulin: Value Beyond Price in Type 2 Diabetes Mellitus. 2021 , 12, 1593-1604	0
439	Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits. 2021 , 14, 35	
438	The influence of living conditions and individual behaviors on the oral-systemic disease connection: a cross-sectional analysis. 2021 ,	
437	Management of type 2 diabetes. 2021 , 90-99	
436	Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes mellitus?. 2020 , 51, 735-742	0
435	Hardware-in-the-loop control of glucose in diabetic patients based on nonlinear time-varying blood glucose model. 2021 , 66, 102467	4
434	Noninvasive blood glucose monitor via multi-sensor fusion and its clinical evaluation. 2021 , 332, 129445	6
433	Association between control of diabetes mellitus and polypharmacy at the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). 2021 , 30, 749-757	0
432	Association between metformin use on admission and outcomes in intensive care unit patients with acute kidney injury and type 2 diabetes: A retrospective cohort study. 2021 , 62, 206-211	4
431	Is there a role for glucagon-like peptide-1 receptor agonists in the treatment of male infertility?. 2021 , 9, 1499-1503	4

430	Experience of emergency department patients after a visit for hyperglycaemia: implications for communication and factors affecting adherence postdischarge. 2021,	0
429	"When nothing happens, nobody is afraid!" beliefs and perceptions around self-care and health-seeking behaviours: Voices of patients living with diabetic lower extremity amputation in primary care. 2021, 18, 850-861	1
428	Ethnopharmacological perspectives of glucokinase activators in the treatment of diabetes mellitus. 2021, 1-15	4
427	Loss of intestinal ChREBP impairs absorption of dietary sugars and prevents glycaemic excursion curves.	
426	Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus: DosInGlar Study. 2021, 38, 3857-3871	0
425	Effect of Lifestyle Modification on Glycaemic Control of Type 2 Diabetic Patients at Suez Canal University Hospitals.	
424	Saffron improves life and sleep quality, glycaemic status, lipid profile and liver function in diabetic patients: A double-blind, placebo-controlled, randomised clinical trial. 2021, 75, e14334	7
423	Treatment Patterns, Effectiveness, and Satisfaction Among Patients with Type 2 Diabetes Treated with Insulin in Saudi Arabia: Results of the RIMODIS Study. 2021, 12, 1965-1978	2
422	Feline comorbidities: Pathophysiology and management of the obese diabetic cat. 2021, 23, 639-648	2
421	The Genetics of Adverse Drug Outcomes in Type 2 Diabetes: A Systematic Review. 2021, 12, 675053	1
420	Safety and Efficacy of SGLT2 Inhibitors: A Multiple-Treatment Meta-Analysis of Clinical Decision Indicators. 2021, 10,	1
419	The effect of apple cider vinegar on lipid profiles and glycaemic parameters: a systematic review and meta-analysis of randomized clinical trials. 2021, 21, 179	3
418	Risk Factors for the Recurrence of CVD Incidents in Post-Stroke Patients over a 5-Year Follow-Up Period Based on the ICF Classification. 2021, 18,	0
417	Special Considerations in the Management and Education of Older Persons With Diabetes. 2021, 9, 30-42	
416	Evidence-based use of newer agents in type 2 diabetes. 2021, 3, 224-234	0
415	Acute metformin administration increases mean power and the early Power phase during a Wingate test in healthy male subjects. 2021, 1-8	1
414	Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus without established cardiovascular disease: Do they have a role in primary prevention?. 2021, 10, 100082	
413	Mortality rates and cardiovascular disease burden in type 2 diabetes by occupation, results from all Swedish employees in 2002-2015. 2021, 20, 129	3

412	Trends in HbA1c and Body Mass Index Among Individuals with Type 2 Diabetes: Evidence from a US Database 2012-2019. 2021 , 12, 2077-2087	2
411	Use Of The GLYCEMIZER [®] Tool By General Practitioners To Meet Individual Glycated Hemoglobin Goals In Patients With Type 2 Diabetes Mellitus. 2021 , 10,	
410	Effects of Incretin-Related Diabetes Drugs on Bone Formation and Bone Resorption. 2021 , 22,	1
409	Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin. 2021 , 22, 34	1
408	Chemical Group Profiling, and Evaluation of α -Amylase and α -Glucosidase Activity. 2021 , 2021, 6679185	3
407	Knowledge, Attitude, and Practice of Metformin Extended-Release Tablets Among Clinicians in China: A Cross-Sectional Survey. 2021 , 12, 634561	0
406	Impact of non-antibiotic drugs on the human intestinal microbiome. 2021 , 21, 911-924	4
405	Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study. 2021 , 64, 2204-2214	1
404	Fasting Glucose of 6.1 mmol/L as a Possible Optimal Target for Type 2 Diabetic Patients with Insulin Glargine: A Randomized Clinical Trial. 2021 , 2021, 5524313	2
403	Influence of Diabetes Duration and Glycemic Control on Dementia: A Cohort Study. 2021 , 76, 2062-2070	0
402	Improving outcomes for older people with diabetes. 2021 , 32, 270-276	
401	Evolution of Type 2 Diabetes Management from a Gluco-centric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care. 2021 , 81, 1373-1379	6
400	Management of bone fragility in type 2 diabetes: Perspective from an interdisciplinary expert panel. 2021 , 31, 2210-2233	2
399	Ameliorative effect of <i>Annona reticulata</i> L. leaf extract on antihyperglycemic activity and its hepato-renal protective potential in streptozotocin induced diabetic rats. 2021 , 12, 415-426	0
398	Effect of different HbA1c levels on the gut microbiota in patients with type 2 diabetes mellitus. 2021 , 3,	
397	Assessment of Patient Satisfaction with On-Site Point-of-Care Hemoglobin A1c Testing: An Observational Study. 2021 , 12, 2531-2544	2
396	Efficacy and safety of 28-day treatment with oral insulin (ORMD-0801) in patients with type 2 diabetes: A randomized, placebo-controlled trial. 2021 , 23, 2529-2538	8
395	Effects of a Lifestyle Intervention on Bone Turnover in Persons with Type 2 Diabetes: A post hoc Analysis of the U-TURN Trial. 2021 ,	0

394	The effect of metformin on mortality and severity in COVID-19 patients with diabetes mellitus. 2021 , 178, 108977	9
393	Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. 2021 , 398, 583-598	49
392	Novel approaches to pharmacological management of type 2 diabetes in Japan. 2021 , 22, 2235-2249	0
391	Oral semaglutide in the management of type 2 DM: Clinical status and comparative analysis. 2021 ,	
390	Metabolic Switch and Cytotoxic Effect of Metformin on Burkitt Lymphoma. 2021 , 11, 661102	1
389	An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes. 2021 , 1-14	0
388	Role of Gliclazide in safely navigating type 2 diabetes mellitus patients towards euglycemia: Expert opinion from India. 2021 , 4, 100102	
387	Erectile dysfunction and diabetes: A melting pot of circumstances and treatments. 2021 , e3494	6
386	Syringaldehyde promoting intestinal motility with suppressing α -amylase hinders starch digestion in diabetic mice. 2021 , 141, 111865	3
385	Diabetes Self-Management Among Healthcare Providers in King Abdulaziz Medical City, Riyadh: A Cross-Sectional Pilot Study. 2021 , 13, e18155	
384	Associations of time-varying obesity and metabolic syndrome with risk of incident heart failure and its subtypes: Findings from the Multi-Ethnic Study of Atherosclerosis. 2021 , 338, 127-135	0
383	Discovery, synthesis and in combo studies of Schiff's bases as promising dipeptidyl peptidase-IV inhibitors. 2021 , 1	0
382	Cardiologist's approach to the diabetic patient: No further delay for a paradigm shift. 2021 , 338, 248-257	0
381	Heterogeneity of Treatment Effects Among Patients With Type 2 Diabetes and Elevated Body Mass Index in a Study Comparing Group Medical Visits Focused on Weight Management and Medication Intensification. 2021 , 59, 1031-1038	
380	Thirty days of combined consumption of a high-fat diet and fructose-rich beverages promotes insulin resistance and modulates inflammatory response and histomorphometry parameters of liver, pancreas, and adipose tissue in Wistar rats. 2021 , 91-92, 111403	
379	Egyptian consensus on treat-to-target approach for osteoporosis: a clinical practice guideline from the Egyptian Academy of bone health and metabolic bone diseases. 2021 , 48,	2
378	Diabetic Foot. 2020 , 355-376	1
377	Metabolic Syndrome. 2020 , 71-107	3

376	Endocrinology. 2017 , 269-282	3
375	Diabetic Foot. 2018 , 355-376	1
374	Metabolic Syndrome. 2018 , 71-107	1
373	Les complications du diabète de type 2 exigent une prévention multifactorielle qui passe obligatoirement par un contrôle optimisé de l'équilibre glychémique. 2015 , 199, 1211-1213	0
372	Impact of hypoglycemic events and HbA1c level on sulfonylurea discontinuation and down-titration. 2017 , 17, 213-220	2
371	Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications. 2018 , 47, 332-345	110
370	Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly. 2017 , 19, 1793-1797	3
369	Early combination versus initial metformin monotherapy in the management of newly diagnosed type 2 diabetes: An East Asian perspective. 2021 , 23, 3-17	3
368	Required reading to remain relevant. 2017 , 71, e12965	0
367	Redesigning ambulatory care management for uncontrolled type 2 diabetes: a prospective cohort study of the impact of a Boot Camp model on outcomes. 2019 , 7, e000731	6
366	Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis. 2017 , 7, e017260	12
365	Short-term outcomes of patients with Type 2 diabetes mellitus treated with canagliflozin compared with sitagliptin in a real-world setting. 2018 , 59, 251-256	2
364	Clinical use of sodium-glucose co-transporter-2 inhibitors in Chinese patients with type 2 diabetes mellitus. 2019 , 60, 309-313	2
363	In vitro antidiabetic potentials, antioxidant activities and phytochemical profile of african black pepper (<i>Piper guineense</i>). 2020 , 6,	2
362	Genomic Characterization of Metformin Hepatic Response. 2016 , 12, e1006449	30
361	Monoconjugation of Human Amylin with Methylpolyethyleneglycol. 2015 , 10, e0138803	15
360	Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth. 2015 , 10, e0139709	23
359	Weight and Glucose Reduction Observed with a Combination of Nutritional Agents in Rodent Models Does Not Translate to Humans in a Randomized Clinical Trial with Healthy Volunteers and Subjects with Type 2 Diabetes. 2016 , 11, e0153151	7

358	Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. 2016 , 11, e0154206	18
357	Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial. 2016 , 11, e0163350	21
356	Metformin Ameliorates Dysfunctional Traits of Glibenclamide- and Glucose-Induced Insulin Secretion by Suppression of Imposed Overactivity of the Islet Nitric Oxide Synthase-NO System. 2016 , 11, e0165668	11
355	Simultaneous Quantification of Antidiabetic Agents in Human Plasma by a UPLC-QToF-MS Method. 2016 , 11, e0167107	9
354	TMG-123, a novel glucokinase activator, exerts durable effects on hyperglycemia without increasing triglyceride in diabetic animal models. 2017 , 12, e0172252	17
353	Relation between cost of drug treatment and body mass index in people with type 2 diabetes in Latin America. 2017 , 12, e0189755	2
352	The effect of concomitant DPPiVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3. 2018 , 13, e0190579	2
351	Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition. 2019 , 22, 1-121	14
350	Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies. 2017 , 20, 220-230	37
349	Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AY. 8th edition. 2017 , 20, 1-121	109
348	Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition. 2019 , 22, 1-121	139
347	Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V. (7th edition). 2015 , 18, 1-112	11
346	Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study. 2017 , 9, 793-801	2
345	Differing Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Ipragliflozin on the Decrease of Fat Mass vs. Lean Mass in Patients With or Without Metformin Therapy. 2019 , 11, 297-300	7
344	New Therapeutic Strategies for Type 2 Diabetes. 2018 , 14, 281-288	8
343	Recurrent lactic acidosis and hypoglycemia with inadvertent metformin use: a case of look-alike pills. 2018 , 2018,	1
342	Quality of Life of Insulin-Naïve People with Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Drugs after the Addition of Insulin Glargine, in Every Day Clinical Practice in Greece. 2015 , 2,	1
341	Effect of Zinc Oxide and Titanium Dioxide Nanoparticles on Supported Lipid Bilayers. 2015 , 2,	1

340	The Multicenter, Open-Label, Observational LEAD-Ph Study: Real-World Safety and Effectiveness of Liraglutide in Filipino Participants with Type 2 Diabetes. 2018 , 33, 114-123	1
339	Development of a Patient Decision Aid on the Choice of Diabetes Medication for Filipino Patients with Type 2 Diabetes Mellitus. 2019 , 34, 44-55	2
338	Potential drug interactions in drug therapy prescribed for older adults at hospital discharge: cross-sectional study. 2019 , 137, 369-378	2
337	The OPT2MISE Study - A Review of the Major Findings and Clinical Implications. 2015 , 11, 70-74	4
336	Basal Insulin Inadequacy versus Failure - Using Appropriate Terminology. 2015 , 11, 79-80	3
335	Individualizing treatment targets for elderly patients with type 2 diabetes: factors influencing clinical decision making in the 24-week, randomized INTERVAL study. 2017 , 9, 769-777	16
334	A 7.0-7.7% value for glycated haemoglobin is better than a . 2019 , 7, S122	1
333	Protective Effects of Pomegranate in Endothelial Dysfunction. 2020 , 26, 3684-3699	4
332	A Review on Molecular Mechanism of Flavonoids as Antidiabetic Agents. 2019 , 19, 762-786	9
331	Comparative Study of Different Derivative Spectrophotometric Techniques for the Analysis and Separation of Metformin, Empagliflozin, and Glimepiride. 2020 , 16, 916-934	1
330	The Prevalence and Correlates of Pre-Diabetes and Diabetes Mellitus Among Public Category Workers in Akure, Nigeria. 2017 , 10, 167-176	1
329	Toward a Digital Platform for the Self-Management of Noncommunicable Disease: Systematic Review of Platform-Like Interventions. 2020 , 22, e16774	10
328	Perceptions of Persons With Type 2 Diabetes Treated in Swedish Primary Health Care: Qualitative Study on Using eHealth Services for Self-Management Support. 2018 , 3, e7	17
327	Overcoming Clinical Inertia: A Randomized Clinical Trial of a Telehealth Remote Monitoring Intervention Using Paired Glucose Testing in Adults With Type 2 Diabetes. 2015 , 17, e178	56
326	User-Centred-Design to improve information exchange in Diabetes Care through eHealth: results from a small-scale exploratory study.	0
325	Metformin Inhibits Migration and Invasion of Cholangiocarcinoma Cells. 2017 , 18, 473-477	14
324	Therapeutic Inertia: Still a Long Way to Go That Cannot Be Postponed. 2020 , 33, 50-57	2
323	Management of diabetes mellitus in chronic kidney disease. 2019 , 44, 273-287	7

322	Unexpected bleeding after Exenatide treatment: a causative relationship or a coincidence?. 2018 , 52, 159-162	2
321	Biomarkers in Obesity. 2018 , 26, 353-358	4
320	Modern approaches to management of cardiovascular risk factors at patients with diabetes mellitus type 2. 2018 , 90, 113-117	1
319	Time in Range: Ein neuer Parameter [komplement] zum HbA 1c.	2
318	Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT. 2018 , 22, 1-64	21
317	Good long-term glycemic compensation is associated with better trabecular bone score in postmenopausal women with type 2 diabetes. 2019 , 68, S149-S156	8
316	Current status of managing diabetes mellitus in Korea. 2016 , 31, 845-50	29
315	Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association. 2017 , 32, 947-958	10
314	Monotherapy in patients with type 2 diabetes mellitus. 2017 , 32, 959-966	5
313	Pratique de l'auto-surveillance glycémique en France?: données d'une enquête nationale. 2017 , 29, 229	3
312	Immunohistochemical Expression of Insulin and Glucagon, Superoxide Dismutase and Catalase Activity in Pancreas in Hyperglycaemia Condition. 2016 , 11, 177-185	5
311	Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance. 2015 , 4, 576-83	22
310	Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea. 2019 , 43, 432-446	2
309	Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial. 2020 , 44, 532-541	3
308	The association between gallstone disease and plaque in the abdominopelvic arteries. 2017 , 22, 11	4
307	Strengthening diabetes management at primary health level. 2015 , 19, 443-7	4
306	Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement. 2015 , 19, 577-96	59
305	Short-term outcomes of type 2 diabetes mellitus patients treated with canagliflozin in real-world setting. 2016 , 20, 137-41	4

304	Flexibility in insulin prescription. 2016 , 20, 408-11	7
303	Liraglutide effect and action in diabetes-In (LEAD-In): A prospective observational study assessing safety and effectiveness of liraglutide in patients with type 2 diabetes mellitus treated under routine clinical practice conditions in India. 2016 , 20, 838-845	4
302	Continuation of Metformin Till Night Before Surgery and Lactate Levels in Patients Undergoing Coronary Artery Bypass Graft Surgery. 2019 , 23, 416-421	2
301	Sodium-glucose Cotransporter-2 Inhibitors in Combination with Other Glucose-lowering Agents for the Treatment of Type 2 Diabetes Mellitus. 2018 , 22, 827-836	11
300	RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020. 2020 , 24, 1-122	33
299	Pentads and Hexads in Diabetes Care: Numbers as Targets; Numbers as Tools. 2017 , 21, 794-796	3
298	Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment. 2017 , 21, 341-354	29
297	Management of Glycemia in Acute Febrile Illness. 2017 , 21, 460-463	2
296	A Review of Pharmacist-led Interventions on Diabetes Outcomes: An Observational Analysis to Explore Diabetes Care Opportunities for Pharmacists. 2019 , 11, 299-309	6
295	Managing diabetes patients in India: Is the future more bitter or less sweet?. 2018 , 9, 1-3	3
294	Simple Insulin Dose Adjustment Using 3-3-1 Algorithm in Japanese Patients with Type 2 Diabetes: Start Kanazawa Study (Self-Titration Aggressive Algorithm with Glargine Trial). 2016 , 06, 197-203	1
293	The Role of Inhaled Insulin in the Management of Type 2 Diabetes. 2016 , 07, 162-169	1
292	Update on biomarkers of glycemic control. 2019 , 10, 1-15	31
291	Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonist's role intreatment; from the past to future. 2019 , 10, 446-453	7
290	Cell-based Screening For Identification Of The Novel Vanadium Complexes With Multidirectional Activity Relative To The Cells And The Mechanisms Associated With Metabolic Disorders. 2019 , 4, 47-54	3
289	Efficacy and safety of sitagliptin added to metformin and insulin compared with voglibose in patients with newly diagnosed type 2 diabetes. 2019 , 74, e736	5
288	Pharmacological Management of Obesity in Patients with Type 2 Diabetes: An Update. 2016 , 25, 121-128	2
287	Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin. 2015 , 4, 212288	5

- 286 Noninvasive Blood Glucose Concentration Measurement Based on Conservation of Energy Metabolism and Machine Learning. **2021**, 21, ○
- 285 ARISE-a prospective, non-interventional, single-arm study assessing clinical parameters associated with the use of insulin degludec/insulin aspart in patients with type 2 diabetes in real-world settings: rationale and design. **2021**, 74, 530-537 ○
- 284 Prevention of Hyperglycemia.
- 283 Magnesium Rich Extract of Cashew Tree (*Anacardium Occidentale*) Nut and its Principal Compound, Anacardic Acid, Stimulate Glucose Uptake in C2C12 Muscle Cells. **2015**, 1,
- 282 Effects of Low-Dose Pioglitazone on Serum Levels of Adiponectin, Dehydroepiandrosterone, Amyloid Beta Peptide, and Lipid Profile in Elderly Japanese People with Type 2 Diabetes. **2015**, 2015, 1-6
- 281 Solid Dose Form of Metformin with Ethyl Eicosapentaenoic Acid Does Not Improve Metformin Plasma Availability. **2016**, 7, 29-35
- 280 The Role of Incretins in Insulin Secretion. **2016**, 1-13
- 279 Retrospective Observational Dose-Titration Study of Subjects with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on 15 mg of Pioglitazone. **2016**, 17, 51
- 278 Incretin Learning and Excellence Academy for Diabetes (iLEAD). **2016**, 20, 887-888
- 277 CHOICE OF THE ADD-ON THERAPY TO METFORMIN IN TYPE 2 DIABETES PATIENTS IN CLINICAL PRACTICE. INITIAL RESULTS FROM A NON-INTERVENTIONAL MULTICENTER STUDY IN ROMANIA (REALITY). **2016**, 12, 455-460 1
- 276 Treating Type 2 Diabetes Mellitus. **2016**, 1-24
- 275 Cardiovascular Outcomes with Empagliflozin - News for Type 2 Diabetes Therapy. **2016**, 12, 31-32
- 274 Phenotypic and genetic characteristics of patients with type 2 diabetes with different responses to metformin therapy in Novosibirsk region. **2016**, 19, 125-131 ○
- 273 Guidelines and recommendations for use. **2016**, 61-75
- 272 12. Diabetes. **2016**,
- 271 Les médicaments du diabète. **2016**, 12, 17-18
- 270 Treatment of type 2 diabetes: the stability of the effectiveness of hypoglycemic medications. **2016**, 13, 32-36
- 269 Guidelines for the Treatment of Type 2 Diabetes Mellitus. **2017**, 37-50

- 268 Diabetes Integrated Care: Are We There Yet?. **2017**, 233-248
- 267 Diabetes-Old Therapies Revisited. **2016**, 3,
- 266 LIRA 365 Plus-A Real World Experience of 19 Months Use of Liraglutide in the Obese Indian Type 2 Diabetic Subjects. **2016**, 5,
- 265 Choice of Insulin in Type 2 Diabetes: A Southeast Asian Perspective. **2017**, 21, 478-481 1
- 264 Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure. **2017**, 21, 618-629 2
- 263 Effect of Initiation of Basal Insulin Glargine on Glycemic Control in Patients with Diabetes: Real Life Experience from Hong Kong. **2017**, 07, 108-120 0
- 262 Knowledge, Attitudes and Practices Survey in Management of Type 2 Diabetes by General Practitioners in Dakar. **2017**, 07, 294-301
- 261 Treating Type 2 Diabetes Mellitus. **2017**, 905-927
- 260 The Role of Incretins in Insulin Secretion. **2017**, 57-69
- 259 Gesamtliteraturverzeichnis. **2017**, 1-153
- 258 Newer Long-Acting Basal Insulin Preparations. **2017**, 23, 13-17
- 257 Concentrated Rapid-Acting Insulin Preparations. **2017**, 23, 18-23
- 256 Treating Type 2 Diabetes Mellitus. **2017**, 1-24
- 255 Long-acting insulins in the treatment of type 2 diabetes and their position in the current treatment algorithm. **2017**, 63, 87-92
- 254 Comments on current guidelines of type 2 diabetes mellitus treatment. **2017**, 63, 211-217 1
- 253 Journal of ISSN: 2374-6947 JDMDC Diabetes, Metabolic Disorders & Control Review Article Volume 4 Issue 2 - 2017 Pharmacoeconomic Meta-Analysis of Oral Dual Therapy Options in Overweight Patients with Uncontrolled Diabetes. **2017**, 4,
- 252 Diabetology: a field of new possibilities. **2017**, 19, 54-56
- 251 Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance. **2017**, 20, 142-150

- 250 Efficiency Evaluation of the Combination Therapy for Comorbid Arterial Hypertension with Diabetes Mellitus 2 Type Depending on the Genetic Polymorphism of the Angiotensin-Converting Enzyme. **2017**, 2, 36-42
- 249 Diabetes mellitus and cognitive disorders from the diabetologist's perspective. **2017**, 63, 717-720 1
- 248 Treatment strategy of type 2 diabetes used in Czech Republic after metformin therapy failure. **2017**, 63, 647-657
- 247 Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes. **2017**, 20, 286-298 3
- 246 Perceptions of Persons With Type 2 Diabetes Treated in Swedish Primary Health Care: Qualitative Study on Using eHealth Services for Self-Management Support (Preprint). 1
- 245 Effects of Resistance and Aerobic Exercise Training or Education Associated with a Dietetic Program on Visfatin Concentrations and Body Composition in Overweight and Obese Women. **2017**, In Press, 1
- 244 Chapter 17: Diabetes Mellitus. **2017**,
- 243 Second line therapy in type 2 diabetes: legacy effect activation. **2017**, 20, 356-362
- 242 Long-term effects of sitagliptin in patients with type 2 diabetes mellitus and hypertension: results from the PROLOGUE study. **2017**, 8, 111979-111997
- 241 Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors and Incidence of Adverse Events in Patients with Type 2 Diabetes. **2017**, 27, 214-220
- 240 PROSPECTS OF NEPHROPROTECTION AGAINST TYPE 2 DIABETES USING THE DPP-4 INHIBITOR VILDAGLIPTIN. **2017**, 8-16 1
- 239 Beginning With Very Low Dose (0.2mg) Liraglutide in Indian Type 2 Diabetic Patients Appears Better Tolerated: Experience from Real Life Practice. **2017**, 4, 0
- 238 Pharmacotherapy of Diabetic Macular Edema and Retinopathy. **2018**, 35-50
- 237 Insulin Treatment. **2018**, 617-640 1
- 236 New Research Progress of the Effect of Metformin on Plasma Vitamin B12 and Homocysteine. **2018**, 08, 480-485
- 235 Diabetes and the Cardiovascular System. **2018**, 131-159
- 234 Comparison of Therapeutic Effects of Linagliptin and Metformin in Patients with Type 2 Diabetes: A systematic Review and Meta-Analysis. **2018**, 18, 21-33 0
- 233 A consensual therapeutic recommendation for type 2 diabetes mellitus by the Slovak Diabetes Society (2018). **2018**, 64, 405-426

- 232 Effectiveness and safety of lixisenatide for treatment of diabetes in the real world: data from the Monitoring Registry in a Real-Life Cohort in the Czech and Slovak Republic. **2018**, 64, 357-366 1
- 231 Modern type 2 diabetes treatment - practical implications. **2018**, 15, 71-75
- 230 . **2018**, 44 Suppl 1, 1-2
- 229 Risk of Type 2 Diabetes Among the Pakistani Population: Results of a Cross-sectional Survey. **2018**, 10, e3144 0
- 228 The Insulin Regimen That Works. **2018**, 11, 165-168
- 227 Diabetes in Kidney Transplant Recipients. **2019**, 113-131 1
- 226 Diabetes mellitus in complex older patients. **2018**, 64, 1005-1008
- 225 Features of Antioxidant Defense Depending on the Thyroid Gland Functional State in Different Age Patients with Comorbid Pathology. **2018**, 3, 129-134
- 224 The Influence of Combined Therapy on Lipid, Glucose Profile in Patients with Diabetes Mellitus Type II. **2018**, 124-127
- 223 Management of cardiovascular risk at patients with a diabetes mellitus type 2.. **2018**, 96, 696-701 1
- 222 Glycemic sensors in treatment of diabetes. **2018**, 14, e10-e17 0
- 221 PROGNOSTIC ROLE AND FEATURES OF INFLUENCE OF ARTERIAL HYPERTENSION, METABOLIC AND ENDOCRINE DISBALANCE ON AGING RATE IN PATIENTS OF DIFFERENT AGE GROUPS WITH COMORBID PATHOLOGY. **2019**, 2, 139
- 220 Diabetic Foot. **2019**, 1-22
- 219 Fiches cliniques. **2019**, 541-557
- 218 Dřordres glycđmiques. **2019**, 53-90
- 217 Metabolic Syndrome. **2019**, 1-37
- 216 Diabetes Management in the United States. **2019**, 255-271
- 215 DIABETES MELLITUS: THE MODERN STATE OF THE ISSUE (PART 2). **2019**, 21, 661-674

214	Mesures hygiĕno-diffĕques et tats diabĕtiques. 2019 , 113-140	
213	Thĕrapeutique des dĕsordres glychniques. 2019 , 141-252	
212	EFFECT OF LEVOTHYROXINE ON THE STATE OF OXIDANT-ANTIOXIDANT BALANCE IN PATIENTS WITH COMBINED COURSE OF HYPERTENSION, TYPE 2 DIABETES AND SUBCLINICAL HYPOTHYROIDISM. 2019 , 4, 126	
211	Reliable choice in therapy of type 2 diabetes mellitus: focus on alogliptin. 2019 , 138-145	1
210	The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: A real-world data. 2020 , 7, 167-173	2
209	Diabetes and the Cardiovascular System. 2019 , 1-29	
208	The Influence of Combined Therapy on Lipid, Glucose Profile in Patients with Diabetes Mellitus Type 2. 2019 , 99-102	
207	How well we treat with insulin in the Czech Republic and in the Slovak Republic A summary of results and comments on the original Czech-Slovak DIAINFORM study. 2019 , 65, 279-283	2
206	Management of diabetic patients with lower extremity peripheral arterial disease. 2019 , 65, 326-334	
205	Metformin poisoning treated with high dose insulin dextrose therapy: a case series. 2019 , 26, 72-78	1
204	Effectiveness and Safety of Hydroxychloroquine compared to Tenueligliptin in uncontrolled T2DM patients as add-on Therapy. 2019 , 34, 87-91	2
203	Effect of Lawsonia inermis Linn. Extracts on Blood Glucose Level in Normal and Streptozotocin-Induced Diabetic Rats. 2019 , 18, 671-676	
202	The Impact of Structured Diabetes Education on Glycemic Control in Patients with Type 2 Diabetes at Initiation of Basal Insulin □The Basal-EDUC-RO Study: A Randomized Prospective Study. 2019 , 26, 185-198	0
201	Vitamin B12 deficiency in the elderly and the possibility of influencing the nature of drug treatment type 2 diabetes. 2019 , 97-99	
200	Insulin-associated Weight Gain in Type 2 Diabetes and Its Relation with Caloric Intake. 2019 , 11, e5275	
199	Metformin-associated Lactic Acidosis Successfully Treated with Continuous Renal Replacement Therapy. 2019 , 11, e5330	2
198	Toward a Digital Platform for the Self-Management of Noncommunicable Disease: Systematic Review of Platform-Like Interventions (Preprint).	0
197	Basal insulin persistence in Brazilian participants with T2DM. 2019 , 65, 1254-1264	

- 196 Clinical potential of treatment with semaglutide in type 2 diabetes patients. **2019**, 8, 212585 2
- 195 Diabetes as a Systemic Factor for Peri-implantitis. **2020**, 59-67
- 194 Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients. **2020**, 2
- 193 The Effect of Levothyroxine on the State of Endothelial Dysfunction in Patients with a Combined Course of Arterial Hypertension, Type 2 Diabetes Mellitus and Subclinical Hypothyroidism. **2020**, 5, 161-166
- 192 Glycemic Control and Future Perspectives for Treatment. **2021**, 73-86
- 191 Diabetes as an Indication for Bariatric Surgery. **2021**, 25-38
- 190 Efecto del tratamiento farmacológico de la diabetes sobre parámetros bioquímicos clásicos y estado redox. **2020**, 67, 17-25
- 189 Is the Ketogenic Diet an Effective and Safe Approach to Type 2 Diabetes Management and Weight Loss?. **2020**, 16, 15
- 188 Diabetes and the Cardiovascular System. **2020**, 131-159
- 187 Introduction. **2020**, 1-4
- 186 Short-term renal and metabolic effects of low dose vildagliptin treatment added-on insulin therapy in non-proteinuric patients with type 2 diabetes: open-label randomized prospective study. **2020**, 64, 418-426 1
- 185 Level of Glycemic Control and Its Associated Factors among Type II Diabetic Patients in Debre Tabor General Hospital, Northwest Ethiopia.
- 184 Gravicentric approach to Type 2 Diabetes therapy. The success prediction. A proof-of-concept. **2020**, 2, 48-60
- 183 Insulin pump therapy and continuous glucose monitoring in adults with type 2 diabetes: where are we now?. **2020**, 1, 314-330 1
- 182 Kontrol altında olmayan tip 2 diyabetes mellitus hastalarında insülin tedavisinden eksenatid bazlı – tedaviye geçiş etkinliği **2020**, 45, 820-826
- 181 Guiding Glucose Management Discussions Among Adults With Type 2 Diabetes in General Practice: Development and Pretesting of a Clinical Decision Support Tool Prototype Embedded in an Electronic Medical Record. **2020**, 4, e17785 2
- 180 Management of Diabetes Mellitus in Acute and Chronic Cardiorenal Syndromes. **2021**, 295-313
- 179 Effects of an actual insulin injection demonstration on insulin acceptance among patients with T2DM: a pragmatic randomized controlled trial. **2021**, 59, 151-158

178	Towards a genotype-based approach for a patient-centered pharmacologic therapy of type 2 diabetes. 2015 , 3, S36	1
177	Serial Medication Nonadherence in Patients with Type 2 Diabetes. 2015 , 8, S12-6	
176	Mitigating the Burden of Type 2 Diabetes: Challenges and Opportunities. 2015 , 8, S3-S11	2
175	Adherence to Insulin Pen Therapy Is Associated with Reduction in Healthcare Costs Among Patients with Type 2 Diabetes Mellitus. 2015 , 8, 148-58	13
174	Glyxambi (Empagliflozin/Linagliptin): A Dual-Acting Oral Medication Approved for the Treatment of Patients with Type 2 Diabetes. 2015 , 8, 171-5	3
173	TREATMENT OF TYPE 2 DIABETES WITH BIPHASIC INSULIN ANALOGUES. 2016 , 4, 74-83	7
172	Prevalence of poor glycemic and blood pressure control and pattern of drug use among primary health-care outpatients in Al Ahsa Saudi Arabia. 2017 , 11, 38-44	1
171	Pharmacological Agents Utilized in Patients With Type-2 Diabetes: Beyond Lowering A1c. 2018 , 43, 214-227	2
170	Cardiovascular outcomes and safety with antidiabetic drugs. 2018 , 12, 70-83	5
169	Effects of 25-hydroxyvitamin D on bone microstructure in T2MD rats. 2018 , 18, 525-529	
168	Bolus Insulin Prescribing Recommendations for Patients With Type 2 Diabetes Mellitus. 2017 , 34, S26-S31	0
167	Some Facts on the Diabetes Surveillance in Rural Regions of Iran. 2018 , 47, 1967-1968	
166	The Effect of Acupressure on Fasting Blood Glucose and Glycosylated Hemoglobin Levels in Diabetic Patients: A Randomized Controlled Trial. 2021 , 9, 152-158	
165	The perspectives of nurse practitioners and physicians on increasing the number of registered nurses in primary care. 2018 , 36, 182-188	1
164	Dynamics of heart rate variability in patients with type 2 diabetes mellitus during spinal anesthesia using dexmedetomidine. 2021 , 13, 5395-5403	
163	Comparison of the Effect of Cardiac Rehabilitation on Functional Capacity of Diabetic and Nondiabetic Patients after CABG. 2021 , 12, 30	
162	Structure and properties of insulin. 2022 , 29-70	
161	Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians. 2021 , 11,	

- 160 Diabetes and Cancer: Risk, Challenges, Management and Outcomes. **2021**, 13, 6
- 159 Low risk of hypoglycemia and high efficacy of gliclazide MB: results of recent studies. **2021**, 24, 350-356
- 158 Dendrocalamus latiflorus and its component rutin exhibit glucose-lowering activities by inhibiting hepatic glucose production via AKT activation. **2021**, 0
- 157 Diabetes mellitus: Antidiabetika ffr.tere mit Bedacht wflren.
- 156 Comparative efficacy and safety of antihyperglycemic drug classes for patients with type 2 diabetes following failure with metformin monotherapy: a systematic review and network meta-analysis of randomized controlled trials.. **2021**, e3515 0
- 155 Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes.. **2022**, 1 4
- 154 Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin-R with the US-licensed Humulin R formulation in healthy subjects: Results from the RHINE-1 (Recombinant Human INsulin Equivalence-1) study.. **2022**, 0
- 153 Efficacy and Safety of Empagliflozin as Add-On Therapy in Patients of Type-2 Diabetes Mellitus. **2022**, 9, 24-27 0
- 152 Optimizing the treatment of newly diagnosed type 2 diabetes mellitus with combination of dipeptidyl peptidase-4 inhibitors and metformin: An expert opinion.. **2021**, 10, 4398-4409
- 151 Long-Term Glycemic Control for Stroke Survivors. **2021**, 229-237
- 150 Effectiveness and safety of basal insulin therapy in type 2 diabetes mellitus patients with or without metformin observed in a national cohort in China.. **2022**, 22, 26 0
- 149 Regulation and role of amp-activated protein kinase at the cellular level and relevance to diabetes mellitus. **2022**, 1, 18
- 148 Combination of mulberry leaf active components possessed synergetic effect on SD rats with diabetic nephropathy by mediating metabolism, Wnt/Eatenin and TGF-βSmads signaling pathway.. **2022**, 115026 0
- 147 Correction to: "Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: A Meta-Analysis".. **2022**, 11, 89-101
- 146 Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials.. **2021**, 175, 106039 3
- 145 Initial Diagnosis and Management of Type 2 Diabetes Mellitus. **2022**, 353-367
- 144 Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases.. **2022**, 82, 311 3
- 143 Patient preferences for the treatment of type 2 diabetes in Australia: a discrete choice experiment. 1

142	Outpatient Management of Type 2 Diabetes Mellitus. 2022 , 369-385	
141	HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial.. <i>Diabetes Care</i> , 2022 ,	14.6 0
140	Differential effects of treatment targets on risks of adverse outcomes according to diabetes duration, age and complications: Can these characteristics be used to individualize diabetes treatment? The Rio de Janeiro type 2 diabetes cohort.. 2022 , 108124	0
139	Metformin alleviates ionizing radiation-induced senescence by restoring BARD1-mediated DNA repair in human aortic endothelial cells.. 2022 , 111706	2
138	Long-term clinical and cost-effectiveness of collaborative care in people with uncontrolled type 2 diabetes mellitus and polypharmacy: A multicenter randomized controlled trial.. 2021 ,	1
137	Increased prevalence of cardiovascular risk factors in newly diagnosed type 2 diabetes patients - a retrospective study.. 2021 , 17, 331-336	
136	Obesity and Diabetes. 2022 , 1-61	
135	Web-based intervention to reduce psychological barriers to insulin therapy among adults with non-insulin-treated type 2 diabetes: study protocol for a two-armed randomised controlled trial of "... 2022 , 12, e051524	0
134	Inhibition Mechanism of Components Isolated from Branches on Diabetes and Diabetic Complications via Experimental and Molecular Docking Analyses.. 2022 , 11,	3
133	Therapeutic Potential of Silybum Marianum and Pergularia Tomentosa Extracts from Jordanian Origin in Diabetes Mellitus. 2022 , 18,	1
132	Results of a multidisciplinary strategy to improve the management of cardiovascular risk factors after liver transplant.. 2022 ,	0
131	New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation.. 2022 , 16, 17	0
130	Metformin reverses tamoxifen resistance through the -medicated mTOR pathway in breast cancer.. 2022 , 10, 366	0
129	Serum ErbB2 concentration positively correlated to the glycemic variations in newly diagnosed Type 2 diabetic patients.. 2022 , 12, 4940	2
128	Assessment of CVD Risk Factors in Secondary Prevention after Ischemic Stroke Using the ICF.. 2022 , 19,	0
127	Pioglitazone, Bladder Cancer and the Presumption of Innocence.. 2022 ,	
126	Socioeconomic Inequalities in Glycaemic Control in Recently Diagnosed Adults with Type 1 and Type 2 Diabetes.. 2022 , e14833	1
125	Effect of liraglutide on markers of insulin production in persons with type 2 diabetes treated with multiple daily insulin injections.. 2021 , 108110	1

124	System usability, user satisfaction and long-term adherence to mobile hyperacuity home monitoring-prospective follow-up study.. 2022 ,			
123	Effects of dapagliflozin in the progression of atherosclerosis in patients with type 2 diabetes: a meta-analysis of randomized controlled trials.. 2022 , 14, 41			0
122	Targeting Myotonic Dystrophy Type 1 with Metformin.. 2022 , 23,			1
121	Safety and Effectiveness of Insulin Glargine 300 U/mL in Participants with Type 2 Diabetes Who Fast During Ramadan in The Gulf Region: A Subgroup Analysis of the Real-World ORION Study.. 2022 , 13, 569			0
120	Evolving Type 2 diabetes management focuses on clinical outcomes. 1			
119	Cyb5r3-based mechanism and reversal of secondary failure to sulfonylurea.			
118	Safety and efficacy of once weekly dipeptidyl-peptidase-4 inhibitor trelagliptin in type-2 diabetes: A meta-analysis.. 2022 , 16, 102469			
117	variant rs163184 is a potential biomarker of glycemic response to exenatide.. 2022 ,			0
116	6. Glycemic Targets: Standards of Medical Care in Diabetes-2022.. <i>Diabetes Care</i> , 2022 , 45, S83-S96	14.6	39	
115	In Vitro and In Vivo Antidiabetic Potential of Monoterpenoids: An Update.. 2021 , 27,			1
114	Adherence, control of cardiometabolic factors and therapeutic inertia in patients with type 2 diabetes in the primary care setting.. 2021 , e00320			1
113	Comprehensive Geriatric Assessment (CGA) in patients with DM. 2021 , 69, 258-261			
112	Circulating Nucleic Acid-Based Biomarkers of Type 2 Diabetes.. 2021 , 23,			1
111	Comparative efficiency and safety of insulin degludec/aspart with insulin glargine in type 2 diabetes: a meta-analysis of randomized controlled trials.. 2022 ,			
110	Cardiovascular and renal outcomes of initial combination therapy with glucose-lowering agents versus stepwise approach in newly diagnosed or treatment naïve type 2 diabetes: a systematic review and meta-analysis.. 2022 ,			
109	table_1.PDF. 2018 ,			
108	table_2.PDF. 2018 ,			
107	Table_1.XLS. 2019 ,			

106 Table_1.docx. **2019,**

105 Image_1.tif. **2018,**

104 Image_2.tif. **2018,**

103 Image_3.tif. **2018,**

102 Table_1.DOCX. **2018,**

101 Table_2.DOCX. **2018,**

100 Table_3.DOCX. **2018,**

99 Table_4.DOCX. **2018,**

98 Table_5.DOCX. **2018,**

97 Table_6.DOCX. **2018,**

96 Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients. **2020,** 35, 1

95 Association Between DPP-4 Inhibitors and Events of Colorectal and Liver Cancers in Patients With Diabetes Receiving Second-Line Agents: A Nested Case-Control Study. **2022,** 12, 0

94 Effects of Diet and Antihyperglycemic Drugs on Erectile Dysfunction: A Systematic Review.. **2022,** 1

93 Perceptions of Type 2 Diabetes Patients for Starting Insulin: A Qualitative Content Analysis. **2021,** 5, 317-324

92 Diabetic vascular disease: Cellular and molecular approach. **2017,** 51, 18-28 1

91 Exploring the Pharmacological Potential of Metformin for Neurodegenerative Diseases.. **2022,** 14, 838173 0

90 Fréquence de l'hypoglycémie chez les patients diabétiques de type 2 traités par insuline basale en Algérie (Hypo Study). **2022,** 0

89 Glycemic control in newly insulin-initiated patients with type 2 diabetes mellitus: A retrospective follow-up study at a university hospital in Ethiopia. **2022,** 17, e0268639 0

- 88 Effects of continuous subcutaneous insulin infusion on the microstructures, mechanical properties and bone mineral compositions of lumbar spines in type 2 diabetic rats. **2022**, 23, 1
- 87 Time to Treatment Intensification in Patients Receiving DPP4 Inhibitors Versus Sulfonylureas as the First Add-On to Metformin Monotherapy: A Retrospective Cohort Study. 13,
- 86 Targeted treatment for type 2 diabetes mellitus and sleep disorders from a clinical and neuroimaging perspective. **2022**,
- 85 Comorbidities in Recent-Onset Adult Type 1 Diabetes: A Comparison of German Cohorts. **2022**, 13, 0
- 84 A Comparative Study of Natural Language Processing Algorithms Based on Cities Changing Diabetes Vulnerability Data. **2022**, 10, 1119
- 83 Efficacy and Safety of Insulin Glargine 300 U/mL in People with Type 2 Diabetes Uncontrolled on Basal Insulin: The 26-Week Interventional, Single-Arm ARTEMIS-DM Study.
- 82 The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis. **2022**, 100944 0
- 81 Chlorogenic acid improves anti-lipogenic activity of metformin by positive regulating of AMPK signaling in HepG2 cells. 0
- 80 Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials. **2022**, 74, 506-551 3
- 79 Knowledge and practice of community pharmacists towards SGLT2 inhibitors. 11, 659
- 78 Self-care management of bothersome symptoms as recommended by clinicians for patients with a chronic condition: A Delphi study. **2022**, 56, 40-49 1
- 77 Twenty Years of Insulin Gla-100: A Systematic Evaluation of Its Efficacy and Safety in Type 2 Diabetes Mellitus.
- 76 Real-world experience of angiotensin receptor neprilysin inhibitor on the glucose-lowering effect. **2022**, 12, 0
- 75 Knowledge and practice of community pharmacists towards SGLT2 inhibitors. 11, 659
- 74 Association of Serum Homocysteine with Controlled and Uncontrolled Type2 Diabetes Mellitus in Sulaimani City. **2022**, 22, 7-19
- 73 Medicinal Plants for the Treatment of Type 2 Diabetes. **2022**, 163-177
- 72 Factores asociados a la insatisfacción con el tratamiento farmacológico en pacientes con diabetes mellitus tipo 2: estudio transversal. **2022**,
- 71 Metformin Exhibits an Attractive Antineoplastic Effect on Human Endometrial Cancer by Regulating the Hippo Signaling Pathway. **2022**, 2022, 1-11

70 Hypoglykämische Notfälle.

69 Insulin Secretory Actions of Ethanol Extract of Eucalyptus citriodora Leaf, including Plasma DPP-IV and GLP-1 Levels in High-Fat-Fed Rats, as Well as Characterization of Biologically Effective Phytoconstituents. **2022**, 12, 757 ○

68 Predictors of HbA1c reduction and hypoglycemia in type 2 diabetes mellitus individuals switching from premixed to basal insulin: an exploratory analysis of optimization study. 1-8 ○

67 The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome. **2022**, 12, 1222

66 Once-Weekly Semaglutide Use in Patients with Type 2 Diabetes: Results from the SURE Spain Multicentre, Prospective, Observational Study. **2022**, 11, 4938 ○

65 CXCL13 and CXCR5 are upregulated in PCOS mice ovaries but downregulated following metformin administration. **2022**, 556, 111730 ○

64 Part Five: The Role of Deprescribing and Adjusting Glycemic Targets in Older People With Diabetes. **2022**, 37, 384-393 ○

63 The consumption of sea buckthorn (*Hippophae rhamnoides* L.) effectively alleviates type 2 diabetes symptoms in spontaneous diabetic rats. **2022**, 152, 261-269 1

62 Pharmacotherapy in Clinical Trials for Abdominal Aortic Aneurysms: A Systematic Review and Meta-Analysis. **2022**, 28, 107602962211204 ○

61 Comparing time to intensification between insulin degludec/insulin aspart and insulin glargine: A single-center experience from India. **2022**, 13, 171 ○

60 The dual role of empagliflozin: Cardio renal protection in T2DM patients. **2022**, 81, 104555 ○

59 Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database. ○

58 Hypoglycemic events and glycemic control effects between NPH and premixed insulin in patients with type 2 diabetes mellitus: A real-world experience at a comprehensive specialized hospital in Ethiopia. **2022**, 17, e0275032 ○

57 Bioactive peptides in fermented foods and their application: a critical review. 1

56 First-Line Therapy for Type 2 Diabetes With Sodium Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. 4

55 Prediction of janagliflozin pharmacokinetics in type 2 diabetes mellitus patients with liver cirrhosis or renal impairment using a physiologically based pharmacokinetic model. **2022**, 179, 106298 ○

54 A retrospective analysis of the incidence, outcome and factors associated with the occurrence of euglycemic ketoacidosis in diabetic patients on sodium glucose co-transporter 2 inhibitors undergoing cardiac surgery. **2022**, 25, 460 ○

53 Methicillin-Resistant Staphylococcus aureus in Diabetic Foot Infections: Protein Profiling, Virulence Determinants, and Antimicrobial Resistance. **2022**, 12, 10803 1

52	Pharmacologic Treatment of Type 2 Diabetes in the U.S., Sweden, and Israel.	0
51	Automated Insulin Delivery Systems as a treatment for Type 2 Diabetes: a Review. 2022,	0
50	Red Blood Cell Lifespan < 74 Days Can Clinically Reduce Hb1Ac Levels in Type 2 Diabetes. 2022, 12, 1738	0
49	Hibiscus sabdariffa L. polyphenolic-rich extract promotes muscle glucose uptake and inhibits intestinal glucose absorption with concomitant amelioration of Fe 2+ -induced hepatic oxidative injury.	0
48	The impact of peer coach-led type 2 diabetes mellitus interventions on glycaemic control and self-management outcomes: A systematic review and meta-analysis. 2022,	0
47	Evaluation of the effectiveness of long-acting insulin analogs in patients with type 2 diabetes mellitus.	0
46	Drug therapy and medication adherence in type 2 diabetes in a care facility: A cross sectional survey. 2022, 100200	0
45	Determinants of response to the glucagon-like peptide-1 receptor agonists in a type 2 diabetes population in the real-world. 2022,	0
44	Glucose-responsive nanoparticles designed via a molecular-docking-driven method for insulin delivery. 2022, 352, 527-539	0
43	Pharmacotherapy of type 2 diabetes: An update and future directions. 2022, 137, 155332	3
42	The Role of the Person Focused IARA Model in Reducing Anxiety and Improving Body Awareness and Illness Management in Diabetics with Acquired Lipodystrophy: A Mixed-Method Study. 2022, 12, 1865	0
41	Imagerie des cancers et prévention de l'insuffisance rénale. 2022,	0
40	Socio-demographic, behavioural and clinical factors influencing control of diabetes and hypertension in urban Mysore, South India: a mixed-method study conducted in 2018. 2022, 80,	0
39	Mode of treatments and achievement of treatment targets among type 2 diabetes patients with different comorbidities in a register-based retrospective cohort study in Finland. 2022, 23,	0
38	Empagliflozin activates JAK2/STAT3 signaling and protects cardiomyocytes from hypoxia/reoxygenation injury under high glucose conditions.	0
37	Insulin degludec/liraglutide versus its monotherapy on T2D patients: A lifetime cost-utility analysis in China. 13,	0
36	Identifying Gaps in Real-World Management of Diabetes in Nigeria: A Subset Analysis of Cross-Sectional Wave-7 Data from the International Diabetes Management Practices Study. 2022, 12, 284-301	0
35	Attenuation of hyperglycemia-associated dyslipidemic, oxidative, cognitive, and inflammatory crises via modulation of neuronal ChEs/NF- κ B/COX-2/NOx, and hepatorenal functional deficits by the Tridax procumbens extract. 2023, 158, 114114	0

- 34 Assessment of Biotransformed Silica Nanoparticle on Blood Glucose Level in Human: An In Vitro Investigation. ○
- 33 HOW did GLP-1RAs bring about a paradigm shift in the guidelines of managing T2DM: A path to gluco-cardio Centricity. **2022**, ○
- 32 6. Glycemic Targets: Standards of Care in Diabetes **2023**. **2023**, 46, S97-S110 1
- 31 Can probiotic, prebiotic, and synbiotic supplementation modulate the gut-liver axis in type 2 diabetes? A narrative and systematic review of clinical trials. 9, ○
- 30 Étude Transversale sur les Effets Indésirables de la Chlorhydrate de Méformine chez 130 Patients Diabétiques Type 2 Admis au Centre Médical et à la Maison du Diabète de Sidi Bel-Abbès. **2022**, ○
- 29 A qualitative study of blood glucose and side effect self-management among patients with type 2 diabetes undergoing chemotherapy for cancer. **2022**, 100172 ○
- 28 Antidiabetic agents: Do they hit the right targets?. **2022**, 2, 225-243 ○
- 27 The effect of saffron (*Crocus sativus* L.) on glycemia, lipid profile, and antioxidant status in patients with type-2 diabetes mellitus: A randomized placebo-controlled trial. ○
- 26 Effectiveness and safety of hydrogen inhalation as an adjunct treatment in Chinese type 2 diabetes patients: A retrospective, observational, double-arm, real-life clinical study. 13, ○
- 25 Effects on glycemic control by combination therapy of gliclazide-metformin and insulin in type 2 diabetes mellitus patients. **2023**, 2, 51 ○
- 24 Heart rate variability in different sleep stages is associated with metabolic function and glycemic control in type 2 diabetes mellitus. 14, ○
- 23 Investigating the Effect of Thyroid Hormones on Diabetic Nephropathy in Type 2 Diabetic Patients Referred to Ahvaz Hospitals in 2017. **2023**, In Press, ○
- 22 Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model. **2023**, 136, 102-104 ○
- 21 Cyb5r3-based mechanism and reversal of secondary failure to sulfonylurea in diabetes. **2023**, 15, ○
- 20 The Role of Gut Microbiota in High-Fat-Diet-Induced Diabetes: Lessons from Animal Models and Humans. **2023**, 15, 922 ○
- 19 Effects of different regimens of insulin on body mass index commonly used in type 2 diabetes mellitus. **2022**, 1, 22 ○
- 18 Effects of marine phenolics on diabetes, obesity, and metabolic syndrome. **2023**, 431-472 ○
- 17 *Artemisia abrotanum* and *Symphytum officinale* Polyphenolic Compounds-Rich Extracts with Potential Application in Diabetes Management. **2023**, 13, 354 ○

- 16 The modifier effect of physical activity, body mass index, and age on the association of metformin and chronic back pain: A cross-sectional analysis of 21,899 participants from the UK Biobank. **2023**, 18, e0282205 ○
- 15 Safety and efficacy of anti-hyperglycemic agents in patients with type 2 diabetes mellitus (T2DM): Protocol for an overview of systematic reviews based on network meta-analysis. **2023**, 18, e0282143 ○
- 14 Design expert software assisted development and evaluation of empagliflozin and sitagliptin combination tablet with improved in-vivo anti-diabetic activities. **2023**, 9, e14259 ○
- 13 Current Strategies of New Drugs for Diabetes Management. **2023**, 22-47 ○
- 12 Update on Medical Management of Diabetes. **2023**, ○
- 11 Adherence to the therapeutic guidelines recommendations among the people with type 2 diabetes mellitus and obesity, frailty, or recent diagnosis, attended in primary health care centers in Spain: A cross-sectional study. 10, ○
- 10 How does HbA1c predict mortality and readmission in patients with heart failure? A protocol for systematic review and meta-analysis. **2023**, 12, ○
- 9 Risk of Lactic Acidosis in Hospitalized Diabetic Patients Prescribed Biguanides in Japan: A Retrospective Total-Population Cohort Study. **2023**, 20, 5300 ○
- 8 Diabetes and Heart Failure. **2023**, 177-204 ○
- 7 Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects. **2023**, 31, 59 ○
- 6 Weight loss to disrupt type 2 diabetes. ○
- 5 Versatile Solid Modifications of Multicomponent Pharmaceutical Salts: Novel Metformin/Rhein Salts Based on Advantage Complementary Strategy Design. **2023**, 15, 1196 ○
- 4 Berry Dietary Interventions in Metabolic Syndrome: New Insights. **2023**, 15, 1906 ○
- 3 Geriatriische Aspekte bei Diabetes mellitus (Update 2023). **2023**, 135, 307-318 ○
- 2 Diagnose und Management der Osteoporose bei Diabetes mellitus (Update 2023). **2023**, 135, 207-224 ○
- 1 Cognitive protection of incretin-based therapies in patients with type 2 diabetes mellitus: A systematic review and meta-analysis based on clinical studies. ○